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4List of abbreviations
ABC (A-G) ATP-binding cassette (subfamily)
AML Acute Myeloid Leukemia
AMP Adenosinemonofosfaat
Ara-C Cytarabine
Asp Asparaginase
ATP Adenosinetrifosfaat
BCRP Breast cancer resistant protein
BSEP Bile salt export pump
CD Cluster of differentiation determinant
CF Cystic fibrosis
CFU-C Colony forming units-cells
CHO Chinese hamster ovary cell line
CLP Common lymphoid progenitor
cMOAT Canalicular multispecific organic anion transporter
CMP Common myeloid progenitor
CsA Cyclosporin A
Cycl Cuclphosphamide
DCF 2’-7’-dichlorodihudrofluorescein
DCFH-DA 2’-7’-dichlorodihudrofluorescein diacetate
DFM Drug free medium
DJS Dubin-Johnson syndrome
DMEM Dulbecco’s minimum essential medium 
DNA Desoxyribonucleïnezuur
DNP-GS Dinitrophenol
DNR Daunorubicin
DOX Doxorubicin
EI Efflux index
ETO Etoposide
FACS Fluorescence-activated cell sorting  
FCS Fetal calfs serum
FISH Fluorescent in situ hybridization
FITC Fluoresceine-isothiocyanaat
FTC Fumitremorgin C
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
G-CSF Granulocyte colony stimulating factor
GMP Granulocyte/macrophage progenitor cell
HEK-293 Human embryonic kidney cell line
5HL-60 Promyelocytic cell line
HMBS Hydroxymethylbilane synthase
HPRT1 Hypoxanthine phosphoribosyltransferase 1
HSC Hematopoietic stem cell
IDA Idarubicin
IMDM Iscove’s Modified Dulbecco’s Medium
KG1a Acute myelogenous leukemia cell line
KO143 Fumitremorgin C analog
LTC4 Leucotriene C4
LTC-IC Long-term culture-initiating cells
LT-HSC Long-term repopulating hematopoietic stem cell
MCF7(-MR) Human breast cancer cell line
MDR Multidrug resistance
MEP Megakaryocytic/erythrocytic progenitor cell
MFC Microfluidic card
MFI Mean fluorescence intensity
MITO Mitoxantrone
MT Mitoxantrone
mRNA Messenger RNA
MRP Multidrug resistance protein
MXR Mitoxantrone resistant protein
NA Material not available for analysis
NBD Nuleotide binding domain
NBF Nucleotide-binding folds
NBM Normal bone marrow
NEM-GS N-ethylmaleimide
NOD/SCID Nonobese diabetic / Severe combined immunodeficient
NS Not significant
PE Phycoerythrin
P-gp P-glycoprotein 
Pred Prednisone 
PXE Pseudoxanthoma elasticum
Rh123 Rhodamine 123
RNA Ribonucleïnezuur
ROS Reactive oxigen species
RPMI Culture medium
RT-PCR Reverse transcriptase - Polymerase chain reaction
SD Standard deviation
SEM Standard error of the mean
6SL-IC SCID leukemia initiating cell
ST-HSC Short-term repopulating hematopoietic stem cell
STI-571 A tyrosine kinase inhibitor
SP Side population
SPGP Sister of P-glycoprotein
SSC Side-scatter characteristics
TM Transmembrane
U937 Human leukemic monocyte lymphoma cell line
VERA Verapamil
VIN Vincristine
7Table of contents
Chapter 1 General Introduction 9
Chapter 2  ABCB1 modulation does not circumvent drug extrusion 37 
from primitive leukemic progenitor cells and may  
preferentially target residual normal cells in acute  
myelogenous leukemia.
    Clinical Cancer Research. 2006 Jun 1;12(11Pt1):3452-8.
Chapter 3  Breast cancer resistance protein in drug resistance op  57 
primitive CD34+CD38- cells in acute myeloid leukemia.
    Clinical Cancer Research. 2005 Mar 15; 11(6): 2436-44.
Chapter 4  Preferential expression of a high number of ATP binding  79 
cassette transporters in both normal and leukemic  
CD34+CD38- cells.
    Leukemia 2006 Apr;20(4):750-4.
Chapter 5  Rapid upregulation of a broad range of ATP binding  97 
cassette transporters upon anthracyclin exposure in  
leukemic progenitor cells. 
    Submitted
Chapter 6  The ATP-binding-cassette transporter ABCC6 is highly  111 
induced in leukemic progenitor cells upon exposure to  
Ara-C and confers protection against Ara-C induced  
cytotoxicity.
    Manuscript in preparation
Chapter 7 Summary and Concluding remarks 129
Chapter 8 Nederlandse Samenvatting 139
Chapter 9 Dankwoord 147
    Curriculum Vitae
    List of publications
Chapter 10 Color figures 155
8
Chapter 1
General Introduction
10
Ch
ap
te
r 1
General introduction
Hematopoiesis
Blood cell production (hematopoiesis) is a tightly regulated process that in adult 
human beings takes place in the bone marrow. The different types of mature cells 
circulating in the peripheral blood are all generated from the hematopoietic stem 
cell (HSC)(1;2). HSCs are characterized by an extensive proliferation and differen-
tiation capacity and with the ability to self-renew. This self-renewal capability is 
necessary to maintain a pool of immature cells in the bone marrow. As such, HSC 
are capable of reconstituting the bone marrow in a transplant setting. The process 
of proliferation and differentiation of HSCs is strictly regulated and balanced by 
interactions between the bone marrow microenvironment and hematopoietic 
growth factors. The most primitive long-term repopulating stem cells (LT-HSC) on 
mobilization with chemokines from their niche and subsequent activation with 
cytokines can rapidly alter their phenotype and become short-term repopulating 
cells (ST-HSC) (figure 1). The ST-HSC may differentiate subsequently into either 
common lymphoid or myeloid progenitors (CLP and CMP). The CLP differentiates 
to mature T- and B-lymphocytes and NK-cells (3). The CMP develops into a common 
granulocyte/macrophage progenitor cell (GMP) or to a common megakaryocytic/
erythrocytic progenitor cell (MEP). Recent work suggests that in mice the MEP may 
directly descent from the HSC (4). The GMP finally gives rise to mature neutrophils 
or monocytes/macrophages, while the MEP differentiation results in mature and 
functional erythrocytes and megakaryocytes (figure 1). 
Hematopoietic stem cells
HSC and committed progenitor cells in human bone marrow can be identified by 
their specific expression of cell surface proteins, like cluster of differentiation 
determinant-34 (CD34) (5). CD34+ cells account for approximately 1-2% of normal 
adult bone marrow mononuclear cells and contain erythroid, granulomonocytic, 
megakaryocytic, B- and T-lymphoid and dendritic cell precursors. Transplantation 
of human CD34+ cells results in reconstitution of hematopoiesis with both long 
term as well as short term mature cells (6;7). Reconstitution of bone marrow by 
CD34+ cells suggests that the HSC is within this specific population. In humans 
these hematopoietic stem cells can be further enriched within the CD34+CD38- 
phenotype as shown by long-term in vitro cultures and transplantation experiments 
(8-11). CD34+CD38- cells have a very low frequency, only comprising 1-10% of the 
CD34+ cells. The protein encoded by the CD38 gene is a 45 kDa single chain trans-
membrane molecule that is ubiquitously distributed in mammalian tissues. Also 
in the bone marrow it is expressed on most mature blood cells, like in precursor 
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cells, the majority of B- and T-cells, NK cells, subsets of monocytes, granulocytes, 
erythroid cells and platelets (12-14). CD34+CD38- cells represent a more homo- 
genous population based on morphology, slightly larger than lymphocytes (11). 
Evidence that the CD34+CD38- population contains pluripotent hematopoietic stem 
cells has come from both in vitro as in vivo studies. CD34+CD38- cells have the 
ability to produce long-term culture-initiating cells (LTC-IC; cells able to generate 
colony-forming unit-cells (CFU-C)) and extended LTC-IC (ELTC-IC). ELTC-IC starts 
to proliferate later in culture, consistent with a more quiescent progenitor popu-
lation. The CD34+CD38- cells may be functionally closer to the human long-term 
repopulating stem cell (8;15). CD34+CD38+ cells can be clearly distinguished from 
CD34+CD38- cells since they do not generate CFU-C beyond day 40. In vivo repopu-
lating assays by transplantation of lethally irradiated mice revealed the functional 
repopulation potential. Human CD34+CD38- cells engraft the bone marrow of (sub)
lethally irradiated NOD/SCID mice and reconstitute hematopoiesis, suggesting that 
this system can support self-renewal of human hematopoietic stem cells. Human 
CD34+CD38- cells differentiated into mature blood cells, including myelomono-
Figure 1. Hematopoiesis. Blood cell development arises from a hematopoietic stem cell (HSC) in the 
bone marrow. HSCs are characterized by the capacity to self-renew or to differentiate into multilineage 
committed progenitor cells: either a common lymphoid progenitor (CLP) or a common myeloid progeni-
tor (CMP). The CLP cells can differentiate into mature T-, B- and NK-cells. Myeloid progenitors cell can 
differentiate into more differentiated progenitor cells; the granulocytes and macrophage progenitors 
(GMP) and megakaryocytes and erythroid progenitor cells (MEP). GMP differentiation results in mature 
neutrophils, monocytes and macrophages, while MEP cells can form megakaryocytes, erythrocytes and 
platelets.
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cytes, dendritic cells, erythrocytes, platelets and lymphocytes. Differentiation into 
each lineage occurred via development of intermediates such as CLP and CMP, 
summarizing the steady-state hematopoiesis (7;9;16). Altogether these studies 
show the specific stem cell characteristics of self-renewal, proliferation and differen-
tiation in the CD34+CD38- cell population.
Leukemia
Hematopoiesis is a tightly regulated system, which is exclusively responsive 
to functional demands, such as blood loss, bacterial infections, parasitic infec-
tions or allergic reactions. Derangements in marrow function can lead to an excess 
of nucleated (white) cells or an inadequate number of cells. Acute leukemia is a 
hematological malignancy that is characterized by a clonal expansion of immature 
hematopoietic cells (blasts). These blasts fail to differentiate into mature functional 
blood cells resulting in the accumulation of a large amount of these cells in bone 
marrow and peripheral blood. The presence of more than 20 percent of leukemic 
blasts in the bone marrow is defined as acute leukemia. The clinical signs and 
symptoms of acute leukemia are diverse and often nonspecific. Typically patients 
present with symptoms of bone marrow failure, fatigue, hemorrhages, infections 
and fever due to decrease in red cells, platelets, or white cells, respectively. Acute 
leukemia can be divided in lymphoid, myeloid and undifferentiated leukemia based 
on the (incomplete) differentiation characteristics of the blast cells. 
Acute Myeloid Leukemia as a stem cell disease
Acute myeloid leukemia (AML) is a clonal disorder defined by the accumulation 
of large numbers of abnormal cells that fail to fully differentiate. Since most AML 
blasts are partially differentiated and have no or limited proliferation capacity it 
suggests that a rare population of leukemic stem cells with extensive proliferation 
and the potential for self renewal maintains the leukemic clone (17;18). The current 
concept is that hematopoiesis in leukemia is hierarchically structured, similar to 
normal hematopoiesis. Leukemic hematopoiesis consists of few stem cells, a larger 
progenitor pool followed by a pool of partially differentiated cells. Studies have 
been performed to investigate the phenotype of AML stem cells and the possibility 
to distinguish them from normal stem cells. Fluorescent in situ hybridization (FISH) 
analyses suggest that the leukemic stem cell may be derived from a primitive cell 
because leukemia specific cytogenetic abnormalities were detected in a propor-
tion of CD34+CD38- cells (19;20). The injection of blasts from AML patients into 
sub-lethally irradiated NOD/SCID mice resulted in engraftment and development 
of leukemia, with a similar phenotype as observed in patients (21-23). Studies with 
sorted subpopulations confirmed the ability of AML stem cells to initiate human 
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AML after transplantation into NOD/SCID mice, termed SCID leukemia initiating cell 
(SL-IC). SL-ICs fulfi ll the two key criteria that defi ne a stem cell. After transplantation 
they are able to proliferate and diff erentiate, producing a disease that is identical 
to the original AML, and they are able to self renew, enabling the reestablishment 
of AML in secondary recipient mice. The SL-IC were found exclusively in the primi-
tive CD34+CD38- fraction of most AML patients; none were found in any other frac-
tion, including the CD34+CD38+ fraction (21;24). These studies suggest that the 
leukemia-initiating transformation and progression-associated genetic events in 
most AML occur in these CD34+CD38- primitive cells and not in the more committed 
CD34+CD38+ progenitor cells.
By self-renewal, stem cells often persist for longer periods implicating a higher 
chance for mutations to accumulate in individual stem cells than in short-living 
mature cells. Mutations in the DNA of progenitor cells will disappear as the cells 
further diff erentiate and will go in apoptosis, while mutations in the stem cell popu-
lation will persist as a result of self-renewal. For example a frequent chromosomal 
abnormalities in AML involves the translocation (8;21), which results in AML1-ETO 
gene fusion in leukemic cells. AML1-ETO transcripts were found in a fraction of 
‘normal’ stem cells, capable of diff erentiating into B cells as well as myeloid 
lineages. This suggests that additional oncogenic events in a subset of hemato-
poietic stem cells will ultimately result in leukemia (25). Nowadays, the concept 
is that most cancer cells lack the ability to form a new tumor, therefore only the pro-
liferation of rare cancer stem cells can lead to metastatic disease (fi gure 2). 
Figure 2. Failure in eradication of tumor stem cells will lead to re-growth of the tumor. Conventional thera-
pies reduce tumour size or tumour load by killing cancer cells with limited proliferation capacity. Tumor 
stem cells are less sensitive to these therapies and incomplete eradication of the tumor/leukemic stem 
cells will lead the re-growth of the tumor. By contrast, if therapies do target the cancer stem cell, the 
tumors are unable to maintain growth. This will eventually lead to complete eradication of the tumor.
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Although currently available drugs can significantly reduce malignant cells, these 
effects are largely transient and often do not appreciably extend the life of patients. 
One reason of the ultimate failure of these treatments is the acquisition of drug re-
sistance by the cancer cells. Another possibility is that existing therapies fail to kill 
cancer stem cells effectively, in part due to their noncycling metabolically inactive 
state (G0 phase) (26). As such, the leukemic stem cell is the crucial target in the 
treatment of AML and therefore elucidation of the mechanisms conferring resis-
tance against (chemo) therapy within this population is of ultimate importance. 
The human ATP-binding cassette (ABC) transporter superfamily
The ATP-binding cassette (ABC) superfamily in humans includes genes whose pro-
ducts represent membrane proteins involved in energy-dependent transport of a 
wide variety of substrates, like amino acids, ions, sugars, lipids and drugs, across 
membranes (27;28). The ABC genes represent the largest family of transmembrane 
proteins. Proteins are classified as ABC transporters based on the sequence and 
organization of their ATP-binding domains, also known as nucleotide-binding folds 
(NBF). The NBFs contain characteristic motifs, Walker A and B, separated by ~90-120 
amino acids, found in all ATP-binding proteins. ABC genes also contain an additional 
element, the signature C motif, located just upstream the Walker B site. This site 
distinguishes members of the ABC superfamily from other ATP-binding proteins. 
The functional protein typically contains two NBFs and two transmembrane (TM) 
domains (Figure 3). 
The TM domains contain 6-11 membrane spanning α-helices and provide the speci-
ficity for the substrate (29). The NBFs are located in the cytoplasm and transfer the 
energy necessary to transport the substrate across the membrane. ABC transport-
ers act mostly unidirectional.
ABC transporters, persistently expressed in all living cells, are essential for many 
transport processes in the cell and their organelles. Mutations in these genes cause 
or contribute to several human genetic disorders including cystic fibrosis (ABCC7), 
pseudoxanthoma elasticum (ABCC6), Dubin-Johnson syndrome (ABCC2), neuro-
logical disease, retinal degeneration (ABCA4), Tangier disease (ABCA1), immune 
deficiency (ABCB2 and ABCB3), cholesterol and bile transport defects, anemia, and 
drug response.
The genes that encode ABC genes are widely dispersed in the genome and show 
a high degree of amino acid sequence identity among eukaryotes. Until now 
49 human ABC transporters have been described. Phylogenetic analyses allowed 
the gene superfamily to be divided into seven subfamilies (A-G). 
15
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ABCA subfamily
This subfamily is composed of 12 full transporters that are further divided into two 
subgroups. The first subgroup contains seven genes dispersed on six different 
chromosomes (ABCA1-4, ABCA7, ABCA12 and ABCA13). The second group of 5 ABCA 
genes (ABCA5, ABCA6, ABCA8-ABCA10) is arranged in a cluster on chromosome 
17q24. Three of the 12 ABCA subfamily members (ABCA1, A3 and A4) have been 
functionally characterized and are involved in lipid transport. All these three trans-
porters are associated with different deficiencies. Mutations in ABCA1, involved 
in efflux of cholesterol, cause Tangier disease: a severe HDL deficiency syndrome 
characterized by the accumulation of cholesterol in tissue macrophages and athero-
sclerosis (30;31). Mutations in ABCA3 are associated with fatal neonatal pulmo-
nary surfactant deficiencies (32), mutations in ABCA4 can cause Stargardt disease 
and other related eye disorders (33). ABCA4 is a retinal specific ABC transporter, 
involved in the transport of N-retinylidene-phosphatidylethanolamine. This action 
promotes the recycling of all-trans retinal, resulting in the accumulation in rods 
and cones, which results in apoptosis and ultimately in degeneration of the photo-
receptors (34). The second group of ABCA genes show a high homology between 
the 5 transporters and is therefore called the ABCA6-like transporters. Although 
Figure 3. Schematic representation of the structure of ABCB1, ABCC1 and ABCG2. ABCB1 and ABCC1 are 
full transporters; ABCB1 is composed of two similar halves, each half containing six transmembrane 
regions and an intracellular region containing the nucleotide binding fold (NBF). ABCC1 is characterized 
by the presence of an extra N-terminal extension with five transmembrane regions. ABCG2 is a half-
transporter having a single NBF domain and six transmembrane regions. 
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the substrates and function of these ABCA transporters are largely unknown, recent 
studies suggest that some of these transporters may function in the transmem-
brane transport of endogenous lipid substrates such as phospholipids and essen-
tial fatty-acids (35-37). 
ABCB subfamily
The ABCB subfamily is unique in mammals since it contains both full and half trans-
porters. Four full transporters and 7 half transporters have currently been described 
as members of the ABCB subfamily. ABCB1 is the first human ABC transporter cloned 
and characterized for its ability to confer a multidrug resistance (MDR) phenotype 
in cancer cells. ABCB1 is primarily expressed in the liver and blood-brain barrier, 
and is thought to be involved in protecting cells from toxic agents. The ABCB4 
and ABCB11 proteins are both located in the liver and are involved in the secre-
tion of bile acids (38). The ABCB2 and ABCB3 genes are half transporters that form 
heterodimers to transport peptides into the ER that are presented as antigens by 
the class I HLA molecules (39). Rare families with defects in these two genes display 
a profound immune suppression. The remaining half transporters are expressed 
in the lyososome (ABCB9) or the mitochondria (ABCB6, B7, B8 and B10). ABCB5 is 
an ubiquitously expressed transporter and recently it was shown that cell fusion, 
growth and differentiation are not merely spontaneous events, but phenomena 
regulated by ABCB5 (40).
ABCC subfamily
The ABCC subfamily contains 13 full transporters with a diverse functional spectrum 
that includes ion transport, toxin secretion and signal transduction. Mutations in 
ABCC7 with loss of function of the ABCC7 transporter lead to cystic fibrosis (CF) an 
inherited multisystemic disorder characterized by abnormalities in exocrine gland 
activity of the lung, pancreas, sweat ducts and intestine. ABCC7 is a channel which 
normally mediates passive diffusion of chloride and bicarbonate through epithelial 
cell membranes (29;41). ABCC8 and ABCC9 proteins bind sulfonylurea and regu-
late potassium channels involved in modulating insulin secretion. The rest of the 
subfamily is composed of nine multidrug resistance protein (MRP) related genes. 
ABCC1 (MRP1, multidrug resistance protein 1) was identified as a multidrug resis-
tance gene and was demonstrated to transport a remarkable range of drugs, in-
cluding organic anions, drugs conjugated to glutathione, glucuronate or sulphate, 
and anthracyclines. ABCC2 and ABCC3 are, like ABCC1, involved in the transport of 
organic anions (42). Similar to ABCB1, ABCC1 confers resistance to a wide variety 
of substrates. Mutations in ABCC2 has been found in patients with Dubin-Johnson 
syndrome (DJS). DJS is a rare autosomal recessive liver disorder characterized by 
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chronic conjugated hyperbilirubinemia. Patients have impaired hepatobiliary 
transport of non-bile salt organic anions (43). Mutations in ABCC6 are responsible 
for pseudoxanthoma elasticum (PXE), a disease characterized by calcification of 
elastic fibers. ABCC6 is mainly expressed in kidney and liver, organs not affected by 
PXE. This suggests that ABCC6 may have an indirect effect in the disorder (44). The 
ABCC4, C5, C11 and C12 proteins are smaller than the other ABCC1-like genes and 
lack the N-terminal domain that is not required for transport function. The ABCC4 
and C5 proteins have been shown to confer resistance to several nucleosides (45). 
Multidrug resistance protein ABCC10, ABCC11, and ABCC12 are recently identified 
members of the MRP family that are at relatively early stages of investigation. Of 
ABCC13 the amino acid sequence corresponding to putative membrane-spanning 
domains was remarkably similar to ABCC1, ABCC2, ABCC3, and ABCC6. Studies 
investigating the expression pattern of ABCC13 suggest that the expression of 
human ABCC13 is related with hematopoiesis (46).
ABCD subfamily
The ABCD subfamily contains four genes in the human genome. All of these genes 
encode half transporters that are located in the peroxisome. All peroxisomal ABC 
transporters are half-transporters and are only functional after dimerization with 
other half-transporters, either as homo- or heterodimers (47). ABCD1 has been 
implicated in the transport of the coenzyme A esters of very-long-chain fatty acids. 
Mutations in ABCD1 are the cause of a severe X-linked disease, X-linked adreno-
leukodystrophy (48). The function of the other ABCD family members is still un-
known, but considering the large homogeneity with ABCD1 suggest that they may 
have related functions in fatty acid metabolism.
ABCE and ABCF subfamily
In contrast with all typical ABC transporters, the ABCE protein, together with the 
ABCF proteins, contains two NBDs but no TM domain. The functions of these single 
ABCE transporter and the three members of the ABCF family are, therefore, unlikely 
to be transport related (49;50).
ABCG subfamily
The human ABCG subfamily comprises five members (ABCG1, G2, G4, G5 and G8). 
In rodents another ABCG member has been described, Abcg3. This gene is closely 
related to the rodent Abcg2 protein and the human ABCG2 protein. Suggestions 
have been made that Abcg3 may also be contained within the human genome 
(51). Most of the human ABCG genes seem to be involved in lipid and sterol me-
tabolism. The ubiquitously expressed ABCG1 is highly expressed in macrophages 
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and is thought to be involved in cellular cholesterol transport. ABCG4, highly ex-
pressed in the brain, is closely related to ABCG1 and may have similar functions in 
the brain. ABCG5 and ABCG8 are transporters of plant sterols in the intestine and 
liver. Both genes are mutated in families with sitosterolemia, a disorder character-
ized by defective transport of sterols and cholesterol. ABCG2 is a drug transporter 
first described in cell lines that do not overexpress ABCB1 or ABCC1 (29). ABCG2 is 
functionally active on stem cells extrusion of a Hoechst dye measured at two wave 
lengths, results in a Hoechst dull population, enriched for stem cells, the so-called 
side population (SP). 
Multidrug resistance 
One of the major problems in repeated treatment of patients with chemotherapy 
is the development of multidrug resistance (MDR). MDR is the phenomenon that 
cells are selected for resistance by a single drug but show cross-resistance to other 
structurally and mechanistically unrelated drugs. Several mechanisms may result 
in MDR: reduced drug uptake, reduced apoptosis, altered cell cycle checkpoints, 
increased DNA repair, activation of detoxifying enzymes and increased efflux of 
drugs (28). Resistance resulting from an increased efflux of drugs is generally due 
to expression of ATP-dependent efflux pumps with a broad drug specificity. ABCB1, 
ABCC1 and ABCG2 are the three most studied multidrug resistance genes.
ABCB1
The best studied ABC transporter is p-glycoprotein, the product of the ABCB1 (MDR1) 
gene. ABCB1 was the first human ABC transporter cloned and characterized for its 
ability to confer multidrug resistance to cancer cells after chemotherapy (52). ABCB1 
is involved in the transport of a wide range of compounds (xenobiotics), including 
several anticancer agents such as anthracyclines (DNR, doxorubicin), anthracenes 
(mitoxantrone), vinca alkaloids (vinblastine, vincristine), etoposide, topotecan 
as well as anti-human immunodeficiency virus agents and fluorophores (53;54). 
Many inhibitors for ABCB1 have been described, including calcium channel block-
ers (verapamil), antiarrythmics (quinidine), hydrophobic peptides (cyclosporin A, 
PSC833), and other drugs (Fucidin, GF120918) (54).
ABCB1 is localized to chromosome 7q21, comprises 28 exons and the cDNA spans 
4.5kb (55). ABCB1 is a classical ABC transporter, composed of two homologous 
halves, each containing six transmembrane (TM) domains and an ATP-binding 
domain (NBD) (figure 3). TM domains are sufficient for drug binding, because a 
deletion mutant lacking the NBD could still bind drug substrates (56). Many mu-
tations have been reported that alter affinity and/or transport of drugs by ABCB1 
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(53). Several of these mutations have been localized to the two TM domains, mainly 
5,6 and 11, 12, but they are also found throughout the rest of the molecule (54). 
ABCB1 is expressed at high levels in polarized epithelial cell layers, generally at the 
apical membrane, in human adrenal, liver, colon and kidney and in many tumors 
derived from these organs (57). The ABCB1 double knock out mice, lacking both 
ABCB1 genes, are viable, healthy and normally fertile. However, these mice are 
extremely sensitive to xenobiotic toxins, suggesting a role for ABCB1 in drug 
absorption, elimination and detoxification pathways (58;59).
ABCC1
The ABCC1/MRP1 gene was identified in the drug-selected human lung cancer cell 
line H69AR, a resistant cell line that did not overexpress ABCB1 (60). The ABCC1 gene 
is located on chromosome 16p13.1 and encodes a 190 kDa membrane protein that 
only shows 19% homology with ABCB1. Compared to ABCB1, ABCC1 is characterized 
by the presence of an extra N-terminal extension with five transmembrane regions 
(figure 3). Substrate specificities for ABCB1 and ABCC1 are partly overlapping, how-
ever, where ABCB1 has its greatest affinity with large hydrophobic cations, ABCC1 
appears most effective in transporting organic anions. ABCC1 transports drugs that 
are conjugated to glutathione, anthracyclines, vinca alkaloids and leukotrienes 
(LTC4) (42;61;62). For ABCC1 a variety of inhibitors have been described such as 
probenecid, MK571 and indomethacin (63-65).
The tissue distribution and subcellular targeting of ABCC1 appeared to be ubiqui-
tously expressed. ABCC1 is widely expressed, with high levels reported in the lung, 
testis, kidney, skeletal and cardiac muscles and the placenta (60;66). ABCC1 is ex-
pressed in a variety of solid tumors, including lung, breast and prostate cancer. 
ABCC1 typically localizes to the plasma membrane and traffics selectively to the 
basolateral component in polarized cells, this in contrast with the apical localiza-
tion of ABCB1.
ABCC1 knockout mice are viable and fertile, but their response to inflammatory 
stimuli is impaired. Lack of ABCC1 demonstrated hypersensitivity to etoposide 
after intravenous administration of the drug and ABCC1 protected the mice against 
oropharyngeal and testicular damage by etoposide. This suggest that ABCC1 is 
involved in the defence against potential harmful compounds (67;68). 
ABCG2
MCF-7/AdrVp is a multidrug resistant human breast cancer subline that shows ATP-
dependent reduction in the intracellular accumulation of anthracycline anticancer 
drugs in the absence of ABCB1 and ABCC1. In 1998, the ABC transporter involved in 
MDR was cloned from these cells and was named Breast Cancer Resistant Protein 
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(BCRP, ABCG2). ABCG2 confers resistance to mitoxantrone, doxorubicin and dauno-
rubicin and causes an ATP-dependent efflux of Rhodamine 123 (69). Fumitremorgin 
C (FTC) was found to be a specific BCRP blocker (70;71).
The ABCG2 gene is located on chromosome 4q22 and differs from ABCB1 and ABCC1 
because it functions as a homodimer composed of two identical subunits, also re-
ferred to as a half-transporter (figure 3). ABCG2 expression is related to cell popula-
tions with a primitive phenotype including embryonic stem cells, pancreas, liver, 
gastrointestinal tract and muscles (72). Overexpression of ABCG2 is frequently ob-
served in MDR cell lines selected with mitoxantrone, including sublines of human 
breast cancer carcinoma, gastric carcinoma, fibrosarcoma and myeloma origins 
(73). ABCG2 knockout mice display no characteristic phenotype at baseline, but 
these mice displayed an increased intracellular accumulation of toxic substances 
(74;75).
Other transporters involved in multidrug resistance
Based on sequence homology 49 ABC transporters have been described in the 
human genome. The functions are very diverse but seem to be involved in absorp-
tion, distribution and excretion of pharmacological compounds, as well as all sort 
of endogenous compounds. Despite these generalizations, relatively little is known 
about the specific functions of most ABC transporters. Given the high degree of 
similarity one may hypothesize that, besides ABCB1, ABCC1 and ABCG2, other ABC 
transporters are involved in drug transport and thereby may be associated with 
decreased sensitivity to chemotherapy. Nowadays, 13 ABC transporters have been 
described to confer resistance to cancer chemotherapeutic drugs (table 1) (76;77). 
Recent studies, screening different multidrug resistant cell lines showed not only 
the overexpression of known multidrug resistant genes but also other ABC genes 
pointing to their possible role in multidrug resistance (ABCA4, ABCA7, ABCB2, 
ABCB3, ABCB6, ABCB8, ABCB9, ABCF2, ABCF3 and ABCG1) (78).
ABCC6
In chapter 6 of this thesis the transporter of main interest is ABCC6. In 1999 a new 
protein of the ABCC subfamily, MOAT-E/Ara/MRP6/ABCC6, was detected based 
on amino acid alignments (79;80). Some years earlier a novel member of the ABC 
transporter family has been described, ARA, which was associated with multidrug 
resistance in leukemia cell lines (81;82). The human ABCC6 gene is located on 
chromosome 16p13, immediately next to ABCC1 and deleted in inv(16) leukemias 
(83;84).
ABCC6 is mainly expressed in kidney and liver, and to a lower extent in many other 
tissues, including skin, eye and vessel wall (85;86). Transport of glutathione conju-
21
Chapter 1
gates is a common feature of ABCC transporters, also ABCC6 is involved in the trans-
port of these conjugates, including N-ethylmaleimide (NEM-GS) and dinitrophenol 
(DNP-GS) as well as leukotriene C4 (LTC-4) (87;88). ABCC6 has been described as 
a drug resistance transporter. It conferred low levels of resistance against several 
natural product agents, such as etoposide, tenoposide, doxorubicin and dauno-
rubicin (87). 
Trans-
porter
Common 
name
Tissue localization Non-chemotherapy 
substrates
Chemotherapy substrates 
(known and suspected)
ABCA2 ABCA2 Brain, monocytes Steroid derivates, lipids Estramustine
ABCB1 P-gp, MDR1 Intestine, liver, kidney, 
placenta, blood-brain 
barrier
Neutral and cationic 
organic compounds, many 
commonly used drugs
Doxorubicin, daunorubicin, 
vincristine, vinblastine, 
actinomycin-D, paclitaxel, doc-
etaxel, etoposide, tenoposide, 
bisantrene, STI-571
ABCB4 MDR2 Liver Phosphatidylcholine, 
some hydrophobic drugs
Paclitaxel, vinblastine
ABCB11 BSEP, SPGP Bile salts Bile salts Paclitaxel
ABCC1 MRP1 All tissues Glutathione and other con-
jugates, organic anions, 
LTC4
Doxorubicin, epirubicin, etopo-
side, vincristine, methotraxate
ABCC2 MRP2, 
cMOAT
Liver, kidney, intestine Glutathione and other con-
jugates, organic anions, 
LTC4 organic anions
Methotraxate, etoposide, doxo-
rubicin, cisplatin, vincristine, 
mitoxantrone
ABCC3 MRP3 Pancreas, kidney, intes-
tine, liver, adrenal glands
Glucuronate and glutathi-
one conjugates, bile acids
Etoposide, tenoposide, metho-
traxate, cisplatin, vincristine, 
doxorubicin
ABCC4 MRP4 Prostate, testis, ovary, 
intestine, pancreas, lung
Nucleotide analogues, 
organic anions
Methotraxate, thiopurines
ABCC5 MRP5 Most tissues Nucleotide analogues, 
cyclic nucleotides, organic 
anions
6-mercaptopurine, 6-thioguanine
ABCC6 MRP6 Liver, kidney,  Anionic cyclic penta-
peptides, glutathione 
conjugates, LTC4
Etoposide, tenoposide, doxorubi-
cin, daunorubicin
ABCC10 MRP7 Many tissues, low  
expression
Amphipatic anions Docetaxel, paclitaxel, vincristine, 
vinblastine
ABCC11 MRP8 Most tissues except kid-
ney, spleen and colon
Steroid sulfates, nucle-
otide analogues
Purine and pyrimidine nucleotide 
analogues
ABCG2 MXR, BCRP Placenta, intestine, breast, 
liver
Prazosin Doxorubicin, daunorubicin,  
mitoxantrone, topotecan, SN-38
Table 1. ABC transporters currently known to be associated with drug transport and drug resistance. P-gp: 
P-glycoprotein, MDR: multidrug resistance, BSEP: Bile Salt Export Pump, SPGP: Sister of P-glycoprotein, 
MRP: Multidrug Resistance-associated Protein, cMOAT: canalicular Multispecific Organic Anion Trans-
porter, MXR: Mitoxantrone Resistant Protein, BCRP: Breast Cancer Resistant Protein, LTC4: Leucotriene 
C4, STI-571: a tyrosine kinase inhibitor.
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Loss of function mutations in ABCC6 results in pseudoxanthoma elasticum (PXE). 
PXE is a heritable systemic disorder affecting elastic structures in the skin, eyes 
and cardiovascular system (44;89-91). A surprising finding is that ABCC6 is mainly 
expressed in kidney and liver, and not in the affected sites. The expression pattern 
of ABCC6 suggests that PXE is a primary metabolic disorder. The ABCC6 knockout 
mice spontaneously develop calcification and elastic fibre abnormalities in Bruch’s 
membrane and blood vessel walls. This phenotype corresponds with the character-
istics of PXE, giving a suitable model for further studies of PXE (92).
ABC transporters and stem cells
Hematopoietic stem cells can be distinguished from (fully) mature cells based on 
many properties. Besides their ability to self-renew, their proliferative capacity and 
the capacity to differentiate into several lineages, stem cells differ in expression of 
cell surface markers and functional characteristics. One particularly intriguing pro-
perty of hematopoietic stem cells is the high expression of ABC transporters. Since 
some of these ABC transporters are involved in the efflux of fluorescent dyes, such 
as Rhodamine 123 (Rh123). Dye uptake and efflux can be used to purify stem cells. 
Separation of mouse bone marrow cells by flow cytometric analysis on the basis of 
Rh123-expression has shown that the population with Rholow cells provides long-
term reconstitution following injection in lethally irradiated mice. In contrast, the 
Rhohigh cells are only capable of short-term repopulation. The mechanism behind 
this phenotype has long been unclear but studies indicate that decreased Rh123 
staining is caused by an efflux process of this fluorescent dye by ABC transporters, 
specifically ABCB1 for Rho123 (93-95). Another fluorescent dye used for the separa-
tion of stem cell fractions is Hoechst 33342. Measured at 2 wave lengths Hoechst-
negative cells can be isolated as a so-called “side-population” (SP) within the bone 
marrow, enriched for immature stem cells with the capacity for hematopoietic 
repopulation. Hoechst is known to be a substrate for ABCB1, ABCC1 and ABCG2. 
Comparison of mRNA levels revealed ABCG2 to be predominantly expressed in 
bone marrow SP cells. Furthermore, enforced expression of ABCG2 in bone marrow 
cells caused significant expansion of cells with the SP phenotype. These findings 
indicate that ABCG2 is a marker for Hoechst-dye-effluxing stem cells (72;96-98). 
Combinations of CD34, Hoechst and Rho123 staining enables isolation of a sub-
population of human primitive hematopoietic progenitor cells, containing specific 
stem cell characteristics. In addition to the role of ABCB1 and ABCG2 as a determi-
nant of the stem cell phenotype, they could serve as novel stem cell markers. ABCG2 
is expressed in a highly regulated manner, with the highest expression in primitive 
cells and is downregulated following differentiation (97). Enforced expression of 
ABCG2 inhibited hematopoietic development and resulted in less progeny in the 
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bone marrow and peripheral blood (99). These data suggested that ABCG2 expres-
sion may play a role in the self-renewal of the early stem cell by partially block-
ing differentiation. In contrast to ABCG2, overexpression of ABCB1 in bone marrow 
cells leads to proliferation of SP cells, resulting in prolonged survival in culture 
and enhanced repopulation after transplantation into mice (100). Therefore, ABCB1 
expression may characterize proliferating stem cells, while ABCG2 expression 
may characterize quiescent stem cells. Further studies in mice deficient in or over- 
expressing these ABC transporters may elucidate their precise role in stem cells.
ABC transporters in the treatment of AML
ABCB1, ABCC1 and ABCG2 are highly expressed on stem cells, and their expres-
sion has been extensively studied on leukemic blasts in AML. ABCB1 is frequently 
expressed in elderly patients with AML. Expression is detected in 17% of adult AML 
patients younger than 35 years, 39% in patients between 35 and 50 years, and in 
71% of patients older than 65 years (101). This parallels a rise in CD34 expression 
with advancing age (102). Overexpression of ABCB1 in blast cells from patients 
with AML is associated with reduced cellular accumulation of anthracyclines (103). 
Additionally, ABCB1 over expression is a prognostic variable associated with 
reduced probability for obtaining a remission and in some reports with reduced 
leukemia-free as well as overall survival (101;104-111). These observations have led 
to the introduction of ABCB1 modulators in the treatment of AML in an attempt to 
circumvent drug resistance by targeting ABCB1 mediated drug efflux in leukemic 
cells, thereby increasing the accumulation of cytotoxic drugs.
Several in vitro studies showed that inclusion of ABCB1 modulators, such as vera-
pamil, cyclosporine A and PSC833, during treatment with chemotherapeutical 
agents may overcome resistance to vincristine, vinblastine, daunorubicin, doxo-
rubicin and idarubicin in ABCB1 expressing cells (103;112-115). These promising 
results formed the basis of clinical trials studying the safety and effectivity of 
ABCB1 modulation in vivo. Initial trials with first generation modulators, such as 
quinine and cyclosporine A (CsA), showed promising results with increased CR and 
OS in some studies (116;117), but this was not confirmed in subsequent studies 
(118;119). First generation modulators represent a chemically diverse group with 
diverse pharmacologic profiles. Since considerable toxicity was observed, these 
promising results of the initial trials stimulated to develop modulators with greater 
potency, specificity, and ABCB1 affinity. PSC833, a cyclosporine-D analogue with 
10-fold greater potency for ABCB1 inhibition than CsA, is a typical example of a 
second generation modulator. Phase III trials have been performed both in elderly 
patients with AML and patients with relapsed or refractory disease. Two of these 
studies were suspended prematurely with no improvement in CR rate but increased 
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mortality in the PSC833 treated arm (120;121). Two other trials failed to reach their 
defined endpoints of improved relapse-free survival or CR rate (122;123). Recently, 
third generation ABCB1 blockers have been developed, such as tariquidar, zosuqui-
dar and laniquidar. These agents are highly specific for ABCB1 and have modest 
or minimal effects on the clearance of chemotherapeutic agents. Phase I studies 
showed that these third generation modulators can be given safely in combination 
with induction doses of conventional chemotherapy (124;125). Although clinical 
trials are still ongoing, the largely disappointing results suggest redundancy in ABC 
transporters and the presence of other, yet unidentified, mechanisms of drug resis-
tance in leukemic cells in AML (126).
Detection of ABC transporter expression
Two commonly used methods to monitor expression of ABC transporter genes are 
micro arrays and real-time RT-PCR. The determination of expression of all 49 ABC 
transporters requires a sensitive, quantitative and reproducible system. Arrays are 
commonly used for the identification of gene expression patterns and molecular 
biomarkers. The main advantage of arrays is the high number of genes (>9000) 
screened in one single experiment. However, those arrays have three major limita-
tions for studies focussing on ABC transporters: (1) a low coverage of ABC transport-
ers on most arrays (15 and 11 in the cDNA and oligonucleotide arrays, respectively), 
(2) a limited sensitivity, lowly expressed genes such as ABC transporters, are hardly 
detectable above background, (3) crosshybridization, due to the large homology 
between close family members. Since reproducibility and quantitative analysis was 
required in our studies we choose the “gold-standard” method real-time RT-PCR. 
Although, this technique is quantitative and is highly reproducible, measurement 
of all 49 ABC transporters in different subsets is very time consuming. Recently, a 
new approach of real-time RT-PCR has been implemented, micro fluidic card (MFC) 
real-time RT-PCR. With this technique it is possible to screen 384 (different) genes 
simultaneous, with low amounts of RNA and in a quantitative manner. The MFC 
consists of 8 lanes, each coupled to 48 wells, of which the format is custom made 
(figure 4). For the ABC transporters, all transporters are spotted once in each lane, 
so for 8 different samples all ABC transporters can be measured simultaneously.
Scope of this thesis
The scope of this thesis is to investigate the expression, function and role in drug 
resistance of ABC transporters in primitive CD34+CD38- hematopoietic cells in AML 
in comparison to their normal counterparts. 
Our initial studies focussed on ABCB1 and ABCG2 since these transporters are 
highly expressed on hematopoietic stem cells and they are known to be involved 
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in multidrug resistance including drugs used in the treatment of AML, such as 
anthracyclines, mitoxantrone and vinca alkaloids. Chapter 2 describes ABCB1 ex-
pression using monoclonal antibodies and transport function by (inhibition) assays 
in normal and leukemic CD34+CD38- cells. The finding that inhibition of ABCB1 in 
leukemic CD34+CD38- cells does not prevent efflux of mitoxantrone suggests in-
volvement of other ABC transporters. Therefore, we investigated ABCG2 expression 
and function in, both normal and leukemic, primitive CD34+CD38- hematopoietic 
cells (chapter 3). Drug efflux still occurs in the presence of ABCG2 specific inhibi-
tors. This finding suggests the presence of other, yet unidentified, drug transport-
ers in leukemic CD34+CD38- cells. For that reason we profiled the expression of all 
ABC transmembrane transporters in normal and leukemic CD34+CD38- cells using 
microfluidic card real-time RT-PCR, described in chapter 4. Besides the primitive 
cells we also analyzed the committed CD34+CD38+ cells, to investigate changes in 
expression during differentiation. 
The use of ABC transporters, especially ABCB1, as prognostic parameters in AML is 
based on the expression level at diagnosis. Some studies have investigated the ex-
pression of ABCB1 at diagnosis versus relapse, but no studies have been performed 
on ABC transporter expression during treatment. In chapter 5 we investigated the 
expression of ABC transporters after short-term expression to mitoxantrone and 
daunorubicin in a primitive leukemic cell line (KG1a). We also exposed CD34+ 
leukemic cells in vitro to mitoxantrone and daunorubicin for 48 and 72 hours, 
respectively. Additionally, blasts cells were isolated from patients during chemo-
therapy and ABC transporter expression was measured. We also exposed the KG1a 
cells to Ara-C, another drug frequently used in the treatment of AML. ABCC6 was 
detected as the most induced transporter after treatment with Ara-C. In chapter 
6 we focussed on the mechanisms behind this strong induction of ABCC6.
Figure 4. Representation of the microfluidic card. The microfluidic card is a 384-well card that contains 
8 loading ports, each attached to 48 wells. Specific primers are pre-loaded into each well on the card.
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Chapter 2
“ABCB1 modulation does not circumvent drug extrusion from 
primitive leukemic progenitor cells and may preferentially target 
residual normal cells in acute myelogenous leukemia”.
MHGP Raaij makers, EPLM de Grouw, BA van der Reij den, TJ de Witte, JH Jansen, 
RAP Raymakers.
Clinical Cancer Research. 2006 Jun 1;12(11Pt1):3452-8.
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Abstract 
Acute myelogenous leukemia (AML) is a disease originating from normal hemato-
poietic CD34+CD38- progenitor cells. Modulation of the multidrug ATP-binding 
cassette transporter ABCB1 has not resulted in improved outcome in AML, raising 
the question whether leukemic CD34+CD38- cells are targeted by this strategy.
ABCB1-mediated transport in leukemic CD34+CD38- cells compared with their 
normal counterparts was assessed by quantitating the effect of specific ABCB1 
modulators (verapamil and PSC-833) on mitoxantrone retention [defined as efflux 
index (EI), intracellular mitoxantrone fluorescence intensity in the presence/ab-
sence of inhibitor].
ABCB1 was the major drug transporter in CD34+CD38- cells in normal bone marrow 
(n = 16), as shown by the abrogation of mitoxantrone extrusion by ABCB1 modula-
tors (EI, 1.99 +/- 0.08). Surprisingly, ABCB1-mediated drug extrusion was invariably 
reduced in CD34+CD38- cells in AML (n = 15; EI, 1.21 +/- 0.05; P < 0.001), which 
resulted in increased intracellular mitoxantrone retention in these cells (mitoxan-
trone fluorescence intensity, 4.54 +/- 0.46 versus 3.08 +/- 0.23; P = 0.004). Active 
drug extrusion from these cells occurred in the presence of ABCB1modulators in the 
majority of samples, pointing in the direction of redundant drug extrusion mecha-
nisms. Residual normal CD34+CD38- cells could be identified by their conserved 
ABCB1-mediated extrusion capacity.
ABCB1-mediated drug extrusion is reduced in leukemic CD34+CD38- progenitor 
cells compared with their residual normal counterparts. Redundant drug transport 
mechanisms confer mitoxantrone transport from leukemic progenitors. These data 
argue that ABCB1 modulation is not an effective strategy to circumvent drug extru-
sion from primitive leukemic progenitor cells and may preferentially target residual 
normal progenitors in AML.
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Introduction
Acute myelogenous leukemia (AML) is considered a disease originating from 
CD34+CD38- hematopoietic stem cells (1). This has been conclusively shown in 
studies using the nonobese diabetic-severe combined immunodeficient mouse 
model showing that cells with leukemic engraftment and self-renewal potential 
in AML are found in the CD34+CD38- subpopulation (2). This CD34+CD38- pheno-
type of leukemia initiating cells was observed regardless of the lineage markers 
expressed by the leukemic blasts, percentage of cells expressing the CD34 surface 
antigen, or the French-American-British subtype. These studies stress that leukemia- 
initiating transformation and progression-associated genetic events occur at the 
level of these primitive CD34+CD38- cells. Consequently, incomplete chemothera-
peutic eradication of these cells may ultimately result in disease relapse. There-
fore, elucidation of the mechanisms conferring resistance against chemotherapy to 
these cells is of crucial importance (3).
The ABCB1-encoded P-glycoprotein is a highly conserved membrane-bound ATP-
binding cassette (ABC) transporter, which extrudes a wide variety of structurally 
unrelated chemotherapeutic compounds across the cell membrane (4), conferring 
the multidrug resistance phenotype in cancer cells. ABCB1 is highly expressed in 
normal hematopoietic CD34+CD38- stem cells (5, 6).
The observation that it is frequently expressed in AML and that expression is 
associated with adverse treatment outcome (7) has led to the introduction of ABCB1 
modulators to enhance chemotoxicity of various chemotherapeutic agents in clinical 
trials. Phase III clinical trials using PSC-833 (valspodar), the most potent and spe-
cific inhibitor of ABCB1 function today, however, failed to reach their intended end 
points of improved complete remission and survival and have been complicated by 
increased toxicity (8–12). In contrast, a clinical trial using cyclosporine A, which is a 
broad-spectrum ABC transporter inhibitor, showed clinical benefit (13). The reasons 
for the lack of benefit of ABCB1 modulation in AML remain to be elucidated. In inter-
preting these negative results, it is important to know whether the leukemia-initi-
ating CD34+CD38-hematopoietic subpopulation is targeted by ABCB1 modulation 
and whether additional transporters confer drug extrusion from these cells, which 
may explain the beneficial effect of broad-spectrum inhibition. The vast amount of 
studies on ABCB1 expression and function in AML has been done on general blast 
populations. The goal of the current study was to investigate ABCB1 expression and 
function in leukemic CD34+CD38- cells and the effect of ABCB1 modulators on drug 
retention in these cells compared with their normal counterparts.
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Materials and Methods
Bone marrow samples. 
Bone marrow was obtained after informed consent from healthy bone marrow 
donors and patients with AML at diagnosis. Mononuclear cells were isolated by 
Ficoll (1.077 g/mL density centrifugation; Pharmacy Biotech, Uppsala, Sweden). 
Isolation, cryopreservation, and thawing procedures of cells have been described 
previously (14) and were identical for normal and leukemic bone marrow samples.
CD34+CD38- hematopoietic cells. 
CD34+CD38- cells were defined flow cytometrically as described previously (15) 
and are shown in Fig. 1A. Flow cytometric assessment of ABCB1 expression. ABCB1 
expression was analyzed using the ABCB1-specific antibody MRK16, recognizing an 
external epitope of the protein in three-color low cytometric assays as described 
previously (7). ABCB1 protein expression was quantitated as the median fluores-
cence channel shift (MRK16/IgG2a isotype control) in CD34+CD38-, CD34+CD38+, 
and CD34- cell populations. Differences in fluorescence are assessed using the 
Kolmogorov-Smirnov statistic, denoted as D. This method accurately identifies 
small differences in fluorescence and is useful in detection of low-level ABCB1 ex-
pression (7). MRK16 staining intensity is categorized as follows: negative (D < 0.10), 
dim (0.10 < D < 0.15), moderate (0.15 < D > 0.25), and bright (D > 0.25). 
Flow cytometric assessment of ABCB1-mediated mitoxantrone transport. 
Cells were stained with CD34-FITC and CD38-PE membrane markers, washed in 
HBSS 1% FCS, and preincubated with or without verapamil (20 µg/mL; Knoll AG, 
Table 1 Patient characteristics
N 20
Sex
   Male 9
   Female 11
Age, median (range) 50 (15-71)
% CD34 30 (1-91)
French-American-British
   M1 6
   M2 8
   M4 3
   M5 3
Cytogenetics
   Normal 9
   t(8,21) 4 (+2 complex)
   (6,11) 2
   45XO 1
   Complex 4
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Figure 1. ABCB1-mediated drug extrusion is reduced in CD34+CD38- progenitor cells in AML compared 
with their normal counterparts. (For color reproduction: see chapter 10) A, representative examples of 
normal bone marrow (NBM; top) and AML (bottom). CD34+CD38- cells were defined flowcytometrically 
as the CD34-FITC + cells (blue) with CD38-PE expression within the first decade of fluorescence emission 
(red) and compared with CD34+CD38+ cells (blue gated) with exclusion of a decade between CD38- and 
CD38+ cells. Gray, CD34- cells. CD34+CD38- cells exhibited restricted light-scattering characteristics 
(SSC), confirming the lymphoid appearance of these cells (inset). The median frequency of CD34+CD38- 
cells was 0.1% of mononuclear cells (range, 0.1-0.3%) in normal bone marrow and 0.2% of mononuclear 
cells (range, 0.1-10%) in AML. No difference existed in average CD38 density between normal and leuke-
mic CD34+CD38- cells (MFI, 0.57 +/- 0.05 SD; range, 0.40-0.70; MFI, 0.53 +/- 0.12 SD; range, 0.30-0.70). 
B, representative examples of flow cytometric assessment of ABCB1-mediated mitoxantrone transport in 
CD34+CD38- cells in normal bone marrow (top) and AML (bottom). Mean intracellular MFI was assessed 
in CD34+CD38- cells as described in Materials and Methods. Normal CD34+CD38- cells display low 
intracellular mitoxantrone fluorescence compared with CD34+CD38+ cells (inset), which can be increased 
significantly by blockage of ABCB1-mediated transport by verapamil/PSC-833 (EI, 2.29). CD34+CD38- 
cells in AML display increased intracellular mitoxantrone retention compared with CD34+CD38- cells 
from normal bone marrow due to reduced ABCB1-mediated transport as illustrated by a lack of effect of 
verapamil/PSC-833 on intracellular mitoxantrone fluorescence (EI, 0.98). C, representative examples 
of the effect of ABCB1 inhibition by verapamil on rhodamine 123 fluorescence in CD34+CD38- cells 
assessed by single-cell image analysis. For experimental procedure, see Materials and Methods. 
Encircled, cells. Normal CD34+CD38- cells (top) display low retention of rhodamine 123, which can be 
significantly increased when verapamil is added (EI, 3.24). ABCB1-mediated rhodamine 123 extrusion 
from CD34+CD38- cells is reduced in AML (bottom), illustrated by the lack of effect of ABCB1 inhibition 
by verapamil on intracellular rhodamine 123 fluorescence (EI, 1.00).
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Ludwigshafen, Germany; (16)) or PSC-833 (2 µmol/L; Novartis Pharma AG, Basel, 
Switzerland; (17)) as inhibitors for ABCB1-mediated transport for 20 minutes in 
Iscove’s modified Dulbecco’s medium supplemented with 1% FCS. Verapamil at the 
concentration used in this study is regarded ABCB1 specific without inhibition of 
ABCG2 [breast cancer resistance protein (BCRP); (18)] and ABCC1 (multidrug resis-
tance protein; (19)), although inhibition of ABCG2 by verapamil has been described 
at higher concentrations (20). Mitoxantrone (Novantrone; 10 µmol/L; Lederle, Etten-
Leur, the Netherlands) was added, and cells were incubated for 2 hours at 37°C, 5% 
CO2, with or without verapamil or PSC-833. Subsequently, cells were allowed an 
additional 1-hour efflux in drug-free medium with or without inhibitor. The com-
bined uptake and efflux with or without inhibitor assay was chosen because it has 
higher sensitivity for ABC transporter function compared with assays using only 
uptake with or without inhibitor (15).
Cellular mitoxantrone fluorescence was measured at a single time point after the 
additional hour of efflux in drug-free medium on a flow cytometer (Coulter Elite, 
Beckman Coulter, Fullerton, CA) equipped with an argon laser. Fluorescence was 
assessed at an excitation wavelength of 635 nm through a 670-nm band pass filter 
in a three-color protocol with CD34-FITC and CD38-PE. At least 200 CD34+CD38- 
cells were analyzed in each sample.
Figure 2. ABCB1 is differentially expressed in CD34+CD38- cells in both normal bone marrow and AML. 
ABCB1 expression was assessed flow cytometrically using the MRK16 monoclonal antibody and valued 
using the Kolmogorov-Smirnov statistic, denoted as D, as described in the Materials and Methods. ABCB1 
was preferentially expressed in CD34+CD38- cells compared with more differentiated CD34+CD38+ pro-
genitors in all normal (n = 10; black dots) and leukemic (n = 10; white dots) samples examined. MRK16 
staining intensity is categorized as follows: negative (D < 0.10), dim (0.10 < D < 0.15), moderate (0.15 < D 
> 0.25), and bright (D > 0.25). No difference existed in levels of expression in CD34+CD38- cells between 
normal bone marrow and AML (median D, 0.13 +/- 0.03 and 0.12 +/- 0.04, respectively).
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ABCB1-mediated transport was depicted as the ratio of intracellular mitoxantrone 
fluorescence intensity (MFI) in the presence or absence of inhibitor [defined as 
efflux index (EI)]. To assess interexperimental reproducibility, ABCB1-mediated 
transport in CD34+CD38- cells was assessed in a normal bone marrow sample 
in completely independent experiments done on separate days (n = 7). ABCB1- 
mediated EI was 2.10 +/- 0.09 (mean +/- SE), indicating good reproducibility of the 
assay. This sample was subsequently included in other experiments as a control. 
Preliminary experiments showed similar ABCB1-mediated efflux in cryopreserved 
samples when compared with fresh cells in normal bone marrow and AML, in line 
with a previous report addressing this issue (21).
Single-cell image analysis for assessment of ABCB1-mediated transport of 
rhodamine 123 in CD34+CD38- cells. 
ABCB1-mediated transport of rhodamine 123 was assessed in CD34+CD38- cells 
sorted on adhesive biolayers as comprehensively described elsewhere (22). Briefly, 
500 CD34+CD38- cells were sorted in 8 µL washing buffer solution containing 0.9% 
NaCl supplemented with sodium diphosphate (6.6%, v/v), albumin (1%, v/v), and 
glucose (1%, v/v) applied on a glass coverslip coated with mussel adhesive pro-
tein (10 µL/cm2). Cells were allowed to adhere for 10 minutes in a perfusion cham-
ber constructed to enable cell environment manipulation (incubation and washing 
steps) within the microscope environment. The microscope was placed in an incu-
bator to allow all procedures to run at 37°C, which is essential for physiologic efflux 
studies.
After immobilization, cells were incubated with rhodamine 123 dissolved in Iscove’s 
modified Dulbecco’s medium containing 0.5% (v/v) heat-inactivated FCS (Hyclone, 
Logan, UT) with or without efflux modulator during 30 minutes. Cells were washed 
with washing buffer at 37°C, again in the presence or absence of efflux modulators, 
and allowed to efflux the dye for an additional 15 minutes. Fluorescence images 
were acquired after 15 minutes of efflux. Cells were excited with a mercury arc lamp 
using bandpass filter of 440 to 490 nm for rhodamine 123 or bandpass filter of 
510 to 560 nm for propidiumiodide. Emission was measured with bandpass filter of 
515 to 565 nm and longpass filter of 610 nm. Cell viability typically exceeded 90% 
of cells. Dead cells were excluded from analysis. Fluorescence intensity analysis 
of individual cells was done on TCLImage 4.6 software package (TNO, Delft, the 
Netherlands). At least 30 cells were evaluated per sample. Fluorescence intensity 
of the overall cell population is expressed as MFI and depicted in arbitrary fluores-
cence units. ABCB1-mediated efflux was quantitated as the ratio of mean fluores-
cence intensity in the presence or absence of verapamil and depicted as ‘‘EI.’’
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Fluorescence in situ hybridization. 
CD34+CD38- cells were sorted and lysed in 15 µL KCl (75 µmol/L) on a glass cover-
slip. Cells were fixed in methanol/acetic acid and stored at 4°C until analysis. Fluo-
rescence in situ hybridization was done using the LSI AML1/ETO dual color, dual-
fusion t(8;21) probe, or LSI EGR1 (5q31) dual-color probe (Vysis, Downers Grove, IL) 
according to the manufacturer’s instructions. Cells (100) were analyzed microsco- 
pically for t(8;21) or chromosome 5 (5q31) cytogenetic abnormalities as appropriate. 
Adapted real-time quantitative reverse transcription-PCR for assessment of CBFB-
MYH11 gene expression in CD34+CD38- cells.
A linear real-time quantitative reverse transcription-PCR approach has been devel-
oped for quantitation of gene expression in low-frequency hematopoietic stem cells 
and was described comprehensively elsewhere (6). Primer and probe sequences 
were as follows: glyceraldehyde-3-phosphate dehydrogenase, glyceraldehyde-3-
phosphate dehydrogenase control reagents (Applied Biosystems, Foster City, CA; 
Figure 3. Reduced ABCB1-mediated drug transport in CD34+CD38- cells is a biological commonality in 
AML. ABCB1-mediated transport in hematopoietic CD34+CD38- cells from normal bone marrow and AML 
samples depicted as an EI of substrate fluorescence in the presence or absence of verapamil. Black dot, 
each sample. Average ABCB1 efflux index ± SEM is indicated. A, ABCB1-mediated mitoxantrone transport 
as determined by flow cytometry. B, ABCB1-mediated rhodamine 123 transport as determined by single-
cell image analysis.
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part 402869); CBFB-MYH11 (type D) fusion gene, 5’-CATTAGCACAACAGGCCTTTGA-3’ 
(forward), 5’-CCTCGTTAAGCATCCCTGTGA-3’ (reverse), and TETATAGAGACAGGTCT-
CATCG (probe).
Normalized gene expression to the internal standard glyceraldehyde-3-phosphate 
dehydrogenase is given by the following equation: To/Ro(Xn) = K (1 + E)(CT,r - CT,t), 
where To is the initial number of target gene copies, Ro is the initial number of stan-
dard gene copies, E is the efficiency of amplification, CT,t is the threshold cycle of 
target gene, CT,r is the threshold cycle of standard gene, and K is constant.
Statistical analysis. 
Differences in ABCB1 protein expression (D of MRK16/isotype control) and function 
(EI) between different normal and leukemic cell populations were calculated using 
the Student’s t test with a level of significance of P < 0.05.
Results
ABCB1 is the major determinant of mitoxantrone extrusion in CD34+CD38- cells in 
normal bone marrow. 
CD34+CD38- hematopoietic cells were flow cytometrically defined as shown in 
Fig. 1A. ABCB1 protein expression was assessed in hematopoietic cell popula-
tions using the monoclonal antibody MRK16. ABCB1 was differentially expressed 
in CD34+CD38- cells compared with more differentiated cell populations (Fig. 2). 
A decrease in ABCB1 protein expression in CD34+CD38+ and CD34- cells was 
observed in all samples examined.
CD34+CD38- cells in normal bone marrow were mitoxantrone ‘‘dull’’ compared 
with CD34+CD38+ cells (MFI, 3.08 +/- 0.23 versus 7.29 +/- 0.50; n = 16; P < 0.001). 
Modulation of ABCB1-mediated transport by verapamil significantly increased 
mitoxantrone fluorescence in CD34+CD38- cells (Fig. 1B). In line with expression 
profiles, ABCB1-mediated efflux was invariably higher in CD34+CD38- cells (mean 
EI, 1.99 +/- 0.08; range, 1.64-2.92) compared with more differentiated CD34+CD38+ 
cells (1.45 +/- 0.06; Fig. 3A). Serial measurements of mitoxantrone fluorescence 
in CD34+CD38- cells both after 2-hour exposure with mitoxantrone and after an 
additional hour of efflux in drug-free medium done in a subpanel of samples (n = 7) 
showed complete abrogation of mitoxantrone extrusion by ABCB1 modulation (Fig. 
4A).
Verapamil is regarded ABCB1 specific, although inhibition of ABCG2 (BCRP) has 
been observed at concentrations considerably higher than used in our experi-
ments. To definitely confirm that the drug efflux from normal CD34+CD38- cells was 
indeed ABCB1 mediated, additional experiments were done. First, similar results 
were found when the ABCB1-specific inhibitor PSC-833 was used in a subgroup of 
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samples (n = 4; mean EI +/- SE, 2.03 +/- 0.12 and 1.38 +/- 0.09 for CD34+CD38- 
and CD34+CD38+ cells, respectively; Fig. 1B), showing that the observed efflux 
is ABCB1 rather than BCRP mediated because PSC833 is not an inhibitor of BCRP. 
This was further confirmed using rhodamine 123 as a substrate, which is not a sub-
strate for BCRP (23), in an independent assay in single CD34+CD38- cells sorted 
on an adhesive biolayer (Fig. 1C). Rhodamine 123 retention was significantly lower 
in CD34+CD38- cells compared with CD34+CD38+ cells in normal bone marrow 
Figure 4. ABCB1 modulation abrogates mitoxantrone extrusion from normal but not leukemic CD34+CD38- 
cells. To assess whether mitoxantrone efflux occurs in CD34+CD38- cells in the presence of ABCB1 modu-
lation, serial measurements were done of mitoxantrone (MITO) fluorescence both after 2 hours of expo-
sure to mitoxantrone and after an additional hour of efflux in drug-free medium, both in the presence 
and absence of ABCB1 modulation. Inhibition of ABCB1 by verapamil (VERA) completely abrogates mitox-
antrone efflux during the additional hour of efflux in drug-free medium in CD34+CD38- cells from normal 
bone marrow (MFI, 6.74 +/- 0.34 versus 6.74 +/- 0.49, respectively; A) but not in AML (MFI, 6.90 +/- 0.55 
versus 6.26 +/- 0.62, respectively, difference using t test for paired samples; P =0.006; B). Bars, 
average value of mitoxantrone fluorescence ± SEM. When cells were put on ice during the additional 
hour of efflux, no decrease in mitoxantrone fluorescence was observed.
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(P < 0.001), similar to the mitoxantrone dull phenotype of CD34+CD38- cells. Blocking 
of ABCB1-mediated transport by verapamil increased rhodamine 123 fluorescence 
significantly. ABCB1-mediated efflux was found in all examined (n = 5) CD34+CD38- 
samples (mean EI, 3.74 +/- 1.81; Fig. 3B). 
Together, these results show that ABCB1-mediated transport is the major deter-
minant of the mitoxantrone dull phenotype of CD34+CD38- cells in human normal 
bone marrow and that its modulation completely abrogates mitoxantrone extrusion 
from these cells.
ABCB1-mediated transport is reduced in CD34+CD38- hematopoietic cells in AML.
Conserved ABCB1-mediated drug extrusion from CD34+CD38- cells after malignant 
transformation would be an important obstacle for chemotherapeutic eradication 
of these cells in AML. We therefore investigated ABCB1 expression and function 
of this cell population in AML compared with their counterparts in normal bone 
marrow.
Investigations were done on a panel of bone marrow samples of 20 untreated AML 
patients (Table 1). The panel consisted predominantly of CD34+ leukemias, with 
CD34+ cells median percentage of 31% (range, 1-91). CD34 +CD38- cells in AML 
were immunophenotypically defined as indicated in Fig. 1A. Fluorescence in situ 
hybridization analyses in AML patients who carried a cytogenetic abnormality and 
from whom sufficient cells were available for analysis showed a predominantly 
leukemic character of CD34+CD38- cells in these samples (n = 5; Table 2) as 
described previously (24).
ABCB1 expression in CD34+CD38- cells in AML as assessed by the MRK16 mono-
clonal antibody was comparable with expression of their counterparts in normal 
bone marrow (Fig.2). Similar to the expression in normal bone marrow, decreased 
protein expression in CD34+CD38+ and CD34- subsets was observed in all samples. 
Surprisingly, ABCB1-mediated mitoxantrone transport was invariably reduced in 
Table 2
Patient 
no
Cytogenetic  
aberrancy
% Cytogenetic aberrant 
CD34+CD38- cells
ABCB1 EI
Rhodamine 123  
[3,74 (1,76-5,66)*]         
Mitoxantrone  
[1,99 (1,64-2,94)*]
1 -5, -7, -15, -17,t(2;3) 56 0.84 1.32
2 t(8;21) 90 NA    0.92
3 t(8;21) 95 0.81  1.15
4 t(8;21) 90 1.39 NA
5 t(8;21) 100 NA 1.28
Table 2. CD34+CD38- cells in AML are predominantly of leukemic origin. Abbreviation: NA, material not 
available for analysis. * Values normal bone marrow: mean (range).
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CD34+CD38- cells in AML compared with their counterparts in normal bone marrow 
as shown by a decreased effect of ABCB1 modulation by verapamil on intracellu-
lar mitoxantrone fluorescence (mean EI, 1.21 +/- 0.05; range, 0.93-1.51; P < 0.0001; 
Figs. 1B and 3A). Similar results were found when PSC-833 was used as an inhibi-
tor (n = 4; mean EI in CD34+CD38- cells, 1.23 +/- 0.16; Fig. 1B). Reduced ABCB1 
function was not restricted to CD34+CD38- cells in AML; reduced ABCB1 function 
compared with normal counterparts was also found for CD34+CD38+ cells (mean 
EI, 1.17 +/- 0.03; range, 1.05-1.31; P < 0.001). Reduced ABCB1-mediated transport 
in CD34+CD38- cells in AML was confirmed using rhodamine 123 as a substrate in 
single cells (Figs.  1C and 3B). CD34 +CD38- cells in AML (n = 8) were rhodamine 123 
dull compared with the more differentiated CD34+CD38+ cells, but ABCB1 modula-
tion by verapamil did not increase intracellular retention (mean EI, 0.99 +/- 0.07; 
Fig. 3B). Of interest, analysis of mitoxantrone efflux mediated by the ABC transport-
ers ABCG2 (BCRP), done in a series of normal and leukemic bone marrow samples, 
including those described in this article, using the ABCG2-specific fumitremorgin C 
analogue KO143 as inhibitor, showed no difference between normal and leukemic 
CD34+CD38- cells (15), further showing that the observed decrease in mitoxantrone 
efflux is indeed due to deficient ABCB1 rather than ABCG2 activity.
Serial measurements both after 2 hours of drug exposure and after an additional 
hour in drug-free medium in a subpanel of AML samples (n = 10; Fig. 4B) showed 
significant extrusion of mitoxantrone in the presence of verapamil in the majority of 
patients, pointing in the direction of redundant drug extrusion mechanisms.
These redundant drug transport mechanisms, however, did not compensate for the 
reduced ABCB1-mediated transport from leukemic CD34+CD38- cells as suggested 
by the significantly higher mitoxantrone retention in leukemic CD34+CD38- cells 
compared with their counterparts in normal bone marrow after drug exposure and 
subsequent efflux in drug-free medium (MFI, 4.54 +/- 0.46 versus 3.08 +/- 0.23; 
P = 0.004). These findings strongly suggest that the decreased efficacy of ABCB1 
modulation on mitoxantrone retention of leukemic CD34+CD38- cells is indeed 
due to reduced ABCB1 activity rather than increased activity of other transport 
mechanisms, which would have resulted in similar or lower retention of mito- 
xantrone compared with their normal CD34+CD38- counterparts.
Translated to the clinical context, these data indicate that modulation of ABCB1 
has limited effect on mitoxantrone retention in leukemic CD34+CD38- cells due to 
reduced activity of ABCB1 in leukemic CD34+CD38- cells. Drug efflux from these 
cells occurs in the presence of ABCB1 modulation due to the activity of promiscuous 
transport mechanisms. 
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ABCB1-mediated drug transport identifies a subpopulation of residual normal 
CD34+CD38- hematopoietic stem cells in a patient with CBFB-MYH11-positive AML. 
The finding that impairment of ABCB1 function is biological commonality in 
CD34+CD38- cells in AML compared with normal bone marrow implies that, in AML, 
residual normal CD34+CD38- hematopoietic cells may be identified by their con-
served ABCB1-mediated transport capacity.
Indeed, during additional monitoring, one patient was identified with a clearly 
discernable CD34+CD38- mitoxantrone dull population caused by ABCB1-mediated 
drug efflux within the range observed in normal bone marrow (Fig. 5). Because the 
intracellular presence of mitoxantrone precluded the use of fluorescence in situ 
hybridization, we used real-time quantitative reverse transcription-PCR to quan-
tify the number of CBFB-MYH11 transcripts in these CD34+CD38- subpopulations. 
The number of transcripts in the CD34+CD38- ABCB1 efflux +/- cell population was 
Figure 5. ABCB1-mediated mitoxantrone transport identifies a subpopulation that harbors residual 
normal CD34+CD38- cells in a patient with CBFB-MYH11 AML. (For color reproduction: see chapter 10). 
A patient was identified in which mitoxantrone discriminated a population of CD34+CD38- mitoxantrone 
dull cells. The dull phenotype was determined by strong ABCB1-mediated efflux (CD34+CD38- ABCB1 
efflux ++) within the range observed in CD34+CD38- cells observed in normal bone marrow (EI, 2.50). 
Real-time PCR confirmed the residual normal character of these cells.
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similar to that in the positive control (blast population from CBFB-MYH11, type D–
positive patient; Xn, 4.3 - 10-3 versus 3.5 - 10-3 copies CBFB-MYH11/copy glyceral-
dehyde-3-phosphate dehydrogenase, respectively), whereas no transcripts were 
detected in the CD34+CD38- ABCB1 efflux ++ subpopulation. This sample provides 
proof of principle that conserved ABCB1-mediated drug efflux may indeed identify 
a subpopulation of CD34+CD38- cells that harbor residual normal cells at least in 
a subgroup of AML patients. This implies that modulation of ABCB1 preferentially 
targets these residual normal cells as shown in Fig. 5.
Discussion
In this report, we show that ABCB1-mediated drug transport is reduced in leukemic 
CD34+CD38- progenitor cells compared with their normal counterparts in AML. 
This finding was initially unanticipated because AML is generally considered to be 
an ABCB1-overexpressing malignancy with conserved physiologic function (25). 
This assumption, however, is based on the observation that ABCB1 is preferen-
tially expressed in CD34+ blasts in AML (26) similar to preferential expression of 
ABCB1 in these cells in normal bone marrow (27), thus reflecting similar patterns of 
expression rather than direct comparison of ABCB1 expression and function of 
normal and malignant cell subpopulations. Expression data in our study confirm the 
preferential expression of ABCB1 in CD34+ cells in AML (26) at levels comparable 
with those observed in normal bone marrow. ABCB1 transport capacity, however, 
was markedly impaired in both CD34+CD38- and CD34+CD38+ cells in AML.
The occurrence of ABCB1- protein+ efflux- leukemic blasts has been observed in 
a minority of AML cases (28) earlier, pointing in the direction of the presence of 
non-functional forms of the ABCB1 protein, but the current report, aimed at direct-
ly comparing ABCB1 function between normal and leukemic primitive progenitor 
cells, shows that impaired ABCB1 function is a biological commonality rather than 
an occasional finding in AML. 
The molecular determinants behind impaired ABCB1-mediated transport in 
hematopoietic cells in AML remain to be elucidated and may comprise both down-
stream event of oncoproteins central in leukemogenesis, such as AML1-ETO (29) and 
TEL-AML1 (30), and factors governed by the cellular environment, such as disruption 
of cellular ATP metabolism, membrane integrity, or cell cycle regulation (31).
Regardless of the underlying mechanism, the finding that ABCB1-mediated 
transport is impaired in CD34+CD38- cells in AML has important clinical implica-
tions. The recognition of AML as a disease originating from these cells dictates 
a paradigm shift in the treatment toward the eradication of this crucial stem cell 
population in AML.
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Our results indicate that ABCB1 modulation does not circumvent drug extrusion 
from these cells and that additional, redundant drug extrusion mechanisms deter-
mine the relatively dull mitoxantrone appearance of these cells. We have recently 
documented ABCG2/BCRP as one of these additional drug transporters in leuke-
mic CD34+CD38- cells (15). Additionally, using low-density real-time PCR arrays, 
we recently showed differential expression of all 13 ABC transporters currently as-
sociated with drug extrusion in CD34+CD38- cells in AML (32). These studies, how-
ever, did not show higher expression or function of these transporters in leukemic 
CD34+CD38- cells compared with their normal counterparts. This may explain the 
observation in this study that intracellular retention of mitoxantrone is increased in 
leukemic CD34+CD38- cells compared with their normal counterparts, suggesting 
that redundant mechanisms confer drug extrusion from leukemic cells but that this 
redundant action does not completely compensate for the reduced ABCB1 function 
in these cells.
The combined data suggest that the prognostic value of ABCB1, one of the main 
rationales for ABCB1 targeting in AML, may be pleiotropoic, identifying leukemias 
with a primitive CD34+ (CD38-) character and innate drug resistance due to dif-
ferential expression of many, promiscuous ABC transporters and possibly other 
mechanisms protecting primitive progenitor cells. Modulation of additional trans-
porters is therefore likely to be required to abrogate drug extrusion and to enhance 
drug induced eradication of leukemic stem cells in AML. These laboratory findings 
provide an alternative explanation for the poor results of ABCB1 modulation by the 
highly potent ABCB1 inhibitor PSC-833 and other inhibitors on long-term disease 
outcome in clinical trials (8–10). The report of improved clinical outcome in a trial 
using cyclosporine as an ABCB1 inhibitor in AML (13) may reflect these findings 
because cyclosporine is a more promiscuous ABC transporter inhibitor with effects 
on ABCB1 and other ABC transporters (33).
Additionally, the current study shows that residual normal CD34+CD38- cells are 
likely to harbor within the ABCB1 efflux ++ subpopulation. This seems congruent 
with the report (34) that the capacity to efflux Hoechst 33342 (side population) 
identifies a subpopulation of CD34+CD38- residual normal cells in AML, whereas 
CD34+CD38- Hoechst bright cells were leukemic. Although these authors could not 
relate Hoechst 33342 efflux with ABCB1 protein expression in the overall side popu-
lation of cells, this was not investigated in the CD34+CD38- subset. The current 
report shows that differences in ABCB1-mediated efflux discriminate normal from 
leukemic CD34+CD38- cells. This finding implies that ABCB1 modulation may pref-
erentially target residual normal hematopoietic cells, whereas drug extrusion from 
leukemic CD34+CD38- cells occurs through the activity of redundant mechanisms. 
Together, these data argue against the use of ABCB1 modulation as a strategy to 
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eradicate leukemic stem cells in AML but prompt further research to elucidate the 
mechanisms involved in the extrusion of drugs from leukemic CD34+CD38- cells to 
provide novel targets for the eradication of this crucial cell population in AML.
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Chapter 3
“Breast cancer resistance protein in drug resistance op primitive 
CD34+CD38- cells in acute myeloid leukemia”.
MHGP Raaij makers, EPLM de Grouw, LH Heuver, BA van der Reij den, JH Jansen, 
RJ Scheper, GL Scheff er, TJ de Witte, RAP Raymakers.
Clinical Cancer Research. 2005 Mar 15; 11(6): 2436-44.
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Abstract
Acute myeloid leukemia (AML) is considered a stem cell disease. Incomplete 
chemotherapeutic eradication of leukemic CD34+CD38- stem cells is likely to 
result in disease relapse. The purpose of this study was to investigate the role of 
the breast cancer resistance protein (BCRP/ATP-binding cassette, subfamily G, 
member 2) in drug resistance of leukemic stem cells and the effect of its modula-
tion on stem cell eradication in AML.
BCRP expression (measured flowcytometrically using the BXP21 monoclonal 
antibody) and the effect of its modulation (using the novel fumitremorgin C 
analogue KO143) on intracellular mitoxantrone accumulation and in vitro chemo-
sensitivity were assessed in leukemic CD34+CD38- cells.
BCRP was preferentially expressed in leukemic CD34+CD38- cells and blockage 
of BCRP-mediated drug extrusion by the novel fumitremorgin C analogue KO143 
resulted in increased intracellular mitoxantrone accumulation in these cells in the 
majority of patients. This increase, however, was much lower than in the mito- 
xantrone-resistant breast cancer cell line MCF7-MR and significant drug extrusion 
occurred in the presence of BCRP blockage due to the presence of additional drug 
transport mechanisms, among which ABCB1 and multiple drug resistance protein. 
In line with these findings, selective blockage of BCRP by KO143 did not enhance in 
vitro chemosensitivity of leukemic CD34+CD38- cells.
These results show that drug extrusion from leukemic stem cells is mediated by 
the promiscuous action of BCRP and additional transporters. Broad spectrum 
inhibition, rather than modulation of single mechanisms, is therefore likely to be 
required to circumvent drug resistance and eradicate leukemic stem cells in AML.
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Introduction
Cancer is increasingly recognized as a disease originating from the transforma-
tion of normal stem cells, retaining the capacity for self-renewal (1). This emerging 
concept for the origin of tumorigenesis was stimulated by the postulation of acute 
myeloid leukemia (AML) as a stem cell disease. Cells with leukemic stem cell char-
acteristics, defined as leukemic engraftment potential and self-renewal capacity, in 
AML are found in the CD34+CD38- cell population. The involvement of CD34+CD38- 
cells in leukemogenesis is suggested by the presence of cytogenetically aberrant 
cells in the CD34+CD38- compartment as shown by fluorescence in situ hybridiza-
tion and PCR for leukemia specific translocations (2, 3). Additionally, leukemic cells 
with long-term proliferative ability both in vitro and in vivo have been identified as 
CD34+CD38- (4). Studies using the nonobese diabetic/severe combined immuno-
deficient mouse model have shown that cells with leukemic engraftment and self-
renewal potential in acute myelogenous leukemia are found in the CD34+CD38- sub-
population (5, 6) and not in more differentiated CD34+CD38+ cells. These studies 
strongly argue that leukemia-initiating transformation and progression-associated 
genetic events occur at the level of these primitive cell populations. Importantly, 
incomplete chemotherapeutic eradication of cancer stem cells is likely to result in 
disease relapse. Elucidation of the mechanisms conferring resistance to these cells 
is therefore essential to provide novel targets for stem cell eradication in AML.
The ATP-binding cassette protein family is a large family of highly conserved 
membrane proteins transporting a wide variety of substrates across the cell 
membrane (7). Several members, among which multidrug resistance 1 [MDR1; ATP 
binding cassette, subfamily B, member 1 (ABCB1)] and breast cancer resistance 
protein [BCRP; ATP-binding cassette, subfamily G, member 2 (ABCG2)], extrude a 
variety of structurally unrelated chemotherapeutic compounds, thereby conferring 
a multidrug resistance phenotype to cancer cells.
BCRP (ABCG2) is a 655-aa member of the ABCG subfamily of ATP-binding cassette 
membrane transporters first described in drug-resistant cell lines (8-10). BCRP is a 
half transporter functioning as a dimer and confers multidrug resistance to topo-
tecan, mitoxantrone, doxorubicin, and related compounds by ATP-dependent drug 
extrusion (9, 11). BCRP is expressed in placental syncytiotrophoblasts, intestinal 
epithelium, and liver canicular membrane (12), suggesting a physiologic role in 
detoxification. Recently, BCRP has been shown to be highly expressed in a wide 
variety of stem cells (13) including immature human hematopoietic progenitors 
(14). BCRP is proposed to protect these long-lived cells from naturally occurring 
toxic substrates (15).
KO143 is a novel fumitremorgin C analogue which has recently been shown to be 
an extremely potent BCRP inhibitor (16). KO143 is a specific inhibitor of BCRP and 
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much more potent than currently known inhibitors of BCRP such as fumitremorgin 
C (17) and GF120918 (18). Importantly, KO143 is nontoxic at effective in vitro and 
in vivo concentrations, which makes it one of the most promising compounds for 
development of clinical modulators of BCRP-mediated efflux. The purpose of the 
current study was to investigate the role of BCRP in drug resistance of leukemic 
CD34+CD38- stem cells and the effect of its modulation on stem cell eradication in 
AML.
Materials and Methods
Bone Marrow Samples and CD34+CD38- Hematopoietic Cells.
Bone marrow was obtained after informed consent from healthy allogeneic bone 
marrow donors and patients with AML at diagnosis. Patient characteristics are 
shown in Table 1. Mononuclear cells were isolated by density gradient centrifu-
gation using Ficoll 1.077 g/mL (Pharmacia Biotech, Uppsala, Sweden). Isolation, 
cryopreservation, and thawing procedures of cells have been previously described 
(19) and were identical for normal and leukemic bone marrow samples. After thaw-
ing, cells were stained with FITC- or CY5-labeled CD34 and CD38-phycoerythrin 
monoclonal antibodies (Becton Dickinson BV, Etten-Leur, the Netherlands) for 30 
minutes at 4°C and washed in HBSS with 1% v/v heat-inactivated FCS (Hyclone, 
Logan, UT). A Coulter Epics Elite Flow cytometer was used to define cell popula-
tions. Gating on forward and right angle scatter was used to exclude dead cells 
and debris. CD34+CD38- cells of both normal bone marrow and AML were de-
fined as the cells with CD38-phycoerythrin fluorescence within the first decade of 
emission. CD34+CD38-cells appeared in a consistently restricted lightscattering 
Table 1 Patient characteristics
N 22
Sex
   Male 12
   Female 10
Age, median (range) 52 (20-68)
% CD34 40 (3-88)
French-American-British
   M1 5
   M2 12
   M4 1
   M5 4
Cytogenetics
   Normal 12
   t(8,21) 4
   t(11,19) 1
   +8 2
   Complex 3
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region confirming the lymphoid appearance of these primitive progenitors (20). 
The CD34+CD38+ cells were sorted from a gate positioned in the bulk of CD34+ 
cells and showed more heterogeneous light-scattering properties.
Breast Cancer Resistance Protein Cell Line.
The human breast cancer cell line MCF7-MR (gift from R. Scheper, Free University 
Hospital, Amsterdam, the Netherlands) is resistant to mitoxantrone and over- 
expresses BCRP but not multiple drug resistance protein (MRP, ABCC1) and ABCB1 
(21). MCF7-MR cells were cultured in RPMI 1640 supplemented with 10% FCS in the 
presence of 80 nmol/L mitoxantrone.
Breast Cancer Resistance Protein Expression. 
BCRP was detected with the BXP21 monoclonal antibody (gift from R. Scheper), 
which recognizes an internal epitope of the protein (12) and has been shown to 
Figure 1 BCRP expression and BCRP-mediated mitoxantrone efflux in MCF7-MR cells. A, flow cytometric 
assessment of BCRP expression using secondary FITC-labeled F(ab)2 fragments against monoclonal 
antibody BXP21 (dotted line) or isotype control. B, mitoxantrone fluorescence (y axis) in the presence 
(dotted line) or absence of the BCRP specific inhibitor KO143 (0.1 µmol/L) after 2-hour accumulation (B1) 
and an additional hour of efflux in drug-free medium (B2).
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specifically bind BCRP, displaying no cross-reactivity with other proteins (12). 
In AML patient samples, BXP21 was more sensitive than BXP34, another BCRP- 
specific monoclonal antibody (22). BXP21 was used in a three-color flow cytometric 
assay, which in preliminary experiments proved to be much more sensitive than 
immunocytochemical assessment using immunofluorescence microscopy, as 
previously recognized for other ATP-binding cassette transporters (23). First, cells 
(1 x106) were fixed and permeabilized (“Fix & Perm,” Caltag Lab.,Burlingame, CA) 
according to the instructions of the manufacturer, and subsequently washed in 
HBSS 1% FCS. Following fixation, cells were blocked with pooled human serum for 
10 minutes and incubated with BXP21 (2.5 µg/mL) or isotype control IgG2a in the 
same concentration for 60 minutes at 4°C. BXP21 was detected by FITC-conjugated 
goat anti-mouse F(ab)2 fragments (5.0 µg/mL) for 30 minutes. A 10-minute incuba-
tion with goat serum to block nonspecific binding was followed by staining with 
CY5-conjugated CD34 and phycoerythrinconjugated CD38. Appropriate BCRP iso-
type control at the same protein concentration as the relevant antibody was used 
as control. BCRP protein expression was quantitated as the median fluorescence 
channel shift (BXP21/isotype control). 
ABCG2 Gene Expression.
RNA was isolated from subfractions (105 cells) of granulocyte colony-stimulating 
factor-mobilized CD34+ hematopoietic cells using cDNA synthesis and real-time 
quantitative reverse transcription-PCR was done as described previously (24). 
ABCG2 target gene expression was quantitated relatively to housekeeping genes 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and hydroxymethylbilane 
synthase (HMBS) as described previously (24). We earlier showed that GAPDH 
is an appropriate gene for standardization of target gene expression in human 
CD34+CD38- and CD34+CD38+ hematopoietic cell populations (24).
Primer and probe sequences for gene amplification were ABCG2, Taqman gene 
expression assay (Applied Biosystems, Foster City, CA) no. HS 00184979; GAPDH, 
Taqman gene expression assay (Applied Biosystems) no. HS 99999905; and HMBS, 
Taqman gene expression assay (Applied Biosystems) no. HS 00609297.
Breast Cancer Resistance Protein-Mediated Mitoxantrone Efflux.
BCRP function was tested using mitoxantrone as a substrate and the fumitremorgin 
C analogue KO143 as an inhibitor for BCRP. Mitoxantrone, rather than an anthra-
cyclin, was used as a substrate because mitoxantrone seems to be a more sensi-
tive substrate to detect BCRP-mediated efflux as suggested by resistance profiles 
in cell line models (8, 11). The novel fumitremorgin C analogue KO143 (0.1 µmol/L) 
was used as a specific inhibitor for BCRP-mediated efflux. KO143 was shown to be 
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Figure 2 Characteristic examples of flow-cytometric assessment of BCRP expression and BCRP-
mediated mitoxantrone efflux in CD34+CD38- hematopoietic in normal bone marrow and 
AML. (For color reproduction: see chapter 10) A, definition of CD34+CD38- hematopoiet-
ic cells in human normal bone marrow and AML. CD34+CD38- cells were defined flow-cyto-
metrically as the CD34-expressing cells (blue) with CD38 expression within the first decade 
of fluorescence emission (red) and compared with CD34+CD38+ cells (blue gated) with an 
exclusion of a decade between CD38- and CD38+. CD34- cells are shown in grey. CD34+CD38- cells 
were found invariably in both normal bone marrow (A1) and CD34+ (> 10% CD34+ cells in bone marrow 
by definition, A2) and CD34- leukemias (A3). The median frequency of CD34+CD38- cells was 0.1% of 
mononuclear cells in normal bone marrow (range 0.1-0.3%) and 0.2% in acute myeloid leukemia (range 
0.1-10 %). B, cellular mitoxantrone fluorescence in different cell populations after 2-hour incubation 
with mitoxantrone (10 µmol/L) in the absence of BCRP inhibitor. CD34+CD38- cells have a mitoxantrone 
“dull” phenotype. C, BCRP protein expression in CD34+CD38- cells as determined by the BXP21 
antibody (dotted line) versus isotype control. D, mitoxantrone fluorescence in CD34+CD38- cells in the 
presence (dotted line) or absence of the BCRP specific inhibitor KO143 (0.1 µmol/L).
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the most potent inhibitor currently available and, importantly, is BCRP-specific 
(without inhibition of ABCB1 or ABCC1) at the concentration used in our assay (16). 
Flow cytometric measurement of fumitremorgin C-sensitive mitoxantrone efflux has 
been shown to be a sensitive and specific method for measuring the function of 
BCRP in both selected and unselected cell lines (25). 
Cells were stained with CD34-FITC and CD38-phycoerythrin membrane markers, 
washed in HBSS 1% FCS, and preincubated with or without BCRP inhibitor for 20 
minutes in Iscove’s modified Dulbecco’s medium supplemented with 1% FCS. 
Mitoxantrone (10 µmol/L) was added and cells were incubated for 2 hours at 37°C, 
5% CO2, with or without inhibitor. Subsequently, cells were washed in ice-cold 
HBSS 1% FCS and kept on ice until flow-cytometric analysis or allowed an additional 
1-hour efflux in drug-free medium with or without inhibitor to further enhance sen-
sitivity of the assay. Cellular mitoxantrone fluorescence was measured on a FACS-
elite cytometer equipped with an argon laser. Fluorescence was assessed at an 
excitation wavelength of 635 nm through a 670- nm band-pass filter in a three-color 
protocol with CD34-FITC and CD38-phycoerythrin. At least 200 CD34+CD38- cells 
were analyzed in each sample.
BCRP-mediated efflux was quantitated as the ratio of mitoxantrone fluorescence 
[mean fluorescence intensity (MFI)] in the presence or absence of KO143 and 
assessed in CD34+CD38-, CD34+CD38+, and CD34- cells as defined. Interexperi-
mental variability was assessed by performing triplicate, independently done, 
experiments in a panel of four different normal bone marrow samples. BCRP- 
mediated efflux, assessed in 200 CD34+CD38- cells and indicated as an efflux 
index, was 1.05 +/- 0.03 (mean +/- SE), 0.88 +/- 0.06, 1.11 +/- 0.02, and 1.09 +/- 
0.03 in these samples. Based on the average SE (0.036) observed in these prelimi-
nary experiments, a cut off level of efflux index 1.05 was used to define significant 
BCRP-mediated efflux in individual samples.
ABCB1- and ABCC1-Mediated Drug Efflux. 
Flow cytometric assessment of ABCB1- and ABCC1-mediated mitoxantrone efflux 
was done as described above using verapamil (20 µg/mL; Knoll AG, Ludwigshaven, 
Germany) and probenecid (0.5 mmol/L) as inhibitors for ABCB1 and ABCC1, respec-
tively.
Fluorescence In situ Hybridization.
CD34+CD38- cells were sorted and lysed in 15 µL KCl (75 µmol/L) on a glass coverslip. 
Cells were fixed in methanol/acetic acid and stored at 4°C until analysis. Fluorescence 
in situ hybridization was done using the LSI AML1/ETO Dual Color, Dual Fusion t(8;21) 
Probe or the LSI EGR1 (5q31) Dual Color Probe (Vysis, Downers Grove, IL) according to 
65
Chapter 3
the instructions of the manufacturer. One-hundred cells were analyzed microscopi-
cally for t(8;21) or chromosome 5 (5q31) cytogenetic abnormalities, as appropriate. 
Ninety-six-Well Chemosensitivity Assay. 
CD34+CD38- cells were sorted in 96-well, round-bottomed, plates (200 cells/well) 
containing Iscove’s medium supplemented with 10% FCS without or with mitoxan-
trone (1.0 µmol/L) and without or with KO143 in different concentrations (0.1, 1.0, 
and 10.0 µmol/L). Plates were incubated at 37°C, 5% CO2 for 48 hours. All experi-
ments were done in quadruplicate. Cell apoptosis was assessed at 24 and 48 hours 
using propidium iodide as a cell death marker. Cell images were acquired on a Zeiss 
Axiovert 35M inverted microscope (Thorwood, NY) equipped with a 40- oil (N.A. 1.3) 
objective and a cooled 756 - 580 pixel resolution CDD camera (Variocam, PCO com-
puter optics, Kellheim, Germany) coupled with the pixel pipeline in a Macintosh 
Quadro 800. Cells were excited with a mercury arc lamp using a 510- to 560-nm 
band-pass filter for propidium iodide. Emission was measured with a 610-nm long-
pass filter. 
Figure 3 BCRP is preferentially expressed and functionally active in CD34+CD38- hematopoietic cells in 
human normal bone marrow. A, BCRP expression indicated as BXP21/IgG2a isotype control. Columns, 
mean values; lines, individual samples. ABCG2 expression is higher in CD34+CD38- cells compared with 
more differentiated CD34+CD38+ progenitors and CD34- cells [7.95 +/- 1.32, 6.81 +/- 0.98 (P = 0.05), 
and 3.36 +/- 0.62 (P < 0.001), respectively]. B, BCRP-mediated mitoxantrone efflux indicated as efflux 
index (EI) in different hematopoietic subpopulations.
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Statistical Analysis. 
The Student’s t test was used to calculate significant differences. Correlations 
were calculated using correlation coefficients. Data are presented as mean +/- SE. 
P < 0.05 was considered significant. 
Results
Breast Cancer Resistance Protein Expression and Breast Cancer Resistance Protein-
Mediated Mitoxantrone Efflux in MCF7-MR Cells
BCRP expression in the MCF7-MR cell line, indicated as BXP21/IgG2a isotype con-
trol, using the current protocol was 44.7 +/- 4.5 (mean +/- SD of three experiments; 
Fig. 1A). BCRP mediated efflux was examined using KO143 as a specific inhibitor of 
BCRP. KO143 has been shown to be specific for ABCG2 at concentrations of 0.1 to 
1.0 µmol/L, with no inhibition of ABCB1 (P-glycoprotein) or ABCC1 at these concen-
trations (16). The effect of KO143 on cellular mitoxantrone (10 µmol/L) fluorescence 
in MCF7-MR cells, measured after 2-hour accumulation with or without inhibitor, 
is shown in Fig. 1B. Mitoxantrone fluorescence (MFI) of MF7-MR cells after 2-hour 
accumulation without mitoxantrone and in the presence of mitoxantrone without 
Figure 4 ABCG2 is highly expressed in normal hematopoietic stem cells. ABCG2 expression was assessed 
in different subfractions from granulocyte colony-stimulating factor-mobilized peripheral blood in two 
normal donors and quantitated relative to the housekeeping genes HMBS and GAPDH (y axis; copies 
ABCG2/copy HMBS/GAPDH).
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and with KO143 were 0.4 +/- 0.1 (SD), 9.1 +/- 0.3, and 28.5 +/- 6.7, respectively 
(n = 3). The mean BCRP-mediated mitoxantrone efflux, indicated as a fluorescence 
shift index, was 3.13 +/- 0.62. Mitoxantrone efflux during an additional hour in drug-
free medium was completely blocked by KO143, illustrating the potency of KO143 as 
a BCRP inhibitor and the increasing sensitivity of BCRP efflux assessment in the 
MCF7 cell line (mean efflux index, 5.70 +/- 0.35; Fig. 1C). Importantly, these data 
confirm that KO143 at the concentration used in our assays (0.1 µmol/L) completely 
blocks BCRP-mediated mitoxantrone efflux, as shown earlier (16).
Breast Cancer Resistance Protein Is Preferentially Expressed and Functionally Active 
in Primitive CD34+CD38- Hematopoietic Cells in Human Normal Bone Marrow
In order to compare BCRP expression and function in normal and malignant 
hematopoietic stem cells, first, ABCG2 expression was assessed in hematopoietic 
subpopulations in seven normal bone marrow samples (Figs. 2 and 3). CD34+CD38- 
cells were flow-cytometrically defined as indicated in Fig. 2A. ABCG2 expression 
was higher in CD34+CD38- cells (mean BXP21/IgG2a index, 7.95 +/- 1.32) compared 
with more differentiated CD34+CD38+ progenitors (6.81 +/- 0.98; P = 0.05, using 
Figure 5 BCRP is preferentially expressed and mediates mitoxantrone efflux in CD34+CD38- hemato- 
poietic cells in AML. BCRP expression (A), indicated as BXP21/IgG2a isotype control, and BCRP-mediated 
mitoxantrone efflux (B), indicated as efflux index, in different hematopoietic subpopulations. Columns, 
mean values; lines, individual samples. 
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Student’s t test for paired samples) and sharply decreased during further differen-
tiation in CD34- cells (3.36 +/- 0.62; P < 0.001; Fig. 3A).
To provide additional evidence that BCRP is preferentially expressed in CD34+CD38- 
hematopoietic cells in comparison with committed progenitors and differenti-
ated cells, ABCG2 gene expression was assessed in these cell populations using 
real-time quantitative reverse transcription-PCR. Because bone marrow samples 
yielded insufficient cell numbers to reliably perform real time quantitative reverse 
transcription-PCR on the relatively low copy transcript ABCG2, we used granulocyte 
colony-stimulating factor-mobilized peripheral blood CD34+ cells obtained from 
two normal controls. ABCG2 expression was assessed relatively to housekeeping 
genes as previously described (24) in CD34+CD38-, CD34+CD38+, and differenti-
ated cells (monocytes; Fig. 4).
These results confirm, in an independent assay, that primitive hematopoietic stem 
cells express high levels of BCRP, in line with previous reports (14, 26).
Next, we investigated BCRP-mediated efflux in CD34+CD38-, CD34+CD38+, and 
CD34- hematopoietic subpopulations using mitoxantrone as a substrate; cellular 
mitoxantrone fluorescence (MFI) after 2 hours of mitoxantrone accumulation was 
low in CD34+CD38- cells compared with more differentiated CD34+CD38+ progeni-
tors and CD34- cells (4.4 +/- 0.29, 9.29 +/- 0.83, and 7.63 +/- 0.55, respectively). 
BCRP-mediated mitoxantrone efflux contributed to the mitoxantrone “dull” appear-
ance of primitive CD34+CD38- cells as evidenced by the ability of KO143 to increase 
fluorescence intensity. Significant BCRP-mediated efflux, defined as a mitoxantro-
ne fluorescence (MFI) index without or with KO143 (0.1 µmol/L) ≥ 1.05 (see Materials 
and Methods), was found in CD34+CD38- cells in 5 of 7 (71%) samples. In 2 of 7 
samples no ABCG2-mediated efflux was found in either hematopoietic subpopula-
Figure 6 Specific inhibition of BCRP does not increase mitoxantrone-induced apoptosis in primitive 
leukemic CD34+CD38- hematopoietic cells. Effect of KO143 on mitoxantrone-induced apoptosis in 
leukemic CD34+CD38- cells. Typical example of microscope images of leukemic CD34+CD38- cells of a 
patient in the presence or absence of mitoxantrone and KO143. Apoptotic (propidium iodide-positive) cells 
are depicted in black (negative images). (DFM, drug-free medium; MITO, mitoxantrone alone; +KO143, 
mitoxantrone in the presence of KO143 at different concentrations).
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tion. In those samples displaying BCRP-mediated efflux, this was invariably and 
significantly higher in CD34+CD38- cells compared with CD34+CD38+ and CD34- 
cells [mean efflux index: 1.22 +/- 0.08, 1.13 +/- 0.04 (P = 0.03), and 1.11 +/- 0.03 (P 
= 0.03), respectively; Figs. 2 and 3B].
These data show that BCRP is preferentially expressed and functionally active in 
primitive CD34+CD38- hematopoietic cells compared with more differentiated cells 
in human normal bone marrow.
Breast Cancer Resistance Protein Expression and Function Is Conserved in Primitive 
Leukemic CD34+CD38- Hematopoietic Cells in Acute Myeloid Leukemia
BCRP expression was assessed in different hematopoietic subpopulations in 22 
de novo AML samples (Figs. 2 and 5). Expression was higher in CD34+CD38- cells 
compared with more differentiated CD34+CD38+ and CD34- cell populations in 19 of 
22 samples investigated. Mean BCRP expression was 9.00 +/- 1.01 (range 1.59-21.4), 
6.53 +/- 0.68 (range 2.84-14.89; P < 0.001), and 5.75 +/- 0.58 (range 1.66-10.13; 
P < 0.001), respectively. BCRP expression in CD34+CD38- cells in AML was not 
significantly different from the expression in these cells in normal bone marrow 
(P = 0.30). These results indicate that BCRP is preferentially expressed in primitive 
CD34+CD38- cells in the majority of AML samples, similar to the expression profile 
in  normal bone marrow. We next investigated whether the preferential expression 
of ABCG2 in leukemic CD34+CD38- cells was reflected by increased ABCG2-mediated 
transport in these cells. In AML, similar to the situation in normal bone marrow, 
CD34+CD38- hematopoietic cells accumulated the lowest amount of mitoxantrone 
relative to more differentiated CD34+CD38+ and CD34- cell populations (MFI: 
6.6 +/- 0.49, 10.0 +/- 0.66, and 10.34 +/- 0.74, respectively). To determine the 
contribution of BCRP-mediated efflux to the mitoxantrone “dull” phenotype of 
leukemic CD34+CD38- cells, ABCG2-mediated mitoxantrone efflux was assessed 
Table 2
Patient Cytogenetics CD34+CD38- aberrant cells (%) ABCG2 ABCG2-mediated transport
1 -5q31 56 4.95 0.94
2 t(8;21) 90 1.59 1.22
3 t(8;21) 90 NA 1.10
4 t(8;21) 100 3.19 1.03
5 t(8;21) 95 8.52 1.18
Table 2. BCRP is expressed and mediates mitoxantrone efflux in leukemic CD34+CD38- cells. Note: BCRP 
expression (BXP21/IgG2a) and BCRP-mediated mitoxantrone efflux (indicated as efflux index) relative to 
percentage of cytogenetically aberrant cells in the CD34+CD38- cell population in AML. Abbreviation: 
NA, no material available for analysis.
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in 22 leukemic bone marrow samples using KO143 (0.1 µmol/L) as an inhibitor. 
In the majority of samples (14/22 = 64%), BCRP-mediated efflux was detected in 
CD34+CD38- cells. The remaining 8 samples displayed no BCRP-mediated efflux in 
either cell population. In the samples displaying BCRP-mediated efflux, efflux was 
significantly higher in CD34+CD38- cells compared with CD34+CD38+ and CD34- 
cells [efflux index: 1.20 +/- 0.03, 1.08 +/- 0.02 (P = 0.003), and 1.06 +/- 0.002 
(P = 0.001), respectively; Fig. 5B]. The differences remain significant when the 
overall population (n = 22) is considered [efflux index: 1.11 +/- 0.04, 1.03 +/- 0.02 
(P = 0.005), and 1.02 +/- 0.02 (P = 0.003), respectively]. No significant differences 
were found when BCRP-mediated efflux in different subpopulations in AML was 
compared with these populations in normal bone marrow. No correlation existed 
between BCRP expression or ABCG2-mediated mitoxantrone efflux and mitoxantrone 
accumulation in leukemic CD34+CD38- cells (r -0.22 and -0.27, respectively).
The CD34+CD38- cell population in AML harbors residual normal CD34+CD38- cells 
(27). To exclude the possibility that the expression and function of ABCG2 is pres-
ent in residual normal cells, rather than leukemic cells, within the CD34+CD38- cell 
compartment in AML, we did fluorescence in situ hybridization analysis on leuke-
mia-associated cytogenetic aberrations in these cells (n = 5). Table 2 shows that 
either BCRP expression or efflux is present in CD34+CD38- cells with predominantly 
leukemic cells within this compartment (samples 2-5). Together, these results show 
that BCRP is preferentially expressed and functionally active in primitive leukemic 
hematopoietic CD34+CD38- cells in the majority of patients. This phenotype reflects 
a conserved physiologic function, similar to the situation in normal bone marrow.
Additional Transporters Are Involved in Drug Efflux in Leukemic CD34+CD38- 
Hematopoietic Cells.
The relatively small effect of BCRP blockage by KO143 on cellular mitoxantrone con-
centration and the lack of correlation between BCRP expression or BCRP-mediated 
drug efflux and mitoxantrone fluorescence in leukemic CD34+CD38- cells suggest 
that BCRP is not the major determinant of the intracellular drug concentration in 
these cells. To assess the contribution of other transporters to mitoxantrone efflux 
in leukemic CD34+CD38- cells, we investigated whether mitoxantrone efflux took 
place in CD34+CD38- cells in the presence of BCRP blockage. For this purpose, cells 
were incubated with mitoxantrone (10 µmol/L) with KO143 (0.1 µmol/L) for 2 hours 
and subsequently allowed to efflux mitoxantrone in drug-free medium for an ad-
ditional hour in the presence of KO143 (0.1 µmol/L). In all AML samples (n = 10) mi-
toxantrone fluorescence (MFI) in CD34+CD38- cells decreased during the additional 
hour of efflux with an MFI decrease of 20 +/- 12% (mean +/- SD). When cells were 
put on ice after mitoxantrone accumulation to block active transport, no decrease 
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in cellular mitoxantrone was observed. The observation that KO143 in BCRP blocking 
concentration cannot completely abrogate drug efflux in CD34+CD38- cells indi-
cates that additional transporters are mediating mitoxantrone efflux in these cells.
To assess the role of other ATP-binding cassette transporters in drug extrusion 
from leukemic stem cells, ABCB1- and ABCC1-mediated mitoxantrone efflux was 
assessed in these 10 samples displaying drug efflux in the presence of BCRP inhi-
bition (Table 3). CD34+CD38- cells in 8 of 10 samples displayed either significant 
ABCB1- or ABCC1-mediated transport or both. The combined effect of ABCB1 and 
ABCC1 inhibition on mitoxantrone accumulation exceeded the effect of BCRP block-
age in all these samples. Additionally, the observation that drug efflux occurs in the 
presence of BCRP blockage in a sample with only BCRP-mediated efflux (sample 4) 
and a sample in which no ATP-binding cassette transporter activity could be shown 
(sample 2) suggests the presence of yet unidentified drug extrusion mechanisms.
Together these results indicate that BCRP is not the predominant drug efflux mecha-
nism in leukemic CD34+CD38- stem cells and that other mechanisms, among which 
ABCB1 and ABCC1, play a role in drug efflux from leukemic stem cells.
Modulation of Breast Cancer Resistance Protein by the Fumitremorgin C Analogue 
KO143 Does Not Enhance Drug-Induced Apoptosis in Leukemic CD34+CD38- Cells
Because inhibition of BCRP with KO143 (0.1 µmol/L) increases mitoxantrone con-
centration only moderately in primitive CD34+CD38- leukemic cells compared with 
the drug resistant MCF-7 cell line, and other drug transporters are active in these 
leukemic cells, we raised the question whether selective modulation of BCRP could 
Table 3
Patient BCRP (ABCG2) ABCB1 ABCC1
1 1.27 1.25 1.51
2 NS NS NS
3 NS 1.15 NS
4 1.22 NS NS
5 1.10 1.13 NS
6 1.10 NS 1.12
7 NS 1.15 NA
8 1.08 NS 1.10
9 1.08 1.19 1.28
10 NS 1.12 NS
Mean +/- SE 1.14 +/- 0.03 1.17 +/- 0.02 1.25 +/- 0.09
Table 3. Additional drug efflux mechanisms are involved in mitoxantrone efflux from leukemic CD34+CD38- 
cells. Note: ABCB1 and ABCC1-mediated mitoxantrone efflux, indicated as efflux index, in leukemic 
CD34+CD38- cells. Abbreviations: NS, not significant (defined as efflux index < 1.05); NA, no material 
available for analysis.
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enhance chemosensitivity of these cells. To investigate this, a 96-well cytotoxicity 
assay was employed on sorted CD34+CD38- cells in five AML samples that displayed 
BCRP-mediated drug efflux [median efflux index, 1.25 (1.21-1.37); Figs. 6 and 7]. 
Mitoxantrone (1.0 µmol/L) significantly induced apoptosis in leukemic CD34+CD38- 
cells at 48 hours of incubation in all samples (relative increase in apoptotic cells 
compared with drug-free medium, 1.66 +/- 0.23; P = 0.007; Fig. 6). KO143 at 
concentrations that completely block BCRP-mediated efflux (0.1-1.0 µmol/L; as 
shown in the MCF7-MR cell line) did not significantly increase drug-induced apop-
tosis (relative increase: 1.81 +/- 0.32 and 1.87 +/- 0.37, respectively). Enhanced 
apoptosis when KO143 was used at high concentration (10 µmol/L; average 
increase, 2.57 +/- 0.58; Fig. 6) likely reflected intrinsic toxicity of the compound 
rather than modulation of drug efflux mechanisms, as shown by increased apoptosis 
in controls lacking mitoxantrone and the observation that KO143 at 10 µmol/L did 
not further increase intracellular mitoxantrone concentration in drug accumulation 
assays (data not shown).
These results argue that specific modulation of BCRP, although functionally 
active in these samples, does not significantly enhance drug-induced apoptosis in 
leukemic CD34+CD38- cells.
Figure 7 Specific inhibition of BCRP does not increase mitoxantrone induced apoptosis in primitive 
leukemic CD34+CD38- hematopoietic cells. Mitoxantrone-induced cell death depicted as relative increase 
in apoptotic cells in sorted CD34+CD38- cells in the presence or absence of KO143. Values represent the 
mean +/- SE of five patients. White columns, control experiments with KO143 at different concentrations 
in the absence of mitoxantrone. No significant increase in mitoxantrone induced apoptosis is seen when 
KO143 is added in BCRP specific concentrations (0.1-1.0 µmol/L). Enhanced apoptosis when KO143 was 
used at high concentration (10 µmol/L) reflects intrinsic toxicity of the compound as shown by increased 
apoptosis in controls lacking mitoxantrone.
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Discussion
Incomplete eradication of cancer stem cells is likely to result in disease relapse. 
Elucidation of the mechanisms conferring chemoresistance to these cells is there-
fore of major importance. In this report, we show that the ATP-binding cassette 
transporter BCRP/ABCG2 is preferentially expressed in the leukemic CD34+CD38- 
stem cell subpopulation and contributes to mitoxantrone efflux in these cells.
Recently, several studies have addressed the expression of BCRP in leukemic blasts 
in AML (22, 26). Abott et al. (26) found relatively low levels of ABCG2 gene expres-
sion compared with drug-resistant ABCG2 clones in newly diagnosed adult AML 
patients. Flow cytometry revealed very small subpopulations of BCRP-expressing 
cells, suggesting that BCRP expression may be limited to a small cell subpopu-
lation. Similar findings have been reported by Sargent et al. (28) who showed, 
using immunocytochemistry with the BXP34 antibody, that BCRP is expressed in a 
minority of leukemic cells in AML. Although the results of these studies suggested 
the possibility of high BCRP expression in a small subpopulation of cells, until now 
the subpopulations of BCRP expressing cells in AML had not been identified. We 
here show that BCRP is preferentially expressed in a subpopulation of primitive 
CD34+CD38- leukemic cells, which have been previously shown to comprise leu-
kemic stem cells. BCRP expression and efflux in leukemic CD34+CD38- cells was 
not different in expression and function from normal CD34+CD38- cells. This shows 
that the high BCRP expression in leukemic CD34+CD38- cells reflects a conserved 
physiologic function of BCRP in primitive hematopoietic cells rather than being a 
leukemia-associated phenotype. BCRP has been previously shown to be highly 
expressed in a wide variety of human normal stem cells (13), including hematopoietic 
stem cell populations (14), and is believed to protect these long-lived cells against 
genetic damage induced by naturally occurring xenobiotic toxins (15).
Incomplete chemotherapeutic eradication of leukemia initiating CD34+CD38- cells 
due to intrinsic chemoresistance is likely to result in disease relapse in AML. The 
preferential expression in the majority of newly diagnosed AML patients suggested 
that BCRP might be a target for stem cell eradication in AML. To test this hypothesis, 
we assessed the effect of BCRP modulation on the chemosensitivity of leukemic 
CD34+CD38- cells. Importantly, selective blockage of ABCG2 by KO143, the most 
potent BCRP inhibitor currently available (16) and capable of completely blocking 
BCRP as confirmed in the MCF7-MR cell line, did not increase mitoxantrone-induced 
apoptosis to leukemic CD34+CD38- cells. This lack of a chemosensitizing effect of 
BCRP modulation by KO143 was anticipated by several observations in this study. 
First, BCRP expression and ABCG2-mediated efflux were not correlated with intra-
cellular mitoxantrone accumulation in CD34+CD38- cells, suggesting that other 
determinants are involved in the mitoxantrone “dull” phenotype. Second, BCRP 
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expression and the effect of KO143 on mitoxantrone accumulation were moder-
ate in leukemic CD34+CD38- cells compared with the drug-resistant MCF7-MR cell 
line in which BCRP confers resistance to mitoxantrone. Finally, we observed 
substantial drug efflux in leukemic CD34+CD38- cells in the presence of BCRP 
inhibition, demonstrating that other drug transporters, among which ABCB1 and 
ABCC1, are active in these cells. The presence of these promiscuous drug extru-
sion mechanisms might provide an explanation for the poor correlation between 
BCRP expression and function reported in literature (22, 29) and the observation in 
this study that KO143 increased mitoxantrone accumulation in only 64% of samples 
expressing ABCG2.
Together, these findings argue that selective modulation of BCRP is not sufficient 
to circumvent resistance of leukemic CD34+CD38- cells. Alternatively, we cannot 
completely exclude the possibility that KO143 does not completely inhibit BCRP in 
leukemic cells. The report that KO143 is the most potent BCRP inhibitor known thus 
far in a panel of tested cell lines and our finding that it completely blocks efflux in 
the MCF7-MR cell line argue against this possibility.
Simultaneous modulation of several transporters, among which BCRP, could be 
required to sufficiently increase drug accumulation and eradicate CD34+CD38- stem 
cells in AML. The report of improved clinical outcome in a trial using cyclosporine 
as a ABCB1 inhibitor in AML (30), in contrast to the other, consistently poor, 
results on selective ABCB1 modulation in long-term disease outcome, could be in 
line with this assumption owing to cyclosporine being a more promiscuous ATP-
binding cassette transporter inhibitor with effects on both ABCB1 and BCRP (31). 
Together, these data warrant further research into the usefulness and feasibility of 
broad-spectrum ATP-binding cassette transporter inhibitors to eradicate leukemic 
stem cells in AML.
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Chapter 4
“Preferential expression of a high number of ATP binding cassette 
transporters in both normal and leukemic CD34+CD38- cells”.
EPLM de Grouw, MHGP Raaij makers, JB Boezeman, BA van der Reij den, LT van de 
Locht, TJ de Witte, JH Jansen, RAP Raymakers.
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To the editor
In most cases of acute myeloid leukemia (AML) malignant stem cells are considered 
to be within the CD34+CD38- population. The involvement of CD34+CD38- cells in 
leukemogenesis is suggested by the presence of cytogenetically aberrant cells in 
the stem cell compartment in AML, as demonstrated by PCR and FISH for leukemia 
specific translocations. Furthermore, transplantation studies using NOD/SCID mice 
have shown that cells with leukemic engraftment and self renewal potential are 
exclusively found within the CD34+CD38- cell population and not in more differ-
entiated CD34+CD38+ populations (1). Incomplete eradication of these primitive 
cells may eventually lead to disease relapse. Multidrug resistance induced by the 
expression of ATP binding cassette (ABC) transporters may hamper the eradication 
of these primitive leukemic cells. 
ABC transporters represent the largest family of transmembrane proteins involved 
in the transport of a wide variety of substrates across biological membranes, 
including phospholipids, ions, peptides, steroids, polysaccharides, amino acids, 
organic anions, bile acids, drugs and other xenobiotics. Currently, the ABC super-
family consists of 48 members; that can be divided into 7 subfamilies based on 
similarity in protein structure (ABCA, B, C, D, E, F and G). Some of these transporters 
(ABCB1, ABCC1 and ABCG2) are expressed at high levels on hematopoietic primitive 
cells (2).
The physiological function of ABC transporters in human stem cell biology is not 
well understood. A role for ABC transporters in the protection from genetic damage 
by naturally occurring xenobiotics has been suggested for hematopoietic stem cells 
(3). This has recently been substantiated by the observation of increased sensitivity 
to xenobiotics in normal bone marrow cells in ABCB1 and ABCG2/BCRP knockout 
mice.
Recently, an increasing number of ABC transporters has been associated with 
extrusion of xenobiotic compounds and chemotherapeutical agents and thus may 
be important for stem cell protection. However, the expression pattern of many 
ABC transporters on hematopoietic CD34+CD38- cells is currently unknown. In AML 
overexpression of ABC transporters involved in drug resistance might represent 
an important mechanism of drug resistance (2). We recently demonstrated similar 
expression and function of ABCG2 in CD34+CD38- cells in AML and normal bone 
marrow but observed significant mitoxantrone extrusion from these cells in the 
presence of ABCG2 inhibition, suggesting the presence of additional drug trans-
porters in these cells.
We assessed gene expression profiles of normal primitive CD34+CD38- and more 
committed CD34+CD38+ progenitor cells by quantitative real-time RT-PCR us-
ing micro fluidic cards, covering all 45 transmembrane ABC transporters. Highly 
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enriched CD34+CD38- and CD34+CD38+ cells (purity above 90%) were isolated by 
FACS sorting either from bone marrow (N=3) or from G-CSF stimulated peripheral 
blood collections (N=8). 
GAPDH-normalized levels of ABC transporter gene expression in the CD34+CD38- 
cell fraction are shown in fi gure 1a. Out of the 45 ABC transporters the expression 
of 36 ABC transporters was detectable in CD34+CD38- cells. 20 ABC transporters 
were detectable in all 11 samples. The lower frequency of detection of the remaining 
16 ABC transporters is probably due to the relatively low expression level of these 
genes which will be refl ected in a binary answer of the PCR (4). In line with this, 
genes with the highest expression level where detectable in all samples whereas 
genes with a lower expression showed a lower frequency. 
The 5 ABC transporters with the highest levels of expression were ABCC1, ABCA2, 
ABCB2, ABCB7, and ABCB1, confi rming the relatively high expression of known stem 
cell transporters ABCB1/MDR1 and ABCC1/MRP1. ABC transporter gene expression 
levels were not signifi cantly diff erent in G-CSF mobilized CD34+CD38- cells com-
pared to CD34+CD38- cells from normal bone marrow (data not shown). 
Figure 1: Many ABC transporters are expressed in normal hematopoietic CD34+CD38- cells and they 
all show a higher expression in normal hematopoietic CD34+CD38- cells compared to more commit-
ted CD34+CD38+ progenitor cells. (A) Gene expression of 45 ABC transporters was investigated in 
CD34+CD38- hematopoietic cells from G-CSF mobilized peripheral blood and bone marrow (N=11). 
Levels of gene expression are depicted as natural logarithmic values on the y-axis normalized for the 
expression of the housekeeping gene GAPDH.  Mean values of gene expression of positive samples 
(+ 95% CI) are represented by bars. On the x-axis ABC transporter gene name together with the 
frequency of expression (number of samples in which gene expression was detectable) is shown. Note 
that expression of 36 out of 45 ABC transporters is detected in the normal CD34+CD38- fraction. (B) 
Diff erence in level of gene expression between CD34+CD38- and CD34+CD38+ cells is depicted on the 
y-axis as mean fold diff erence (+ 95% CI) in samples that expressed the ABC transporter in both 
fractions. Transporters for which diff erentially expression reached statistically signifi cance (using 
student t-test for paired samples, p<0.05) are indicated with an asterix.
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Except for ABCB5, that was detected in all G-CSF mobilized samples (8/8) but not in 
normal bone marrow (0/3).
To gain more insight in the biological relevance of ABC transporter expression 
in CD34+CD38- cells, we compared this expression pattern to more committed 
CD34+CD38+ progenitor cells. In CD34+CD38+ cells 38 ABC transporters were 
detectable. Strikingly, all ABC transporters detectable in the CD34+CD38- fraction 
showed a lower expression in the CD34+CD38+ fraction (figure 1b). In 22 of the 36 
ABC transporters this difference was statistically significant. Among these genes 
are known transporters associated with hematopoietic stem cells including ABCB1 
(mean 7.57-fold difference, p<0.001), ABCC1 (mean 2.67-fold difference, p=0.004) 
and ABCG2 (mean 1.81-fold difference, p=0.016). Among the 10 most differential-
ly expressed ABC transporters in the normal CD34+CD38- versus CD34+CD38+ 
fraction 5 members of the ABCA family are listed (ABCA5, ABCA6, ABCA9, ABCA10 
and ABCA2). Four of these genes, ABCA5, ABCA6, ABCA9 and ABCA10, representing 
a phylogenetically distinct subgroup within the ABCA gene subfamily, are arranged 
in a cluster on chromosome 17q24. Although the substrates and function of these 
ABCA transporters are largely unknown, recent studies suggest that some of these 
transporters may function in the transmembrane transport of endogenous lipid 
AML Patient 
number
Age at 
diagnosis
Sex FAB clas-
sification
% blasts % CD34+ 
cells
% CD34+
CD38- cells
% CD34+
CD38+ cells
1 55 M M0 89 89 3.1 21.1
2 26 F M1 85 85 1.3 15.1
3 59 F M1 76 54 8.0 11.1
4 72 F M1 64 64 1.2 16.5
5 71 F M4 87 87 0.5 27.3
6 67 M M0 90 90 1.4 44.7
7 10 M M2 82 82 1.5 33.6
8 67 F M2 86 86 25.6 11.1
9 72 M M4E 24 24 0.9 12.3
10 40 M M5B 55 48 1.7 17.4
11 62 F M5 82 19 2.0 2.1
12 57 F M4 28 5 0.2 0.4
13 50 F M5 90 7 - 5.1
Mean 
(range)
54
(10 - 72)
72
(24 - 90)
57
(5 - 90)
4.0 
(0 - 25.6)
13.0
(0.4 - 44.7)
 Table 1: Patient characteristics. Percentages of blasts and CD34+ cells are based on morphology and 
immunophenoptypic staining, respectively. CD34+CD38- cells were defined as the cells with CD38-
PE fluorescence within the first decade of emission. The CD34+CD38+ cells were sorted from a gate 
positioning in the bulk of CD34+ cells separated by a decade from CD34+CD38- cells. The percentages 
of CD34+CD38- and CD34+CD38+ cells are the percentages of cells within the gates used in the sorting 
procedure relative to the total amount of cells. 
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substrates such as phospholipids and essential fatty-acids, substrates involved in 
the regulation of differentiation of hematopoietic cells (5). Clearly, further research 
is warranted to elucidate the role of these ABCA transporters in stem cell biology. 
The ABC transporter expression profiles of all individual samples are included in 
the supplementary data (Supplementary figure 1 and 2).
The preferential expression of ABC transporters in normal primitive cells and 
the possible implications of high expression in drug resistance, prompted us to 
investigate the expression of these transporters in leukemic CD34+CD38- cells. 
ABC transporter gene expression was assessed in CD34+CD38- and CD34+CD38+ 
cells from 12 untreated AML patients. In one leukemic patient sample we were only 
able to sort the CD34+CD38+ fraction due to a very low percentage of CD34+CD38- 
cells. Patient characteristics are shown in table 1. Others and we have previously 
shown that CD34+CD38- cells in AML are predominantly of leukemic origin. GAPDH 
was used as a reference gene since we have earlier demonstrated that this is an 
appropriate gene for normalization of target gene expression with similar expres-
sion levels in both normal and leukemic CD34+CD38- and CD34+CD38+ cells (6).
In the leukemic CD34+CD38- cell fraction 40 out of 45 ABC transporters were 
detectable (figure 2a). All genes that were detectable in normal CD34+CD38- 
progenitor cells were also detectable in leukemic CD34+CD38- cells, with the 
exception of ABCA8 that was found only in one of the 11 normal CD34+CD38- 
samples. The level of expression of 31 out of 35 ABC transporters was comparable in 
both normal and leukemic CD34+CD38- cells. A statistically significant lower expres-
sion in the CD34+CD38- cells in AML compared to the same fraction in normal cells 
was found for four ABC transporters, ABCA3 (p=0.003), ABCA5 (p=0.003), ABCB1 
(p=0.001) and ABCC1 (p=0.011). A significant difference in frequency of expression 
between normal and leukemic CD34+CD38- cells was found for ABCA13 (10/11 vs. 
3/11 respectively; p<0.05) and ABCB5 (8/11 vs. 1/11 respectively, p<0.05). Finally, in 
the leukemic CD34+CD38- cell population 5 ABC transporters were detectable that 
were not found in their normal counterparts (ABCA4, ABCC7, ABCC9, ABCC11 and 
ABCG4).  The frequency of detectable expression of these transporters, however, 
was very low (ABCA4; 2/11, ABCC7; 1/11, ABCC9; 4/11, ABCC11; 2/11 and ABCG4; 
1/11) and may reflect a binary answer of the PCR in case of borderline expression 
levels, rather than indicating leukemia specific expression of these genes. The ABC 
transporter expression results of the individual AML patients are included in the 
supplementary data (Supplementary figure 3 and 4).
Similar to the expression pattern in normal bone marrow, statistically significant 
higher expression in the CD34+CD38- cells compared to the CD34+CD38+ cells was 
found for 27/40 ABC transporters in AML (figure 2b). 
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Currently, 13 ABC transporters are thought to be involved in transport of cytostatic 
drugs, and may therefore be involved in multidrug resistance. In addition to the 
expected transporters, ABCB1, ABCC1 and ABCG2, all other ABC transporters 
involved in drug transport were expressed in CD34+CD38- cells in AML at varying 
frequencies. Six ABC drug transporters were expressed in CD34+CD38- cells of all 
AML patients and statistically significant differential expression in CD34+CD38- 
cells compared to CD34+CD38+ cells was found in 8/13 ABC drug transporters. 
The current study is the first reporting the ABC transporter gene expression pro-
file of human hematopoietic primitive cells using real-time RT-PCR but differential 
expression of ABC transporters in (non-human) hematopoietic stem cells has been 
described earlier for some transporters. Ramalho-Santos et al (7) investigated the 
expression pattern in mouse (Sca+cKit+Lin-) hematopoietic stem cells in compari-
son to their differentiated counterparts using micro-array expression profiling. 
They showed that 8 ABC transporters were differentially expressed. All these genes, 
except ABCB8, showed significantly higher expression in normal CD34+CD38- cells 
in comparison to committed progenitor cells in our study. Similarly, gene expres-
Figure 2: ABC transporters are similarly expressed in leukemic and normal CD34+CD38- cells and virtually 
all expressed ABC transporters show a higher expression in hematopoietic CD34+CD38- cells in compari-
son to more committed CD34+CD38+ progenitor cells in AML. (A) Gene expression of 45 ABC transporters 
was investigated in CD34+CD38- hematopoietic cells from AML patients at diagnosis (N=12). Levels of 
gene expression are depicted as natural logarithmic values on the y-axis normalized for the expres-
sion of the housekeeping gene GAPDH. Mean values of gene expression of positive samples (+ 95% CI) 
are represented by bars. On the x-axis the ABC transporter gene name together with the frequency of 
expression (number of samples in which gene expression was detectable) is shown. (B) Difference in 
level of gene expression between CD34+CD38- and CD34+CD38+ cells is depicted on the y-axis as mean 
fold difference (+ 95% CI) in samples that expressed the ABC transporter in both fractions. Transport-
ers for which differentially expression reached statistically significance (using student t-test for paired 
samples, p<0.05) are indicated with an asterix. All transporters, except for ABCB11 and ABCG4, are high-
er expressed in the CD34+CD38- fraction compared to the CD34+CD38+ fraction.
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sion profiling in fetal Sca+AA4.1+Kit+Lin- liver hematopoietic cells versus stem cell-
depleted AA4.1- cells (8) identified 14 differentially expressed ABC transporters, all 
of which, when included, have higher expression in human CD34+CD38- cells in 
our study, except ABCG3 which has no human ortholog. These comparisons indi-
cate that the reported expression profiles of ABC transporters in hematopoietic 
(stem) cell populations show high concordance with the results from our study. In 
addition to the expected differentially expressed ABC transporters we identified 
a large number of ABC transporter genes, previously unknown to be expressed 
in CD34+CD38- and CD34+CD38+ cells, which displayed higher expression in 
hematopoietic primitive cells compared to more committed progenitor cells. The 
higher sensitivity of real-time RT-PCR in comparison to cDNA and oligonucleotide 
arrays, especially in low copy genes, may explain the identification of these genes 
in the current study. 
We demonstrate expression of all 13 ABC transporter members currently associated 
with drug resistance. The conserved expression of these drug resistance associated 
transporters after malignant transformation in AML could greatly impede sensitivity 
of the leukemic CD34+CD38- cells to chemotherapeutical eradication, if mRNA ex-
pression levels reflect protein levels and function. If so, these data suggest that 
many members of the ABC transporter family may be involved in drug efflux medi-
ated resistance of leukemic CD34+CD38- cells. Modulation of multiple transporters 
might be required to increase drug accumulation and induce chemotherapeutical 
eradication of primitive leukemic cells in AML.
This has to be taken into account when interpreting the largely poor results of ABCB1 
modulation using the potent inhibitor PSC833 on long-term disease outcome in 
clinical trials. It is important to stress that one of the main rationales for ABCB1 
targeting is its prognostic value for remission induction in AML. Based on the 
results of the current study, it is conceivable that ABCB1 may be a prognostic marker 
for AML cases that consist predominantly of immature CD34+ cells that co-express 
a high number of ABC transporter molecules with putative involvement in drug 
extrusion and chemotherapy resistance. 
Additionally, the similar patterns of ABC transporter expression in normal and 
leukemic hematopoietic CD34+CD38- cells predict that modulation of these trans-
porters in AML as a therapeutic strategy to target leukemic primitive cells will 
target residual normal hematopoietic primitive cells as well and is therefore likely to 
encounter increased bone marrow toxicity. 
Finally, the identification of previously unrecognized ABC transporters in leukemic 
primitive cells offers the basis for future studies investigating the functional role of 
these ABC transporters in leukemia resistance and their usefulness as therapeuti-
cally targets to eradicate this crucial cell population in AML.
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SUPPLEMENTARY FIGURES
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Supplementary fi gure 1: ABC transporter expression profi le in normal hematopoietic CD34+CD38- cells 
from 11 samples. Gene expression of 45 ABC transporters was investigated in CD34+CD38- hematopoietic 
cells from G-CSF mobilized peripheral blood and bone marrow from 11 samples. Levels of gene expres-
sion for each individual sample are depicted as natural logarithmic values on the y-axis normalized for 
the expression of the housekeeping gene GAPDH. On the x-axis ABC transporter gene name is shown.
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Supplementary fi gure 2: Fold diff erence in ABC transporter expression levels between normal CD34+CD38- 
and CD34+CD38+ cells. Diff erence in level of gene expression between CD34+CD38- and CD34+CD38+ 
cells is depicted on the y-axis as fold diff erence.
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Supplementary fi gure 3: ABC transporter expression profi le in leukemic hematopoietic CD34+CD38- cells 
from 12 patients with AML at diagnosis. Gene expression of 45 ABC transporters was investigated in 
CD34+CD38- hematopoietic cells from 12 AML patients at diagnosis. Levels of gene expression for each 
individual sample are depicted as natural logarithmic values on the y-axis normalized for the expression 
of the housekeeping gene GAPDH. On the x-axis ABC transporter gene name is shown.
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Supplementary fi gure 4: Fold diff erence in ABC transporter expression levels between leukemic 
CD34+CD38- and CD34+CD38+ cells. Diff erence in level of gene expression between CD34+CD38- and 
CD34+CD38+ cells is depicted on the y-axis as fold diff erence.
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Chapter 5
“Rapid upregulation of a broad range of ATP binding 
cassette transporters upon anthracyclin exposure in 
leukemic progenitor cells”. 
Elke P.L.M. de Grouw, Gabriele A Buda, Bert A van der Reĳ den, Theo J de Witte, Joop 
H Jansen, Reinier AP Raymakers, Marc HGP Raaĳ makers.
Submitted
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Abstract
Drug efflux by ABC-transporters is a well-established mechanism by which leukemic 
cells escape chemotherapeutical eradication. Expression of a small subset of trans-
porters is well studied in leukemic blasts at diagnosis and relapse but surprisingly 
little is known about ABC-transporter expression during chemotherapy. We profiled 
gene expression of all transmembrane ABC-transporters after anthracycline expo-
sure in KG1a cells and in leukemic CD34+ cells exposed in vivo by real-time RT-PCR 
using low density arrays. 
In KG1a cells significant induction of many ABC-transporters was observed within 
72 hours of exposure to both mitoxantrone and daunorubicin (14 and 19 transport-
ers respectively). Among the highest induced genes were known drug transporters 
(ABCB1, ABCB11, ABCC2, ABCC6 and ABCG2) but also transporters currently not 
associated with transport of chemotherapeutical compounds. Rapid and hetero-
geneous upregulation of ABC-transporters was found in CD34+ blasts from all 8 
patients studied. There was overlap between transporters upregulated in KG1a cells 
and CD34+ cells although the fold induction was less apparent in CD34+ blasts. 
In conclusion, these data show that already after short-term drug exposure a broad 
range of ABC-transporters is found upregulated in leukemic progenitor cells. These 
findings challenge the rationale of inhibition of single transporters to circumvent 
drug resistance of leukemic progenitors. 
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Introduction
Drug efflux by ATP binding cassette transporters is a well established mechanism 
of leukemic cells to evade chemotherapeutical eradication. ATP binding cassette 
(ABC) transporters represent the largest family of transmembrane proteins. Cur-
rently, the human ABC transporter superfamily consists of 48 members, which can 
be divided into 7 subfamilies based on similarities in protein structure (ABCA, B, 
C, D, E, F and G). ABC transporters are involved in the transport of a wide variety of 
substrates across biological membranes, including phospholipids, ions, peptides, 
steroids, polysaccharides, amino acids, organic anions, bile acids, drugs and other 
xenobiotics. The physiological role of most ABC transporters is largely unknown as 
is their potential role in chemoresistance.
Currently, 15 members of the ABC transporter family are known to be involved in 
the transport of chemotherapeutical compounds, thereby conferring multidrug 
resistance (MDR) (1). Modulation of the prototype ABC drug transporter ABCB1 
(P-glycoprotein) has been largely unsuccessful in clinical trials in AML (2-7). One of 
the explanations for the failure of this strategy may be that the modulation of spe-
cific ABC transporters does not target the primitive leukemic progenitors (8), which 
co-express many redundant ABC transporters at high levels (9, 10). Alternatively, 
the upregulation of redundant transporters in leukemic blasts upon exposure to 
chemotherapeutical drugs may overcome the modulation of the single ABCB1 trans-
porter.  
Studies investigating the kinetics of ABC transporters during chemotherapy are 
largely lacking. Such studies could be important to identify additional members of 
the ABC transporter family involved in the defense against drug-induced apoptosis 
of leukemic progenitor cells. In the current study, we used low-density real-time RT-
PCR arrays to study the expression of the entire ABC-transporter family in leukemic 
progenitor cells upon exposure to anthracyclines both in vitro in a cell line as well 
as in vivo in patients treated for leukemia.
Material and Methods
Cell isolation and culture
KG1a cells were cultured in IMDM supplemented with 10% fetal bovine serum and 
1% penicillin/streptavidine. Cells were separately exposed to mitoxantrone and to 
daunorubicin, both at a concentration of 100 ng/ml. At baseline and 24, 48 and 72 
hours after exposure cells were collected for gene expression profiling. 
Patient blood samples were obtained after informed consent at different time points 
during chemotherapy treatment, mononuclear cells were isolated by Ficoll 1077 g/
mL gradient and cryopreserved. After collection of all samples the cells were thawed 
and  stained with monoclonal antibodies: CD45 to distinguish the major leukocyte 
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population, CD34 and leukemia-specific markers (e.g. CD10, CD19 or CD117). The 
leukemic CD34+ cells were sorted by a Beckman Coulter Epics Altra with Hypersort. 
Isolation, cryopreservation and thawing procedures of the CD34+ cells have been 
described previously (11).
RNA isolation, reverse transcription PCR and real-time RT-PCR
Total RNA from KG1a cells was extracted by using RNAzol, according to the manufac-
turer’s protocol and diluted to a concentration of 0.2 µg/µl. Reverse transcriptase 
PCR was performed using 5x 1st strand buffer (Life Technologies), 10 mM DTT (Life 
Technologies), 1 µl of a 5 mg/ml solution dN6 (Amersham Pharmacia Biotech), 0.625 
mM dNTP (Amersham Pharmacia Biotech), 20 U RNAse inhibitor (Promega) and 200 
U M-MLV reverse transcriptase (Life Technologies) with 1 µg RNA in a total volume of 
20 µl. From leukemic CD34+ blasts total RNA was extracted using a Zymo research 
Mini RNA isolation II kit (Zymo research, USA). RNA was eluted in a total volume of 
50 µl. A volume of 11 µl was added in the cDNA reaction in a total volume of 20 µl. 
The reaction mixture was incubated at 20°C for 10 minutes, 42°C for 60 minutes 
followed by heat inactivation of the enzyme at 95°C for 10 minutes. Before storage 
at -80°C the cDNA was diluted in distilled water to a final volume of 100 µl. Levels of 
mRNA expression were measured by low density arrays. Primers and probes for all 
ABC transmembrane transporters (complete ABCA, B, C, D and G family), GAPDH, 
HMBS and HPRT1 were developed by Applied Biosystems.
Data analysis
Normalized gene expression to the internal standard GAPDH is given by the follow-
ing equation: T0/R0 = K.(1 + E) (Ct,r – Ct,t).
T0: initial number of target gene copies; R0: initial number of standard gene 
copies; E: efficiency of amplification; Ct,t: threshold cycle of target gene; Ct,r: 
threshold cycle of standard gene; and K: constant.
ABC transporter gene expression was quantified relatively to housekeeping genes 
GAPDH, HMBS and HPRT1. Analysis of the ABC transporter gene expression normal-
ized with all three housekeeping genes showed similar results. Earlier we showed 
that GAPDH is an appropriate gene for normalization of target gene expression in 
human CD34+CD38- and CD34+CD38+ hematopoietic cell populations from normal 
bone marrow and AML (12), therefore all data shown are normalized using GAPDH 
expression.
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Results
ABC transporter gene expression profile after anthracycline exposure in KG1a cells
We assessed ABC transporter gene expression profiles of the primitive leukemic 
KG1a cell line after short-term exposure to mitoxantrone and daunorubicin by quanti- 
tative real-time RT-PCR using micro fluidic cards, covering all 45 transmembrane 
ABC transporters. KG1a cells were used as a model because they represent primitive 
leukemic cells with a CD34+CD38- immunophenotype and NOD-SCID repopulating 
capacity (13). The interexperimental reproducibility of ABC transporter gene ex-
pression using low density arrays was assessed in 4 independently obtained RNA 
samples. Mean relative mRNA expression of four different RNA samples of KG1a 
cells are shown in figure 1. The expression of 29/45 ABC transporters was detect-
able in KG1a cells. Eighteen ABC transporters were detectable in all four samples. 
The lower frequency of detection of the remaining ABC transporters was associated 
with a relatively low expression level of these genes, probably reflecting a binary 
answer of the PCR in case of low-copy genes. The small error bars indicate a high 
reproducibility, confirming earlier experience with these micro fluidic cards (9). The 
mean expression value was used to compare ABC transporter gene expression after 
exposure to anthracyclines.
KG1a cells were exposed to mitoxantrone and to daunorubicin at clinically achiev-
able plasma levels (100 ng/ml). We detected a broad upregulation of ABC transport-
ers with maximum levels of induction after 48 and 72 hours for mitoxantrone and 
daunorubicin exposure, respectively. Figure 2 shows levels of ABC transporter gene 
Patient 
nr
Diagnosis Age at 
diag-
nosis
% 
blasts 
PB
Leucocyte 
counts before 
diagnosis 
Days of 
analysis
Immunopheno-
typic
Expression (CD)
Treatment
1 CML blast crisis 43 75 47 x109/ml 0/3/5/7 45+/34+ DNR/Eto/Ara-C
2 AML-M6 60 26 12 x109/ml 0/3 45+/34+ IDA/Ara-C
3 AML-M4eo 34 54 21 x109/ml 0/3/5 45+/34+/117+ DNR/Eto/Ara-C
4 CML blast crisis 58 79 70 x109/ml 0/3/7 45+/34+/10+ Cycl/DNR/VIN/Pred
5 AML M4 50 31 50 x109/ml 0/3/5 45+/34+/117+ DNR/Eto/Ara-C
6 AML-M5 62 61 26 x109/ml 0/3 45+/33+/117+ MT/Ara-C/Eto
7 AML-M2 67 33 114 x109/ml 0/3/5/7 45+/34+/117+ MT/Ara-C/Eto
8 Relapse pro-
B-ALL
21 42 6.5 x109/ml 0/3 45+/34+/19+ Cycl/DOX/VIN/Asp
Table 1. Patient characteristics. The percentage blasts in PB is the percentage of blasts at diagnosis. 
The immunophenotypic expression (CD) refers to the CD markers used for the selection of the leukemic 
cell population. CML Chronic Myeloid Leukemia; AML Acute Myeloid Leukemia; DNR daunorubicin; Eto 
etoposide; MT mitoxantrone; IDA idarubicine; Cycl cyclophosphamide; VIN vincristine; Pred prednisone; 
DOX doxorubicin; Asp asparaginase; 
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expression relative to GAPDH for these time points as the mean of two indepen-
dently performed experiments. 
After exposure a significant increase in expression (arbitrarily defined as more 
than 3-fold above baseline) was observed in 14/29 and 19/29 transporters for mito- 
xantrone and daunorubicin, respectively. Interestingly, there was complete overlap 
between the significantly induced genes after exposure to mitoxantrone compared 
to daunorubicin with fold-induction invariably higher in daunorubicin exposed cells. 
The significantly upregulated ABC transporter genes included transporters already 
known to be involved in the transport of anthracyclines (ABCB1, ABCC2, ABCC6 and 
ABCG2) and other chemotherapeutical compounds (ABCB4, ABCB11, ABCC10), but 
also many transporters, currently not associated with transport of chemothera- 
peutical compounds including a striking number of members of the ABCA subfamily 
of transporters (ABCA1, ABCA5, ABCA6, ABCA7, ABCA8, ABCA9, ABCD1 and ABCG4). 
Of note, the highest upregulated ABC transporters for both drugs were ABCC6, 
ABCA6, ABCB11 and ABCG4 whereas the established drug transporters ABCB1 and 
ABCG2 ranked 9 and 13 in the most upregulated gene ranking for mitoxantrone and 
5 and 14 for daunorubicin, respectively.
Additionally, 12 transporters displayed expression after exposure to anthracyclines 
(both mitoxantrone and daunorubicin) that were not detected in unexposed cells. 
Among these, we found the remaining members of the ABCG family. 
Figure 1. ABC transporter gene expression in leukemic primitive KG1a cells. Relative mRNA expression of 
all ABC transmembrane transporters in KG1a cells (n=4) as assessed by real-time RT-PCR on low density 
array. The ABC transporter expression is compared to the housekeeping gene GAPDH ± SD. On the x-axis 
ABC transporter gene name and  the frequency of expression (number of samples in which gene expres-
sion was detectable) is shown.
103
Chapter 5
ABC transporter gene expression profiling in CD34+ leukemic cells during 
chemotherapy treatment in vivo
Rapid upregulation of ABC transporters upon exposure to anthracyclines in leuke-
mic progenitor cells may have important implications for the treatment of leukemia, 
especially regarding the duration of current chemotherapy schedules. To investi-
gate whether ABC transporter upregulation upon chemotherapeutical exposure 
occurs in primary leukemic progenitor cells in vivo, we sorted leukemic blasts, 
based on CD45 and CD34 expression and other leukemic markers (CD117, CD10 and 
CD19) if expressed from the peripheral blood of patients before start of the treat-
ment and at day 3, 5 and 7 during chemotherapeutical treatment (table 1). Eight 
sequential leukemic patients who presented with blasts in the peripheral blood 
at the start of the treatment were included in this study. Patient characteristics 
and treatment schedules are presented in table 1. RNA was isolated from leukemic 
CD34+ blasts before start of treatment, at day three and at later time points (day 
5 and 7) if sufficient CD34+ cells were available at these time points.  
Many ABC transporters (25/45) were intrinsically expressed in CD34+ blast cells of 
all patients, whereas 8 ABC transporters were not detectable in any of the patients. 
Interestingly, in this heterogeneous patient group regarding both diagnosis and 
treatment, all patients showed an induction of ABC transporters (table 2). The total 
number of upregulated ABC transporters varied widely, from 3 ABC transporters 
Figure 2. Upregulation of many ABC transporters in leukemic primitive KG1a cells after exposure to mito-
xantrone or daunorubicin. All ABC transmembrane transporters in KG1a cells (n=4) exposed to mitoxan-
trone (100 ng/ml, t=48 hours, n=2) or daunorubicin (100 ng/ml, t=72 hours, n=2). Data are depicted as 
number of target gene copies/copy GAPDH ± SD. No SD is presented for ABC transporters that displayed 
detectable expression in only one experiment, reflecting the binary answer of the PCR in low-copy gene 
expression. 
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in patient 5 and 6 up to 21 ABC transporters in patients 4 and 7. These included 
transporters associated with chemo resistance (B1, B11, C1, C2, C3, C4, C5, C6, C10 
and G2) and others (A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A12, A13, B2, B3, B6, 
B8, B9, B10, C7, C13, D1, D2, D3, D4, G1 and G8). In line with expression pattern in 
vitro, there was a striking representation of members of the ABCA subfamily among 
upregulated transporters with all examined patients displaying upregulation of at 
least two ABCA transporters. 
All upregulated transporters in the patient samples were also upregulated in the 
KG1a cell line, with the exception of ABCA3, ABCA10, ABCB6, ABCB9, ABCB10, 
ABCC7 and ABCD3,  suggesting concordance between transporters upregulated in 
vitro and in vivo although, the number of ABC transporters and the fold increase 
in patient samples was lower in comparison to KG1a cells. Together these findings 
confirm our in vitro observation that short-term exposure to anthracyclines can 
induce rapid upregulation of a heterogeneous set of ABC transporters in primary 
CD34+ leukemic blasts in vivo.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
ABC 
trans-
porter
+/- fold +/- fold +/- fold +/- fold +/- fold +/- fold +/- fold +/- fold
ABCA1 + 33.4 5 + + + 4.62 3 + + 13.94 3 + + 7.33 3
ABCA2 + 3.42 5 + + + 3.01 7 + + + 3.16 7 +
ABCA3 + + 3.65 3 + 3.71 3 + + + + +
ABCA4 - - + + 34.28 7 + - - -
ABCA5 + + + 4.22 3 + 3.67 7 + + 5.91 3 + 5.75 7 +
ABCA6 + + + + + + + 42.10 7 -
ABCA7 + + 3.17 3 + + 6.04 7 + + + 5.09 7 + 7.06 3
ABCA8 - - - - - - - nq -
ABCA9 + + 4.81 3 + + 15.78 7 + 5.57 3 + + 43.33 5 -
ABCA10 + - + + + - + 13.33 7 -
ABCA12 - nq - - - nq - nq - - -
ABCA13 + - + 3.02 3 - + + - +
ABCB1 + 3.6 5 + + + 3.88 7 + + 4.56 3 + 3.19 7 +
ABCB2 + 3.3 5 + + + 3.51 7 + + + 3.79 7 +
ABCB3 + 3.53 7 + + + 5.20 7 + + + 3.44 7 + 3.85 3
ABCB4 + + - + + + + +
ABCB5 + + - + + - - -
ABCB6 + + 3.64 3 + 4.75 5 + 5.00 7 + + + 7.79 5 +
ABCB7 + + + + + + + +
ABCB8 + + + + 3.67 7 + + + +
ABCB9 + + 3.36 3 + 3.57 3 + 4.50 7 + + + 4.21 7 +
ABCB10 + + + + + + + 3.05 5 +
ABCB11 + 3.52 3 - - + - + - -
ABCC1 + + + 3.74 5 + + + + +
ABCC2 + + + + 5.00 3 + + + + 3.74 3
ABCC3 + + + 42.27 5 + 5.67 3 + 13.00 3 + + -
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Discussion
The current report shows that short-term anthracyclin exposure rapidly induces 
ABC transporters in leukemic progenitor cells both in vitro in a cell-line and in vivo. 
These transporters included both known drug transporters as well as transport-
ers not previously associated with drug transport or drug resistance, among which 
many members of the ABCA subfamily of ABC transporters. 
To our knowledge, a broad profiling of ABC transporters upon chemotherapeutical 
exposure has not been performed in primary leukemic cells before. Transporters 
upregulated in patient cells displayed overlap with transporters induced in KG1a 
cells in vitro, but the number of induced transporters and level of induction was 
generally higher in KG1a cells in comparison to primary CD34+ blasts. Several fac-
tors may explain these differences. First dose scheduling of anthracyclins may have 
an important impact. KG1a cells were exposed continuously for a prolonged period, 
whereas dosing in vivo occurred intermittently and at the time of blood collection 
on day three most patients had only received a single dose of anthracyclins. Indeed, 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
ABCC4 + + + + 3.18 7 + + + 6.68 7 +
ABCC5 + + + 3.86 5 + + + + +
ABCC6 + + + 92.51 5 + 3.51 3 + + - -
ABCC7 - - - - - - + 5.07 7 -
ABCC8 - - - - - - - -
ABCC9 - - - - - - - -
ABCC10 + + + + 6.16 7 + + + 3.94 7 + 4.99 3
ABCC11 - - - - - - - -
ABCC12 - - - - - - - -
ABCC13 - + - + 4.58 3 + + + 5.09 5 -
ABCD1 + + + + + + + + 4.91 3
ABCD2 + - - nq + + - - +
ABCD3 + + + + + + + 4.27 5 +
ABCD4 + + + + 3.88 7 + + + +
ABCG1 + 10.93 5 + + + 6.02 3 + + + +
ABCG2 + + + 3.20 3 + + + + 5.28 5 +
ABCG4 + - - + - + - -
ABCG5 - - - - - - - -
ABCG8 - - - - - - - nq -
Total 34 8 30 5 30 11 35 21 34 3 32 3 30 21 26 6
Table 2. Expression and fold-upregulation of ABC transporters in CD34+ leukemic cells after chemothera-
peutical exposure in vivo. Absence (-) or presence (+) of baseline ABC transporter expression 3,5,7; day of 
the highest induction, nq; not quantitative, due to an undetectable expression at the control time point 
we were not able to calculate a quantitative fold induction. 
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in those patients with sufficient cells for analysis at later time-points, an increase 
in number and level of ABC-transporters was observed as exemplified by the high-
est expression of many transporters on day 7 in patient 4 and patient 7, suggesting 
that further increase of number and level of expression may occur at subsequent 
exposure to anthracyclins. 
Alternatively, the difference in inducability of ABC transporter gene expression 
may be caused by the more primitive nature of CD34+CD38- KG1a cells in compa- 
rison to CD34+ blasts. We have demonstrated before that primitive leukemic 
CD34+CD38- cells display higher expression of ABC transporters in comparison 
to more committed CD34+CD38+ leukemic progenitor cells and it is conceivable 
that the mechanisms governing ABC transporter gene expression upregulation 
are also more active in these cells (9). Interestingly, differential expression of ABC 
transporters in leukemic CD34+CD38- cells (comprising approximately 1-10% of 
CD34+ cells) included many members of the ABCA family, transporters also found 
upregulated in leukemic CD34+ blasts upon exposure to anthracyclins, raising 
the question whether the observed increase in gene expression reflects induction 
or selection of a resistant primitive subset of leukemic cells. Although our in vivo 
observations cannot exclude selection of highly expressing subpopulations, the 
concomitant increase of the same ABCA transporters in the homogeneous KG1a 
cell population suggests induction rather than selection as the underlying mecha-
nism. It is conceivable that there is constitutive differential expression in leukemic 
stem cells of ABC transporters that are important for cell defense and that these are 
the transporters upregulated in more differentiated progenitors when exposed to 
chemotherapeutical agents. Noteworthy, in patients that had sufficient leukocytes 
at diagnosis to warrant their examination at day 7 after start chemotherapy (patient 
4 and 7), the highest number and level of upregulation of transporters was found 
at the latest time-points. Number and level of upregulated transporters in these 
patients exceeded that of patients in which samples could be evaluated only at 
earlier time-points due to insufficient cell numbers at later time-points, supporting 
the notion that the increased expression in these patients was due to prolonged 
exposure to chemotherapy rather than selection. Regardless the underlying 
mecha-nism, the striking upregulation of members of the ABCA family, both the 
in vitro and in vivo setting, may indicate that these proteins are involved in the 
protection against anthracyclin induced cytotoxicity. Indeed, ABCA2 and ABCA3 
have recently been implicated in drug resistance against anthracyclins in leuke-
mic cells (14, 15) and the current results warrant further research into the emerging 
role of other ABCA transporters in drug resistance. In addition to the ABCA sub-
family, several other transporters not previously associated with drug resistance 
appeared up-regulated upon chemotherapeutical exposure in leukemic progenitor 
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cells both in vitro and in vivo. The highly conserved homology between different ABC 
transporters predicts that additional members may be involved in the extrusion of 
xenobiotic and chemotherapeutical compounds. Indeed, an increasing number of 
ABC transporters have been demonstrated to cause resistance to cancer chemo-
therapeutical agents (1, 16). Additionally, recent studies examining ABC transporter 
gene expression in drug-selected cancer cell lines demonstrated overexpression of 
a number of transporters not previously recognized as associated with drug resis-
tance (ABCA4, ABCA7, ABCB2, ABCB6, ABCB8, ABCB9 and ABCG1) (17). Remarkably, 
all these transporters were upregulated upon chemotherapeutical exposure in vivo 
in a varying number of patients, reinforcing a potential role in drug resistance of 
these transporters. 
Together, these data outline the emerging picture that ABC transporter mediated 
protection against xenobiotics and other toxic substrates may be conferred by 
simultaneous activity of many redundant family members in addition to ABCB1, 
ABCC1 and ABCG2.
The observation of rapid and heterogeneous upregulation of ABC transport-
ers upon exposure to anthracyclins may have important clinical implications. In 
current practice, expression of individual ABC transporters at diagnosis is being 
used to determine its relation with chemoresistance and prognostic value which 
is subsequently used as a rationale for modulation strategies. This approach is 
exemplified by ABCB1 (P-glycoprotein) of which clinical modulation trials have 
been largely unsuccessful (4, 18). The current gene expression data suggest that 
the effect of ABC transporters on drug resistance and patient prognosis is likely 
conferred by the simultaneous expression of many transporters at diagnosis and, 
perhaps even more importantly, the (heterogeneous) capacity of leukemic cells to 
broadly induce transporter expression upon chemotherapeutical exposure. This 
notion warrant further investigation in subsequent prospective studies to address 
the therapeutic significance and prognostic value of ABC transporter upregulation 
in leukemia. 
108
Ch
ap
te
r 5
Reference List
 (1)   Ross DD, Doyle LA. Mining our ABCs: pharmacogenomic approach for evaluating 
transporter function in cancer drug resistance. Cancer Cell 2004 Aug;6(2):105-7.
 (2)   Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, et al. Treatment of 
refractory and relapsed acute myelogenous leukemia with combination chemother-
apy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 1999 Feb 
1;93(3):787-95.
 (3)   Baer MR, George SL, Dodge RK, O’Loughlin KL, Minderman H, Caligiuri MA, et al. 
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated 
patients 60 years of age and older with acute myeloid leukemia: Cancer and Leuke-
mia Group B Study 9720. Blood 2002 Aug 15;100(4):1224-32.
 (4)   Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, et al. Mitoxantrone, 
etoposide, and cytarabine with or without valspodar in patients with relapsed or re-
fractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III 
trial (E2995). J Clin Oncol 2004 Mar 15;22(6):1078-86.
 (5)   Liu Yin JA, Wheatley K, Rees JK, Burnett AK. Comparison of ‘sequential’ versus ‘stan-
dard’ chemotherapy as re-induction treatment, with or without cyclosporine, in re-
fractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research 
Council AML-R trial. Br J Haematol 2001 Jun;113(3):713-26.
 (6)  Solary E, Witz B, Caillot D, Moreau P, Desablens B, Cahn JY, et al. Combination of 
quinine as a potential reversing agent with mitoxantrone and cytarabine for the 
treatment of acute leukemias: a randomized multicenter study. Blood 1996 Aug 
15;88(4):1198-205.
 (7)   van der HB, Lowenberg B, Burnett AK, Knauf WU, Shepherd J, Piccaluga PP, et al. The 
value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine 
in the treatment of elderly patients with previously untreated acute myeloid leukemia 
(AML), in relation to MDR1 status at diagnosis. Blood 2005 Oct 15;106(8):2646-54.
 (8)  Raaijmakers MH, de Grouw EP, van der Reijden BA, de Witte TJ, Jansen JH, Raymakers 
RA. ABCB1 modulation does not circumvent drug extrusion from primitive leukemic 
progenitor cells and may preferentially target residual normal cells in acute myelog-
enous leukemia. Clin Cancer Res 2006 Jun 1;12(11 Pt 1):3452-8.
 (9)   de Grouw EP, Raaijmakers MH, Boezeman JB, van der Reijden BA, van de Locht LT, de 
Witte TJ, et al. Preferential expression of a high number of ATP binding cassette trans-
porters in both normal and leukemic CD34+. Leukemia 2006 Apr;20(4):750-4.
 (10)  Raaijmakers MH, de Grouw EP, Heuver LH, van der Reijden BA, Jansen JH, Scheper RJ, 
et al. Breast cancer resistance protein in drug resistance of primitive CD34+CD38- 
cells in acute myeloid leukemia. Clin Cancer Res 2005 Mar 15;11(6):2436-44.
109
Chapter 5
 (11)  Smeets M, Raymakers R, Vierwinden G, Pennings A, van de LL, Wessels H, et al. A 
low but functionally significant MDR1 expression protects primitive haemopoietic 
progenitor cells from anthracycline toxicity. Br J Haematol 1997 Feb;96(2):346-55.
 (12)  Raaijmakers MH, van EL, de WT, Mensink E, Raymakers RA. Quantitative assessment 
of gene expression in highly purified hematopoietic cells using real-time reverse 
transcriptase polymerase chain reaction. Exp Hematol 2002 May;30(5):481-7.
 (13)  Lehne G, Sorensen DR, Tjonnfjord GE, Beiske C, Hagve TA, Rugstad HE, et al. The 
cyclosporin PSC 833 increases survival and delays engraftment of human multi-
drug-resistant leukemia cells in xenotransplanted NOD-SCID mice. Leukemia 2002 
Dec;16(12):2388-94.
 (14)  de Grouw EP, Raaijmakers MH, Boezeman JB, van der Reijden BA, van de Locht LT, de 
Witte TJ, et al. Preferential expression of a high number of ATP binding cassette trans-
porters in both normal and leukemic CD34+. Leukemia 2006 Apr;20(4):750-4.
 (15)  de Grouw EP, Raaijmakers MH, Boezeman JB, van der Reijden BA, van de Locht LT, de 
Witte TJ, et al. Preferential expression of a high number of ATP binding cassette trans-
porters in both normal and leukemic CD34+. Leukemia 2006 Apr;20(4):750-4.
 (16)  Efferth T, Gillet JP, Sauerbrey A, Zintl F, Bertholet V, de LF, et al. Expression profiling of 
ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. 
Mol Cancer Ther 2006 Aug;5(8):1986-94.
 (17)  Raaijmakers MH. ATP-binding-cassette transporters in hematopoietic stem cells and 
their utility as therapeutical targets in acute and chronic myeloid leukemia. Leukemia 
2007 Oct;21(10):2094-102.
 (18)  Ross DD, Doyle LA. Mining our ABCs: pharmacogenomic approach for evaluating 
transporter function in cancer drug resistance. Cancer Cell 2004 Aug;6(2):105-7.
 (19)  Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, et al. 
Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer 
cells. Cancer Cell 2004 Aug;6(2):129-37.
 (20)  Gillet JP, Efferth T, Steinbach D, Hamels J, de LF, Bertholet V, et al. Microarray-based 
detection of multidrug resistance in human tumor cells by expression profiling of 
ATP-binding cassette transporter genes. Cancer Res 2004 Dec 15;64(24):8987-93.
 (21)  Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, et al. Mitoxantrone, 
etoposide, and cytarabine with or without valspodar in patients with relapsed or re-
fractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III 
trial (E2995). J Clin Oncol 2004 Mar 15;22(6):1078-86.
 (22)  List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, et al. Benefit of 
cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid 
leukemia: a Southwest Oncology Group study. Blood 2001 Dec 1;98(12):3212-20.
110
Ch
ap
te
r 5
Chapter 6
“The ATP-binding-cassette transporter ABCC6 is highly induced 
in leukemic progenitor cells upon exposure to Ara-C and confers 
protection against Ara-C induced cytotoxicity”.
Elke P.L.M. de Grouw, Saskia M. Bergevoet, Jeroen J. van den Heuvel, Bert A. van der 
Reij den, Roos Masereeuw, Theo J. de Witte, Joop H. Jansen, Reinier A. Raymakers, 
Marc H.G.P. Raaij makers.
Manuscript in preparation
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Abstract
ABC transporters represent the largest family of transmembrane proteins involved 
in the transport of a huge variety of substrates including drugs used in the treatment 
of acute myeloid leukemia (AML). Ara-C is the single most effective drug in the treat-
ment of AML, however several resistance mechanisms have been described, which 
negatively influences therapy outcome. Elucidation of the mechanisms conferring 
resistance to Ara-C is therefore of significant importance. To study the potential 
involvement of ATP binding cassette transporters in Ara-C resistance we examined 
the mRNA expression of 45 transmembrane ABC transporters in primitive KG1a cells 
upon exposure to Ara-C, using low density array real-time RT-PCR.
Twelve ABC transporters were significantly upregulated, of which ABCC6 showed 
the highest upregulation (400-fold). ABCC6 upregulation upon Ara-C exposure was 
confirmed in other cell-lines (HL-60 and U937) and in CD34+ cells in vivo in a patient 
treated with Ara-C only. Overexpression of ABCC6 in CHO cells conferred resistance 
to Ara-C as demonstrated in clonogenic assays. Additionally, overexpression of 
ABCC6 induced increased proliferation of transfected cells. The mechanism behind 
ABCC6 mediated Ara-C resistance remains to be elucidated, resistance was not 
conferred by active efflux of Ara-C nor protection against oxidative stress. 
Together these data imply the involvement of an ABC transporter in Ara-C resis-
tance. Additionally, the data suggest a previously unrecognized role for ABCC6 
in cell proliferation. These combined effects of ABCC6 overexpression may be of 
considerable importance in leukemia since ABCC6 is highly induced in leukemic 
progenitor cells upon exposure to Ara-C.
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Introduction
Cytarabine (Ara-C), a deoxycytidine analog, is one of the most important anti-
leukemic drugs available for the treatment of acute leukemia. Upon entering cells 
through the nucleoside transporter ENT1, Ara-C is sequentially tri-phosphorylat-
ed to Ara-CTP, which interferes with the synthesis of DNA. There is a correlation 
between the cellular accumulation and retention of Ara-CTP, the manifestation 
of Ara-C mediated cytotoxicity and clinical response (1). In patients with acute 
leukemia, in vitro resistance to Ara-C has been correlated with a poor response to 
treatment (2). Resistance against Ara-C is multifactorial and includes reduced up-
take and enhanced activity of metabolizing enzymes preventing the formation of 
Ara-CTP (3). The identification of these resistance mechanisms has not led to the 
identification of molecular targets that can be modulated to increase Ara-C cyto-
toxicity in clinical practice. 
The ATP-binding cassette (ABC) transporters represent the largest family of trans-
membrane proteins involved in the transport of a huge variety of substrates, 
including sugars, peptides, inorganic anions, amino-acids, oligopeptides, polysac-
charides, vitamins and metallic ions. Some members of the ABC transporter family 
have the ability to export a wide variety of structurally unrelated chemotherapeuti-
cal compounds from cells, thereby conferring multiple drug resistance. The best 
studied ABC transporters in drug transport and drug resistance in AML are ABCB1, 
ABCC1 and ABCG2. Targeting of these molecules in clinical trials in an attempt to 
enhance chemosensitivity of leukemic blasts, however, has been limited to ABCB1. 
In analyzing the disappointing results of ABCB1 modulation in AML (4-6), it is 
important to realize that ABCB1 does not confer resistance to cytarabine (Ara-C). 
To date, no drug efflux mechanisms conferring resistance to Ara-C have been identi-
fied. Their presence, however, has been suggested by a report demonstrating that 
Ara-C cytotoxicity could be enhanced by inhibiting its efflux by dipyridamole (7). In 
investigating the possible role of ABC transporters in drug resistance against Ara-
C we examined the expression dynamics of 45 ABC transmembrane transporters 
upon exposure to Ara-C using real-time RT-PCR on low-density arrays. 
Materials and methods
Cell isolation and culture
Chinese Hamster Ovary (CHO)-pcDNA and CHO-mrp6 were kindly provided by G.D. 
Kruh (Medical Science Division, Fox Chase Cancer Center, Philadelphia, Pennsyl-
vania 19111). CHO cells were grown in RPMI supplemented with 10% fetal bovine 
serum, 2mM glutamine and 1% penicillin/streptavidine. The same culture condi-
tions apply for U937 and HL60. The KG1a cell line was cultured in IMDM supple-
mented with 10% fetal bovine serum and 1% penicillin/streptavidine. HEK293 cells 
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were grown in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/
streptavidine. All cell lines were grown as stock cultures maintained at 37°C in a 
humidified atmosphere of 5% CO2. 
Leukemic blasts were sorted on a Beckman Coulter Epics Altra with Hypersort based 
on the immunophenotypic expression pattern. Cells were stained with CD45 to 
distinguish the major leukocyte population, in combination with side scatter. 
Besides CD45, cells were stained with different other marker (e.g. CD34 and CD117) 
to sort the leukemic population.
RNA isolation and reverse transcription PCR
Total RNA was extracted by using RNAzol and diluted to a concentration of 0.2 µg/
µl. Reverse transcriptase PCR was performed using 4 µl of the 5x 1st strand buffer 
(Life Technologies), 10 mM DTT (Life Technologies), 1 µl of a 5 mg/ml solution dN6 
(Amersham Pharmacia Biotech), 0.625 mM dNTP (Amersham Pharmacia Biotech), 
20 U RNAse inhibitor (Promega) and 200 U M-MLV reverse transcriptase (Life Tech-
nologies) with 1 µg RNA in a total volume of 20 µl. The reaction mixture was incu-
bated at 20°C for 10 minutes, 42°C for 60 minutes followed by heat inactivation of 
the enzyme at 95°C for 10 minutes. Before storage at -80°C the cDNA was diluted in 
distilled water to a final volume of 100 µl.
Real-time RT-PCR
Levels of mRNA expression were measured by real-time RT-PCR. Primers and 
probe for glyceraldehydes-3-phospate-dehydrogenase (GAPDH) and ABCC6 were 
pre-developed assays (Applied Biosystems). The following real-time RT-PCR was 
performed with Syber green and specific primers (all from 5’ to 3’): ABCC1 for-
ward: gccctgtttgcggtgatc, ABCC1 reverse: gatgttggtttccatttcagatga. ABCB1 was also 
performed with a probe. ABCB1 forward: ctgagcctggaggtgaaga, ABCB1 reverse: 
ggtagctcttcgtgaca, ABCB1 probe: tcctggagcggttctacgacccctt.
Data analysis
Normalized gene expression to the internal standard glyceraldehydes- 
3-phosphate-dehydrogenase (GAPDH) is given by the following equation: T0/R0 = 
K.(1 + E) (Ct,r – Ct,t).
T0: initial number of target gene copies; R0: initial number of standard gene 
copies; E: efficiency of amplification; Ct,t: threshold cycle of target gene; Ct,r: 
threshold cycle of standard gene; and K: constant.
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Generation of human ABCC6 baculovirus
The Bac-to-Bac system was made suitable for protein expression in mammalian 
cells by cloning the vesicular stomatitis virus G protein cDNA behind the P10 pro-
motor of the pFastBacDual vector. Next the CMV promoter and Gateway destination 
elements were introduced in the pFastBacDual vector. The human ABCC6 coding 
sequences were cloned into the Gateway entry vector. The sequences of the ABCC6 
construct were identical to the sequences described by Belinsky and Kruh (8). This 
ABCC6 cDNA was transferred to the newly constructed Bac-to-Bac vector with the 
gateway LR reaction. Baculoviruses were produced as described in the Bac-to-Bac 
manual. As a control, the enhanced yellow fl uorescent protein (EYFP) was also 
cloned into the gateway entry vector.
Figure 1. ABCC6 is highly induced upon exposure to Ara-C in leukemic progenitor cells. A) Gene 
expression of all ABC transmembrane transporters in KG1a cells upon exposure to Ara-C  (10 ng/ml for 
72 hrs) assessed by real-time RT-PCR on low density array. Data are expressed as fold increase/de-
crease ± SD in comparison to unexposed cells (n=2). B) ABCC6 expression in time upon exposure to 
Ara-C (10 ng/ml) in KG1a, U937 and HL60 cells.  KG1a cells (n=3),  HL60 cells (n=1), X U937 cells 
(n=1). Data are expressed as relative ABCC6 mRNA expression compared to GAPDH (±SD). C) Isolation of 
leukemic CD45dimCD34+CD117+ progenitor cells from a patient treated with Ara-C monotherapy. Cells 
were isolated before treatment and at day 3 and 7 during treatment. Flow-cytometric analysis demon-
strates a decrease in CD34+ leukemic cells. D) Relative mRNA expression levels, compared to GAPDH, of 
ABCC6 (  ), ABCB1 ( ∆ ) and ABCC1 (  ) are presented.  
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Transduction of HEK293 cells
HEK293 cells were cultured in 175 cm2 flasks till 70% confluence, after which the 
culture medium was removed and 1.5 ml virus and 3.5 ml medium were added. The 
cells were incubated for 30-60 minutes at 37°C, after which 20 ml medium was 
added. After 24 hours of transduction, sodium butyrate (5 mM) was added. Two 
days after transduction cells were harvested.
Clonogenic survival assay
A total of 1x105 CHO and HEK293 cells were plated in 100mm Petri dishes and incu-
bated at 37°C for 24 hours. Cells were trypsinized, rinsed, counted and plated for 
microscopic colony formation. Cells were seeded at 1000 cells per well of a 6-well 
plate in triplicate in agarose containing various concentrations of Ara-C. The cul-
tures were incubated for 7 days at 37°C in humidified 5% CO2 in air, after 7 days 
colonies were scored on an inverted microscope.
Figure 2. ABCC6 overexpression induces proliferation. A) ABCC6 expression in mock (I) and ABCC6 trans-
fected (II) CHO cells assessed by immunocytochemistry using the specific monoclonal antibody M6II-7. 
B) Clonogenic assay to determine differences in proliferation rate in mock versus ABCC6 transfected 
cells. Mock and ABCC6 transfected CHO and HEK293 cells were plated in triplicate, in the absence of 
Ara-C for 7 days. Data from four (CHO) and two (HEK) independent experiments is expressed as absolute 
number of colonies (±SEM). C) Increased proliferation in ABCC6 transfected CHO cells. Mock and ABCC6 
transfected CHO cells were plated in the absence of Ara-C for 7 days. Photos of formed colonies are 
depicted.
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Preparation of membrane vesicles
Cell pellets were resuspended in 35 ml ice-cold hypotonic buffer (0.5mM sodium 
phosphate, 0.1mM EDTA, 0.1mM PMSF at pH 7.0) and shaken on ice for 90 minutes. 
Cells were centrifuged for 40 minutes at 100.000xg at 4°C and the pellet was re-
suspended in 35 ml ice-cold TS (isotonic) buffer (10mM Tris-Hepes, 250mM sucrose 
at pH 7.4) with protease inhibitors. Pellets were homogenized using a “tight-fit” 
douncer and centrifuged for 20 minutes at 1000xg at 4°C. The supernatants were 
centrifuged for 1 hour at 100.000xg at 4°C, and the pellet were resuspended in 500 
µl TS buffer and passed through a 27-gauge needle 30 times. Vesicles were stored 
at -80°C, after freezing them in liquid nitrogen.  
Vesicle transport experiments
Uptake of [3H]Ara-C into membrane vesicles was performed as described (9), with 
modifications. Membrane vesicles (20 µg of protein) were thawn for 1 minute at 
37°C and added to prewarmed TS buffer supplemented with an ATP-regenera-
tion mix (4 mM AMP or ATP, 10 mM MgCl2, 100 µg/ml creatine kinase and 10 mM 
creatine phosphate) and 0.7 µM [3H]Ara-C or 1 nM [3H]LTC-4 in a final volume of 60 µl. 
The reaction mixture was incubated at 37°C, and at indicated times, samples were 
taken from the mixture, diluted in 900µl of ice-cold TS buffer and filtered through 
Whatman NC 45 µm filters using a filtration device. Filters were washed once with 
5 ml of ice-cold TS buffer and dissolved in liquid scintillation fluid to determine the 
bound radioactivity. In all uptake experiments, net ATP-dependent transport was 
calculated by subtracting values in the presence of AMP from those in the presence 
of ATP. Measurements were corrected for the amount of ligand bound to the filters.
Figure 3. ABCC6 overexpression confers resistance to Ara-C induced cytotoxicity.  Clonogenic assay to 
determine Ara-C resistance in mock versus ABCC6 transfected cells. Mock and ABCC6 transfected CHO 
cells were plated in triplicate, in the presence of increasing concentrations of Ara-C for 7 days. Data from 
three independent experiments are expressed as relative number of colonies (±SEM) in comparison to 
untreated cells. 
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Measurement of reactive oxygen species
The generation of intracellular reactive oxygen species (ROS) was evaluated 
based on the intracellular peroxide-dependent oxidation of 2’-,7’-dichlorodihydro- 
fluorescein diacetate (DCFH-DA) to form the fluorescent compound 2’-,7’-dichloro-
fluorescein (DCF). The cells were plated in 24-well plates at the density of 2x105 cells 
per well. After treatment of the cells with either Ara-C or H2O2, the cells were incu-
bated with 10 µM DCFH-DA (from a stock solution of 4 mM DCFH-DA in ethanol) at 
37°C for 1 hour. The culture medium was removed, cells were washed with PBS and 
fluorescence intensity was determined using a Beckman Coulter Cytomics FC500 
with excitation at 488 nm and emission at 525 nm. The untreated groups were 
used as control and the results are expressed as a percentage of fluorescence with 
respect to the control.
Results
ABCC6 is highly induced in leukemic progenitor cells after exposure to Ara-C
In order to identify ABC transporters potentially involved in Ara-C resistance, we 
assessed gene expression of all transmembrane ABC transporters upon exposure 
to this drug in leukemic KG1a progenitor cells. We exposed KG1a cells to clinically 
achievable concentrations of Ara-C (10 ng/ml) for 72 hours, isolated RNA and 
determined the effect on expression of the ABC transporters by quantitative real-
time RT-PCR on low-density arrays. Figure 1a shows the fold-increase of all 45 ABC 
transporters after 72 hours of exposure. Twelve ABC transporters were identified 
that displayed significant upregulation (more than five fold) upon Ara-C exposure 
in KG1a cells. ABCC6 was the most highly induced transporter (409.9 ± 412.5 fold, 
n=2). Interestingly, no induction of the genetically closely linked ABCC1 transporter 
was observed in these cells, although co-regulation has been suggested (10, 11). 
Other highly induced genes included members of the ABCA6 subfamily (ABCA5, 
ABCA6, ABCA8, ABCA9 and ABCA10) and ABCB11. Also the known drug transporters 
ABCB1 and ABCG2 were upregulated 10.7 and 6.3 fold, respectively.
ABCC6 gene induction upon exposure to Ara-C was also observed in other human 
leukemic cell lines (U937 and HL60). In U937 cells the induction was 19-fold 96 
hours after treatment and in HL60 cells 38-fold at time point 72 hours (figure 1b).
ABCC6 is highly induced in CD34+ cells of a patient during Ara-C treatment
After we observed an ABCC6 induction in cell lines, we determined the ABCC6 
expression in leukemic progenitors (CD45dimCD34+CD117+) in a patient treated 
with Ara-C monotherapy for a relapsed AML (age 70 years, AML-M1 with normal 
cytogenetics). Anthracyclines could not be administered due to cardiac co-morbidity. 
CD45dimCD34+CD117+ leukemic cells were sorted from peripheral blood before 
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therapy and at day 3 and 7 during treatment (figure 1c). As foreseen, the number of 
blasts decreased during Ara-C exposure. By single real-time RT-PCR the expression 
of ABCC6, ABCB1 and ABCC1 was measured during treatment (figure 1d). Strikingly, 
ABCC6 was induced more than 1000-fold after 7 days of treatment with Ara-C, reach-
ing expression levels comparable to the housekeeping gene GAPDH. No upregula-
tion was observed for ABCB1 or ABCC1, confirming a lack of co-regulation of ABCC1 
and ABCC6 in leukemic primitive cells. Together these data demonstrate that ABCC6 
is highly upregulated in leukemic progenitor cells after exposure to Ara-C in vivo. 
ABCC6 overexpression in CHO cells induces increased proliferation and protection 
against Ara-C induced cytotoxicity
The strong upregulation of ABCC6 upon exposure to Ara-C in different leukemic cell 
lines and in an AML patient in vivo may indicate a role for ABCC6 in the protec-
tion against Ara-C induced apoptosis. This would be of particular importance since 
Ara-C is considered the key drug in leukemia treatment and molecular targets to 
Figure 4. ABCC6 mediated Ara-C resistance is substrate efflux independent. A) ABCC6 expression in 
vesicles from ABCC6 transfected CHO cells. Western blot loaded with vesicles of mock- and ABCC6 
transfected CHO cells stained with monoclonal antibody M6II-7. B) ATP dependent [3H]-Ara-C uptake, 
corrected for control (AMP) uptake, of mock and ABCC6 transfected CHO vesicles. Data are given as mean 
(±SD)(n=2). No ABCC6 mediated transport is observed. C) Transport of LTC4 by ABCC6 is not inhibited by 
the addition of Ara-C. [3H]-LTC4 transport (1nM) was measured in vesicles of CHO and CHO-ABCC6 cells 
without the addition of Ara-C. In addition, [3H]-LTC4 transport (2nM) was determined in the presence of 
Ara-C (4mM). Net ATP dependent [3H]-LTC4 uptake, corrected for control (AMP) uptake, of CHO vesicles 
is presented (±SD).
A
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circumvent Ara-C resistance are lacking. To address whether ABCC6 confers protec-
tion against Ara-C induced cytotoxicity we performed clonogenic assays using a 
stably ABCC6 transfected CHO cell line, with the empty vector transfected cell line 
as a control (12). Protein overexpression in ABCC6 transfected cells was demon-
strated with immunohistochemistry, using the monoclonal antibody M6II-7 (13) 
(figure 2a). 
ABCC6 expressing CHO cells showed enhanced clonogenic growth compared to 
empty vector transduced cells in the absence of Ara-C. Figure 2b shows the signifi-
cant increased colony number in CHO cells overexpressing ABCC6 compared with 
controls (empty vector) (CHO 213.7 ± 47.8 versus CHO-ABCC6 340.3 ± 39.9; p<0.05). 
In addition, colonies derived from ABCC6 expressing cells were significantly larger 
than the control cells (figure 2c). To rule out the possibility that these results were 
due to clonal variation, we repeated the experiments using baculovirus ABCC6 or 
YEFP transduced HEK293 cells. A significant higher number of colonies were formed 
also in ABCC6 transduced HEK293 cells (HEK 266.6 ± 12.1 versus HEK-ABCC6 410.0 ± 
7.2, p=0.01). The observed increased clonogenic growth suggests a role for ABCC6 
in cell proliferation.
ABCC6 overexpression protected CHO cells against Ara-C induced cytotoxicity as 
demonstrated by a stronger inhibition (p<0.05) of colony formation in the mock 
transfected cells compared to the ABCC6 transfected cells (figure 3). 
Since Ara-C is a cell cycle dependent drug, rapidly proliferating cells are expected 
to show higher drug sensitivity. Interestingly, the impaired chemosensitivity of 
ABCC6 transfected cells was observed despite a higher proliferation rate in com-
parison to their parental counterparts in unexposed cells. Together these data 
show that overexpression of ABCC6 induces proliferation and confers resistance to 
Ara-C induced cytotoxicity. 
ABCC6 mediated Ara-C resistance is drug efflux and oxidative stress independent
To unravel possible mechanisms behind Ara-C resistance in ABCC6 overexpress-
ing cells, we tested efflux of Ara-C by ABCC6. Transport studies using radioactive 
labeled Ara-C in membrane vesicles prepared from mock and ABCC6 transfected 
CHO cells were performed. 
Expression of ABCC6 in vesicles of ABCC6 transfected CHO cells was confirmed 
using Western blot analysis (Figure 4a). No ATP dependent transport of Ara-C 
by ABCC6 was found in the mock and ABCC6 transfected CHO cells (figure 4b). 
Active efflux of leukotriene C4 (LTC4) by ABCC6 has been demonstrated (12). In the 
presence of ATP, CHO membrane vesicles did show an ATP dependent transport of 
[3H]-LTC4 (figure 4c). The net ATP dependent transport increased in the CHO-ABCC6 
vesicles (1.7 fold compared to mock-transfected cells), showing active transport of 
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[3H]-LTC4 by ABCC6. The observed transport in the parental CHO cell line can be 
due to endogenous ABCC6 but also the presence of other transporters could be 
involved in transport of LTC4, such as ABCC2. 
The use of Ara-C in a competition assay with LTC4 did not influence the transport of 
LTC4 by ABCC6 (figure 4c). These results argue against a direct role of ABCC6 in the 
efflux of Ara-C in membrane vesicles of CHO and HEK293 cells.
As an alternative mechanism of conferring drug resistance, the role of ABCC6 in 
reducing oxidative stress was addressed. Induction of oxidative stress has been 
described as a crucial mechanism of Ara-C induced cytotoxicity (14, 15). A role for 
ABCC6 in the protection against oxidative stress has been described in fibroblasts 
isolated from pseudoxanthoma elasticum (PXE) patients, a disease caused by loss-
of-function mutations in the ABCC6 gene (16). We measured intracellular reactive 
oxygen species (ROS) production by flow cytometry for DCFH-DA. Figure 5a showed 
a concentration dependent induction of ROS after exposure to Ara-C. However, 
no difference in ROS production was found in the ABCC6 transfected CHO cells 
compared to the mock transfected CHO cells. Exposure to H2O2, another oxidative 
stress inducer, leads also to an increase in ROS production (figure 5b). Again, no 
protection against ROS production was found in the CHO cells transfected with 
ABCC6 compared to the mock transfected CHO cells. In conclusion these results do 
not support a role for ABCC6 in protection against oxidative stress.
Figure 5. ABCC6 does not protect against oxidative stress. A-B) CHO cells were exposed to increasing 
concentrations of Ara-C or H2O2 and the level of reactive oxygen species (ROS) was determined flow-
cytometrically using the DFCA probe. Data represent relative fold induction of ROS (±SD) after 48 hours 
of Ara-C (A) (n=3) and 2 hours of H2O2 (B) (n=2). No protection against oxidative stress was observed in 
ABCC6 transfected versus mock transfected cells. 
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Discussion
In the present study, we investigated the expression of ABC transporters during 
treatment with the antileukemic drug Ara-C. We show a strong upregulation of 
ABCC6 upon Ara-C exposure, while other transporters show moderate induction. 
This was shown in cell lines as well as in a patient during Ara-C only treatment. 
Moreover, overexpression of ABCC6 conferred increased proliferation and protec-
tion against Ara-C induced cytotoxicity. 
The ABCC6 gene has been localized to the short arm of chromosome 16p13.1 (17). 
The 4.5-kb ABCC6 mRNA encodes a 1503 AA protein that is located in the plasma 
membrane. The efflux pump is expressed in several secretory tissues but primarily in 
kidney and liver, suggesting a role in cellular detoxification. Glutathione conjugates, 
including leukotriene C4, S-(2, 4-dinitrophenyl)glutathione, the cyclopentapeptide 
BQ123 and N-ethylmaleimide S-glutathione (NEM-GS), are actively transported by 
human ABCC6. Organic anions inhibit the ABCC6 mediated NEM-GS transport in a 
specific manner, indicating that ABCC6 has a unique substrate specificity (12, 18). 
Loss of transport function mutations in the ABCC6 gene causes pseudoxanthoma 
elasticum (PXE), a heritable disorder characterized by calcification of elastic 
tissues. The pathogenetic role of ABCC6 in this disease remains unresolved (19, 
20). Recently, generated ABCC6-/- mice developed spontaneous calcifications of 
elastic fibers in blood vessel walls (21). 
We found only a single report investigating the potential of ABCC6 to confer resis-
tance to chemotherapeutical agents (12). ABCC6 transfected CHO cell lines conferred 
low level of resistance to several chemotherapeutics, like etoposide, tenoposide, 
doxorubicin and daunorubicin by effluxing these agents. Ara-C was not investigat-
ed in this study. Kool et al. (10) examined a large panel of resistant cell lines for the 
(over)expression of ABCC6. They described that overexpression of ABCC6 was only 
detectable in resistant cell lines known to have a high overexpression of ABCC1. 
Based on these results the authors concluded that overexpression of ABCC6 is a 
consequence of its coamplification with the ABCC1 gene, and that ABCC6 does not 
contribute to resistance in the analyzed cell lines, but Ara-C resistant cell lines were 
not investigated. We found no evidence of ABCC1 co-amplification in Ara-C exposed 
cells, suggesting a specific pathway of ABCC6 upregulation upon exposure to this 
agent. 
Of importance ABCC6 gene expression upregulation was confirmed in vivo in a 
patient treated with Ara-C monotherapy. The level of ABCC6 expression increased 
while the number of blasts in the peripheral blood decreased. We can argue that 
this increase in ABCC6 expression is due to either selection or induction. In other 
words, will only cells with relatively already high expression at diagnosis survive 
the Ara-C treatment, or is there a real induction of ABCC6 upon exposure to Ara-C? 
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Based on the results obtained in the KG1a cell line, a homogenous population with 
a very low ABCC6 expression, we hypothesize a mechanism of induction of ABCC6 
rather than selection. However, a definitive answer cannot be given based on our 
results. Nevertheless, both mechanisms stress the importance of the transporter 
in drug resistance.
Although we showed resistance to Ara-C by ABCC6, neither efflux of Ara-C by ABCC6 
nor inhibition of LTC4 transport by Ara-C was found. Co-expression of other trans-
porters could diminish the efflux of Ara-C by ABCC6, but still a difference between 
the control and ABCC6 transfected CHO cells was expected. Active transport of 
Ara-C metabolites, like the active metabolite Ara-CTP, has not been investigated, 
although the metabolites are expected to be also radioactively labeled. Membrane 
vesicles only contain the membranes of the cells, thereby lacking factors that may 
be essential for transporters functioning. Addition of factors previously identified 
to be important for ABCC transporters, e.g. GSH and BSA, did not improve transport 
function. These data support the conclusion that Ara-C is not transported by ABCC6 
in membrane vesicles of CHO and HEK293 cells. 
We showed that ABCC6 is highly induced upon different stress-inducing stimuli, 
including Ara-C and H2O2, but overexpression of ABCC6 does not protect the cells 
against oxidative stress. Evidence for a role of ABCC6 in diminishing oxidative stress 
was suggested by Pasquali-Ronchetti et al. (16). It was shown that in fibroblasts 
from patients suffering from PXE (caused by a mutation in ABCC6) a mild chronic 
oxidative stress due to the imbalance between production and degradation of 
oxidant species. Recently, also for ABCC1 cytoprotection against doxorubicin-
induced oxidative stress was shown, by extruding glutathione disulfide (GSSG) 
in cardiomyocytes (22). ABCC1 is known to be involved in the transport of non 
chemotherapeutic substrates, including glutathione and other conjugates, 
organic anions and LTC4. ABCC6 has a high similarity with ABCC1, and overlapping 
substrates. We used only a single method to determine ROS production. Further 
research on ROS production is needed to definitively exclude a role for ABCC6 in the 
protection against Ara-C induced oxidative stress.
Overexpression of ABCC6 resulted in an induction of proliferation, an unexpected 
finding. Furthermore it conferred resistance against Ara-C induced cytotoxicity. For 
two other transporters, ABCB1 and ABCG2, an effect on proliferation is described. 
Enforced expression of ABCB1 in bone marrow cells led to proliferation of side 
population (SP) cells, resulting in prolonged survival in culture and enhanced 
repopulation after transplantation into mice (23). Overexpression of ABCG2 inhibited 
hematopoietic development and resulted in less progeny in the bone marrow and 
peripheral blood (24). These transporters could potentially serve as novel stem cell 
markers and may confer required functional properties to these cells. We showed 
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that hematopoietic CD34+CD38- cells have a broad and high expression of ABC 
transporters, down regulated upon differentiation (25).
Both high proliferation rate as well as resistance are characteristics of malignant 
cells. So, ABCC6 could be an important target for modulation in reversing the 
proliferative and resistant phenotype. Although substrates for ABCC6 are known, a 
specific modulator has not been described. There is only one report investigating 
the inhibitory effect of various anionic compounds on the transport by ABCC6 (18). 
In that report it was shown that indomethacin had an inhibitory effect of 80% on 
ABCC6 mediated transport. In addition, orthovanadate, a well known non-covalent 
inhibitor of the ABC-ATPases completely inhibited the LTC4 transport activity of 
ABCC6. These two compounds could be candidates for modulation of ABCC6.
Besides ABCC6, 11 other ABC transporters were more than five fold induced after 
exposure to Ara-C in the KG1a cell line. ABCB11, that shows highest upregulation 
next to ABCC6, is a transporter already known to be involved in taxol resistance 
(26), although a role for ABCB11 in Ara-C transport is unknown. Also the ABCA6-
like family, consisting of ABCA5, ABCA6, ABCA8, ABCA9 and ABCA10, showed an 
upregulation upon exposure to Ara-C. Although the substrates and function of 
the ABCA transporters are largely unknown, the induction upon exposure to Ara-C 
either suggest a role for these transporters in drug resistance, or a common path-
way of induction. 
In conclusion, ABCC6 expression is strongly induced in leukemic progenitor cells 
upon exposure to Ara-C and confers increased proliferation and resistance against 
Ara-C induced cytotoxicity in overexpression models. Further studies will address 
the mechanisms behind the observed phenotypes and the role of ABCC6 as a 
molecular target to enhance chemosensitivity of leukemic progenitor cells in AML. 
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Summary and concluding remarks
Summary
Acute myeloid leukemia (AML) is a malignant clonal disorder, characterized by an 
arrest in differentiation, which results in an accumulation of immature abnormal 
myeloid cells in the bone marrow and peripheral blood. Consequently, the normal 
blood cell production is suppressed and the patient usually suffers from anemia, 
granulocytopenia and thrombocytopenia. As a consequence, the major symptoms 
are fatique, infections and bleeding. Most patients with AML achieve morphologi-
cal complete remission (<5% blasts in the bone marrow) after chemotherapeutical 
treatment, but the majority will relapse eventually. AML is considered a disease 
originating in transformed hematopoietic stem cells in most AML confined to the 
CD34+CD38- population. Recognition of AML as a stem cell disease directs the 
treatment of leukemia away from the blast cells towards the stem cell. This stem 
cell concept may be generalized to many other cancers.
Standard treatment of AML is chemotherapy, which can be hampered by multidrug 
resistance (MDR) against the cytotoxic drugs. MDR is defined as an increased efflux 
of structurally unrelated drugs and is generally due to expression of ABC transport-
ers. ABCB1, ABCC1 and ABCG2 are the best-studied transporters associated with 
drug efflux and leading to drug resistance. 
The studies described in this thesis focus on the expression, function and role 
of ABC transporters in drug resistance in CD34+CD38- normal and leukemic 
hematopoietic stem cells. Both in normal and leukemic stem cells we observed a 
high baseline expression of many transporters. ABC transporter expression was 
mainly conserved after malignant transformation of stem cells, which might be an 
important mechanism of intrinsic drug resistance in this leukemia-initiating cell 
population. To improve AML treatment, inhibitors of drug efflux have been devel-
oped to increase the cellular accumulation of chemotherapeutics. Although the 
expression of ABCB1 and ABCG2 has been widely studied in AML, only a limited 
number of studies investigated expression and function within the CD34+CD38- cell 
population. To our knowledge no studies compared the expression and function of 
ABC transporters between normal and malignant hematopoietic primitive and more 
committed progenitor cells. In drug resistance studies the expression and function 
of ABC transporters is measured only at diagnosis and in relapse samples. Studies 
which measure the kinetics of ABC transporters during in vivo exposure to drugs, 
such as anthracyclines, are lacking. All these elements, the focus on the leukemic 
stem cell population, the high expression and redundancy of ABC transporters on 
stem cells and the dynamics of ABC transporter expression in leukemic cells upon 
exposure to chemotherapeutical agents addressed in this thesis may have major 
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implications for chemotherapy scheduling and the use of ABC transporter inhibi-
tors in drug resistance. 
In chapter 2 and 3 we investigated expression and function of the classical MDR 
genes ABCB1 and ABCG2 in hematopoietic CD34+CD38- primitive cells in AML in 
comparison to their normal counterparts. These two ABC transporters are highly 
expressed on a variety of stem cells, including hematopoietic stem cells, and 
they mediate transport of drugs used in the treatment of AML (e.g. mitoxantrone, 
anthracyclines and vinca alkaloids).
In chapter 2 we studied ABCB1 mediated transport and expression in CD34+CD38- 
in AML in comparison to the immunophenotypically identical fraction in normal 
bone marrow. We demonstrated that ABCB1 was the major drug transporter in 
normal CD34+CD38- cells. The mitoxantrone and rhodamine123 dull phenotype 
could be abrogated by the use of specific ABCB1 modulators (verapamil and PSC833). 
Surprisingly, ABCB1 mediated transport of mitoxantrone was invariably reduced in 
CD34+CD38- cells in AML, which resulted in increased intracellular mitoxantrone 
levels in these cells. Both verapamil and PSC833, specific inhibitors of ABCB1, 
did not enhance intracellular mitoxantrone and rhodamine 123 fluorescence. The 
observation that the function of ABCB1 is impaired in leukemic CD34+CD38- cells 
indicates that influencing ABCB1 efflux may preferentially affect normal and non-
leukemic primitive progenitors.  Furthermore, the observed efflux of drugs from 
CD34+CD38- cells in the presence of ABCB1 modulators suggests the activity of 
other ABC transporters in leukemic cells. 
In chapter 3 we investigated the role of the Breast Cancer Resistance Protein (BCRP/
ABCG2) in drug resistance of leukemic CD34+CD38- primitive cells and the effect 
of modulation of this transporter on eradication of this primitive cell population 
in AML. ABCG2 was preferentially expressed (measured by both real-time RT-PCR 
and at the protein level by flow-cytometry using the BXP21 monoclonal antibody) 
and functionally active in primitive CD34+CD38- hematopoietic cells compared 
with more differentiated cells in human normal bone marrow. Also in AML, ABCG2 
was preferentially expressed in the CD34+CD38- cells, which accumulated less 
mitoxantrone compared to the more committed CD34+CD38+ progenitor cells. 
Selective inhibition of ABCG2 by KO143, the most potent ABCG2 inhibitor available, 
increased cellular mitoxantrone levels only marginally and did not result in a sig-
nificant increase in mitoxantrone induced apoptosis to leukemic CD34+CD38- cells. 
Moreover, we observed substantial drug efflux in leukemic CD34+CD38- cells in the 
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presence of ABCG2 inhibitors, demonstrating that other drug transporters must be 
active in these cells. 
These two studies confirmed that ABCB1 and ABCG2 are involved in transport of 
chemotherapeutical drugs from normal and leukemic CD34+CD38- primitive cells, 
but also it became clear that additional drug efflux mechanisms must be active 
in leukemic stem cells. To identify additional drug efflux mechanisms we decided 
to study the expression of all transmembrane ABC transporters in human hema-
topoietic CD34+CD38- cells in comparison to the more committed CD34+CD38+ 
progenitor cells (chapter 4). Cells were isolated from healthy donor peripheral blood 
and bone marrow stem cell collections (n=11) and from AML bone marrow (n=13). 
We assessed gene expression profiles with a novel quantitative real-time RT-PCR 
using microfluidic cards (low density arrays). In normal CD34+CD38- cells 36/45 
ABC transporters were expressed and strikingly, all 36 ABC transporters showed 
a higher expression in the CD34+CD38- fraction. For 22 the expression difference 
was statistically significant. Among the differentially expressed genes the known 
MDR ABC-transporters (ABCB1, ABCC1 and ABCG2) were found but in addition we 
found many members of the ABC transporter family not described to be expressed 
on stem cells. In leukemic CD34+CD38- cells the ABC transporter profile was largely 
conserved, although exceptions occurred. All currently known ABC transporters 
involved in drug resistance were expressed in normal and leukemic primitive 
cells. We also identified many ABC transporters currently not associated with drug 
resistance, which may be involved in drug efflux mediated resistance of leukemic 
CD34+CD38- cells. These transporters can be potential new targets to enhance 
chemotherapeutical eradication of leukemic stem cells in AML, although many of 
these are almost equally expressed on normal stem cells in steady state condi-
tions.
The basal ABC transporter expression may be changed by drug exposure, as has 
been described in cell lines and AML at relapse. In most drug resistance studies 
the expression and function of ABC transporters has been compared in diagnosis 
and relapse samples. In Chapter 5 we determined the kinetics of all ABC transmem-
brane transporters during exposure to antileukemic drugs, in a cell line in vitro, 
primary AML samples but also in vivo in patients on chemotherapy for acute leuke-
mia. The dynamics of ABC transporter expression in leukemic cells upon exposure 
to chemotherapeutical agents could identify novel transporters involved in drug 
resistance and may have implications for chemotherapy scheduling. We assessed 
gene expression in the AML cell line KG1a and in AML CD34+ cells after short-term 
exposure to anthracyclines by quantitative real-time RT-PCR on microfluidic cards. 
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Short-term exposure to anthracyclines in vitro rapidly induced a large range of ABC 
transporters in leukemic progenitor cells. These induced transporters included 
both known drug transporters as well as transporters not previously associated 
with drug transport or drug resistance. We also collected blood samples of patients 
before and during treatment for acute leukemia.  In different acute leukemia’s and 
for different therapy schedules, ABC transporters were induced in all patients. If 
mRNA expression reflects protein expression and efflux function, these transport-
ers may also be involved in chemoresistance of leukemic progenitor cells.
Next to anthracyclines, Ara-C (cytarabine) is one of the most important antileukemic 
drugs currently available for the treatment of AML. Many mechanisms for resistance 
to Ara-C have been identified, but an effect on ABC transporters has never been 
described. In Chapter 6 we investigated the effect of Ara-C on ABC transporter 
expression. We examined the expression of all ABC transmembrane transporters 
in KG1a cells upon exposure to Ara-C by real-time RT-PCR on micro fluidic cards. 
In KG1a cells a number of ABC transporters were induced, ABCC6 showed the 
strongest induction. This ABCC6 induction after exposure to Ara-C was confirmed 
in other leukemic cell lines and was also observed in vivo, in a patient with AML 
treated by Ara-C monotherapy. The strong upregulation of ABCC6 suggests a role 
for ABCC6 in the protection against Ara-C induced apoptosis. Overexpression of 
ABCC6 resulted in impaired chemosensitivity to Ara-C, confirming a role for ABCC6 
in Ara-C resistance. To unravel the mechanism of Ara-C resistance of ABCC6 we used 
CHO cells stably transfected with ABCC6. No active transport of Ara-C by ABCC6 was 
found in a vesicle assay using radio-active Ara-C. Furthermore, a role for ABCC6 in 
the protection against oxidative stress has been suggested. Ara-C is also an inducer 
of oxidative stress, but our results did not support a role for ABCC6 in the protection 
against oxidative stress. Further studies are warranted to unravel the mechanism 
behind the Ara-C resistance in ABCC6 expressing cells.
Concluding remarks and future perspectives
Studies in this thesis demonstrate that in primitive leukemic CD34+CD38- cells 
ABCB1 mediated transport is impaired in comparison to normal CD34+CD38- stem 
cells. An explanation for this phenomenon should be the topic of future studies. 
Sequencing for mutations in the ATP binding domain region did not show mutations 
explaining the functional defect (data not shown). Since ABCB1 modulation did not 
lead to an increased intracellular drug accumulation, activity of other ABC trans-
porters in leukemic cells was supposed. ABCG2 was studied as a candidate ABC 
transporter explaining additional drug efflux. ABCG2 is preferentially expressed in 
CD34+CD38- cells and blockage of ABCG2 mediated transport resulted in increased 
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drug accumulation in these cells. However, efflux still occurred in the presence of 
ABCG2 blockage, which implies more redundancy in efflux mechanisms. We decided 
to perform gene expression profiling for all 45 ABC transmembrane transporters in 
normal and leukemic CD34+CD38- cells, which revealed:
•	 	The	expression	of	many	ABC	transporters	both	in	normal	(36	out	of	45)	and	in	
leukemic (40 out of 45) CD34+CD38- hematopoietic progenitor cells, including 
many ABC transporters already associated with drug transport. 
•	 	The	 ABC	 transporter	 expression	 profile	 of	 CD34+CD38-	 cells	was	 largely	 con-
served in AML, 31 out of  35 were comparable.
•	 	Upon	exposure	to	anthracyclines	and	cytarabine	many	ABC	transporters	showed	
a rapid  (within 24-72 hours) increase in gene expression.
II. Implications for targeting ABC transporters as a strategy to eradicate leukemic 
stem cells
Based on these data, we hypothesize that modulation of a single drug efflux 
mechanism, such as ABCB1 or ABCG2, will not result in sufficient increase in drug 
accumulation, to significantly enhance eradication of the leukemic stem cell 
population. Additionally, ABCB1 efflux is reduced in leukemic CD34+CD38- cells 
compared to their normal counterparts. Therefore, the ABCB1 modulation may even 
preferentially affect normal hematopoietic stem cells. 
This outcome challenges the rationale for the use of ABCB1 modulation in the treat-
ment of AML and may explain the disappointing results from clinical trials showing 
no clear antileukemic benefit of ABCB1 modulation. On the contrary, an increased 
toxicity was observed, most probably due to altered plasma kinetics, since ABCB1 
(as many other ABC transporters) plays a major role in liver and kidney for drug 
elimination. The clinical observation that ABCB1 modulation has not resulted in 
increased overall and relapse-free survival in AML, which would be expected if ABC 
drug transport inhibitors function as “leukemia stem cell sensitizing agent”, seems 
congruent with the laboratory findings described in this thesis.
Another argument against targeting ABCB1 is that most studies, including ours 
have shown that stem cells overexpress ABCG2, rather than ABCB1. ABCG2 
appeared to be preferentially expressed in leukemic CD34+CD38- cells and to 
contribute to mitoxantrone efflux in these cells. ABCG2 expression and efflux in 
leukemic CD34+CD38- cells are not different from expression and function in normal 
CD34+CD38- cells, thus reflecting a conserved physiological function of ABCG2 in 
primitive hematopoietic cells rather than a leukemia-associated phenotype. Selec-
tive blockade of ABCG2-mediated drug extrusion by the novel fumitremorgin (FTC) 
C analogue KO143, the most potent ABCG2 inhibitor currently available, resulted in 
increased intracellular mitoxantrone accumulation in leukemic CD34+CD38- cells 
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in most patients but did not significantly increase chemosensitivity to this agent. 
This lack of a chemosensitizing effect by KO143 was anticipated by the observation 
of substantial drug efflux in leukemic CD34+CD38- cells in the presence of ABCG2 
inhibition, conferred by other drug transporters, among which are ABCB1, ABCC1 
and other transporters.
The observation that drug efflux in leukemic CD34+CD38- cells is conferred by 
simultaneous action of many ABC transporters suggests that the use of broad-spec-
trum inhibitors is required for more effective eradication of leukemic stem cells 
rather than the modulation of single efflux mechanisms. The report of improved 
clinical outcome in a trial using cyclosporine, in contrast to the poor results of 
trials using more selective ABCB1 modulators, could be in line with this assumption 
since cyclosporine is a more promiscuous ABC transporter inhibitor with effects on 
both ABCB1 and ABCG2 (and perhaps also other ABC transporters). The disadvan-
tage of the strategy of broad spectrum modulation of ABC transporters is enhanced 
hematological toxicity, since the majority of these ABC transporters is present and 
functional on normal hematopoietic CD34+CD38- cells. Furthermore, these ABC 
transporters are also involved in detoxification processes in liver and kidney, so 
broad spectrum inhibition will also lead to increased non-hematological toxicity. 
In our approach to exploit ABC transporter modulation to target leukemic stem 
cells it was important to show the high redundancy and relatively high expression 
level as well as the largely conserved expression of many transporters after leuke-
mic transformation. Nevertheless, some transporters show a different expression 
pattern in the normal and leukemic stem cell population, which may be exploited in 
a more selective eradication of leukemic cells. Furthermore, comparing ABC trans-
porter expression profiles at diagnosis and relapse as well as in refractory leukemia 
may be important to identify transporters involved in clinical drug resistance. 
It was an intriguing finding that drug exposure resulted in a rapid and significant 
upregulation ABC transporters, within 24-72 hours after starting drug exposure, 
while the chemotherapy exposure was still ongoing. These regulated transporters 
may have an important role in drug resistance and as such deserve specific atten-
tion in future studies. In that respect it is also relevant to get more knowledge on 
the regulatory pathways of ABC transporters in normal and malignant stem cells 
during drug exposure. Differences, which may be specific for certain leukemia’s 
could be exploited for a more individualized eradication approach of leukemic stem 
cells.
When performing these investigations it remains important to realize that ABC 
transporters are not the only players in drug resistance in cancer stem cells. These 
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long-lived cells are likely to be naturally resistant to chemotherapy through their 
quiescence, precluding efficacy of drugs that target either the cell cycle or rapidly 
dividing cells, their capacity for DNA repair and reluctance to enter apoptosis. 
Solving the problem of drug resistance in cancer warrants further research into all 
mechanisms of drug resistance, with focus on the cancer stem cells to offer future 
patients an increasing change on cure from this disease.
III. Role of ABC transporters in stem cell biology
A striking observation we made in these studies was, apart of the large redundancy 
of transporters the preferential expression on stem cells: all transporters showed 
a decrease in expression during differentiation to more committed progenitor 
cells. This raises questions regarding the role of ABC transporters in normal and 
malignant stem cells. The function of these ABC transporters in human stem cells is 
largely unknown. Insights in the potential role of ABC transporters in differentiation 
of cells, came from studies in Dictyostelium demonstrating that a rhodamine-123 
cellular efflux pump with the properties of an ABC transporter was able to prevent 
differentiation of prespore cells. Blockade of the pump resulted in differentia-
tion. A proposed mechanism is efflux of differentiation factors from the cell by the 
transporter to maintain the stem cells stage. Additionally, for two ABC transport-
ers, ABCB1 and ABCG2, an effect on the balance between proliferation and differ-
entiation has been described. Enforced expression of ABCB1 in bone marrow cells 
led to proliferation of side population (SP) cells, resulting in prolonged survival 
in culture and enhanced repopulation after transplantation into mice. Overexpres-
sion of ABCG2 inhibited hematopoietic development and resulted in less progeny 
in the bone marrow and peripheral blood. These transporters may serve as novel 
stem cell markers and may confer required functional properties to these cells. 
The differential expression of 5 members of the ABCA subfamily (ABCA6-like 
subfamily on chromosome 17q24 and ABCA13) within the top ten ranking order 
of highest expressed genes in CD34+CD38- cells compared to CD34+CD38+ cells 
supports a  potential role in stem cell maintenance. Recent studies suggest that 
members of the ABCA subclass are involved in the transmembrane transport of 
endogenous lipid substrates, such as phospholipids and essential fatty-acids, 
involved in the regulation of differentiation of hematopoietic cells.
To identify ABC transporters that are crucial for stem cell biology it will be impor-
tant to establish a profile of ABC transporter expression not only in hematopoietic 
stem cells but also stem cells from other tissues. Moreover, the functional role of 
ABC transporters in stem cell biology and normal hematopoiesis may be relevant 
in leukemia, since its role does originate from the normal stem cells. It is conceiv-
able that molecules involved in cell fate decisions and differentiation of these 
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stem cells have a key role in carcinogenesis, a process characterized by failure of 
differentiation. Furthermore, differences between leukemic and normal stem cells, 
for example ABCA13, should be further characterized as being potential candidates 
for specific targeting.
The increasing recognition that cancer originates from normal stem cells and that 
molecules involved in cell fate decisions and differentiation of stem cells have a 
key role in carcinogenesis prompts further investigations in this direction. Whether 
these aberrant expression patterns reflect differences in differentiation state of 
leukemic and normal stem cells or are directly involved in the differentiation failure 
of HSC in leukemia, however, is currently unknown. The role of these ABC transport-
ers must be characterized functionally using both in vitro RNA inhibition and vector 
overexpression studies and in vivo transplantation models.
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Nederlandse samenvatting
De vorming van bloedcellen vindt plaats in het beenmerg waar de beenmergstam-
cellen zich bevinden. Uit deze stamcellen ontstaan na proliferatie en differentiatie 
de verschillende soorten bloedcellen: rode en witte bloedcellen en bloedplaatjes. 
Specifieke veranderingen in het erfelijke materiaal (DNA) in een normale been-
mergstamcel kan uiteindelijk leiden tot acute myeloide leukemie (AML). Bij patiënt-
en met AML is sprake van gestoorde uitrijping van beenmergstamcellen. De cellen 
blijven steken in een onrijp stadium, onder de microscoop te zien als een toename 
van blasten. We spreken van een acute leukemie indien het beenmerg meer dan 
20% blasten bevat. Door deze ophoping van leukemiecellen komt de productie van 
normale bloedcellen in het gedrang. Bij AML ontstaan in korte tijd klinische symp-
tomen, vooral veroorzaakt door het tekort aan normale bloedcellen. Veel voorko-
mende verschijnselen zijn: vermoeidheid, bleekheid, spontane bloedingen, infec-
ties, koorts en gewichtsverlies. Zonder behandeling is de gemiddelde overleving 
van een patiënt met AML enige weken tot maanden.
De behandeling van patiënten met AML bestaat meestal uit het geven van chemo-
therapie kuren, welke bestaan uit combinaties van verschillende soorten celrem-
mende medicijnen, cytostatica genoemd. Na intensieve chemotherapeutische be-
handeling bereikt een groot aantal patiënten een complete remissie, dat wil zeggen, 
dat minder dan 5% blasten aantoonbaar zijn in het beenmerg. Na het bereiken van 
een complete remissie volgen een aantal kuren om de overgebleven leukemiecellen 
nog verder te reduceren. Helaas komt bij veel patiënten de ziekte na verloop van 
tijd toch weer terug; dit wordt een recidief genoemd. Dit betekent dat leukemische 
stamcellen de chemotherapie overleven en uitgroeien tot een recidief van de acute 
leukemie. Het lijkt dus belangrijk te achterhalen wat de mechanismen zijn waardoor 
juist deze stamcellen overleven, zodat een therapie ontwikkeld kan worden gericht 
op de leukemische stamcellen.
De gebruikte cytostatica in de behandeling van AML zijn geneesmiddelen die alleen 
effectief werken wanneer ze op de juiste plaats in de cel komen. Dit proces wordt 
echter bemoeilijkt door de aanwezigheid van transporteiwitten in de leukemie-
cellen. Sommige van deze transporteiwitten zijn namelijk in staat cytostatica de 
cel uit te pompen. Hierdoor wordt de effectieve concentratie in de cellen verlaagd 
en hebben de leukemiecellen een grotere kans te overleven. Belangrijke transpor-
ters zijn de ATP bindende cassette (ABC) transporters, die meerdere klassen van 
cytostatica kunnen uitpompen en daarom ook wel multi drug resistentie pompen 
worden genoemd. Van deze groep van transporters zijn er in mensen 49 bekend, 
verdeeld over zeven subfamilies (A-G). Van enkele van deze transporters is bekend 
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dat ze een rol spelen bij het optreden van ongevoeligheid voor cytostatica in AML, 
dit zijn ABCB1, ABCC1 en ABCG2.
Doel van dit proefschrift is inzicht krijgen in de expressie, functie en rol van ABC 
transporters in chemotherapieresistentie van leukemische stamcellen, waarbij de 
normale stamcel als referentie gebruikt wordt. 
Hematopoietische stamcellen zijn zeldzaam in het beenmerg, slechts 1 op de 10.000 
cellen is een stamcel. Eiwitten op de celwand die in combinatie stamcelspecifiek 
zijn en aangekleurd kunnen worden middels monoclonale antistoffen, maken het 
mogelijk lage concentraties stamcellen aan te tonen. De aanwezigheid van het 
eiwit CD34 en een lage expressie van het eiwit CD38 kenmerkt de stamcelpopula-
tie (CD34+CD38-). Wanneer deze cellen uitrijpen neemt de hoeveelheid CD38 eiwit 
toe, aanvankelijk met behoud van CD34-expressie (CD34+CD38+).
In hoofdstuk 2 en 3 hebben we gekeken naar de expressie en functie van ABCB1 en 
ABCG2 in normale en leukemische hematopoietische stamcellen. ABCB1 en ABCG2 
zijn twee transporters waarvan beschreven is dat ze hoog tot expressie komen op 
velerlei stamcellen waaronder de hematopoietische stamcellen. Deze transpor-
tereiwitten zijn ook betrokken bij het transport van cytostatica (bijvoorbeeld mito-
xantrone en daunorubicine) welke gebruikt worden in de behandeling van AML. 
In hoofdstuk 2 hebben we gekeken naar ABCB1-expressie en -functie in leuke- 
mische CD34+CD38- cellen, en vergeleken met dezelfde celfractie in normaal been-
merg. We laten zien dat ABCB1 de belangrijkste transporter is voor de fluorescente 
kleurstof rhodamine-123 en het cytostaticum mitoxantrone in normale CD34+CD38- 
cellen. Voor ABCB1 zijn specifieke remmers bekend, verapamil en PSC833, hiermee 
kan transport van ABCB1 worden geremd waardoor mitoxantrone de cel niet meer 
kan verlaten. Dit bleek ook het geval te zijn in de normale CD34+CD38- cellen, 
alleen in de leukemische CD34+CD38- cellen werd mitoxantrone nog steeds de cel 
uit gepompt ondanks de aanwezigheid van de specifieke remmers. In alle AML mon-
sters die gemeten zijn hebben we een verlaagd ABCB1 transport gevonden, terwijl 
de eiwitexpressie vergelijkbaar was voor normale en AML stamcellen. Dat remming 
van ABCB1 transport in leukemie niet leidde tot blokkade van transport duidt erop 
dat andere transporters betrokken moeten zijn bij het pompen van mitoxantrone in 
leukemische CD34+CD38- cellen. Op basis van verschil in transportfunctie in AML 
beenmerg konden we zelfs de nog aanwezige normale CD34+CD38- cellen identi-
ficeren.
Verscheidene klinische studies beschrijven bij AML patiënten de toepassing van 
remmers van ABCB1 om het uitpompen van cytostatica uit leukemische stamcel-
len tegen te gaan. In hoofdstuk 2 laten we echter zien dat dit een niet erg zinvolle 
benadering lijkt te zijn: de leukemische cellen zullen hier geen ernstige hinder van 
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ondervinden, maar wel kunnen de resterende normale stamcellen geschaad worden. 
Deze bevindingen geven mogelijk een verklaring voor de overwegend teleurstel-
lende resultaten van het gebruik van specifieke ABCB1 remmers in eerdere studies 
bij AML patiënten.
 
Het gegeven dat in leukemische CD34+CD38- cellen nog steeds efflux van mito-
xantrone plaatsvindt in de aanwezigheid van specifieke remmers van ABCB1 
suggereert dat andere transporters betrokken zijn bij transport van mitoxantrone. 
ABCG2 is zo’n ABC transporter waarvan bekend is dat deze tot expressie komt op 
hematopoietische stamcellen. Daarnaast is van ABCG2 bekend dat het betrokken 
is bij geneesmiddelresistentie in leukemische CD34+CD38- cellen. In hoofdstuk 3 
hebben we gekeken naar de expressie en de rol van ABCG2 in geneesmiddelresistentie 
in leukemische CD34+CD38- cellen en het effect van specifieke remming van 
transport van ABCG2. ABCG2 komt hoger tot expressie op normale en leukemische 
CD34+CD38- stamcellen in vergelijking tot meer uitgerijpte CD34+CD38+ cellen. 
Remming van transport door ABCG2, met een specifieke ABCG2 remmer KO143, 
resulteerde in een toename van de hoeveelheid mitoxantrone in de leukemische 
CD34+CD38-cellen in de meerderheid van de AML patiënten. Echter, in vergelijking 
met de cellijn MCF7-MR, een cellijn met hoge expressie van ABCG2, was deze 
toename in accumulatie gering. Dit suggereert dat in leukemische CD34+CD38- 
stamcellen, in de aanwezigheid van een specifieke remmer voor ABCG2, nog steeds 
efflux van mitoxantrone plaatsvindt. Belangrijk was de bevinding dat de specifieke 
remming van ABCG2 transport ook niet leidde tot een toename in gevoeligheid voor 
chemotherapie in leukemische CD34+CD38- stamcellen.
De resultaten van de eerste twee hoofdstukken laten zien dat ABCB1 en ABCG2 
betrokken zijn bij het transport van chemotherapeutica in normale en leukemische 
CD34+CD38- stamcellen maar dat ook andere transporters betrokken zijn bij de 
efflux van chemotherapie. Wij concluderen dan ook dat het remmen van alleen deze 
transporters onvoldoende effectief zal zijn om het ontsnappen van leukemische 
stamcellen aan chemotherapie te voorkomen. 
Om de betrokkenheid van andere transporters aan te tonen hebben we in hoofd-
stuk 4 gekeken naar de expressie van alle transmembraan ABC transporters (fami-
lie A, B, C, D en G) in normale en leukemische CD34+CD38- cellen. Dit hebben we 
gedaan met een nieuwe methode van real-time RT-PCR de microfluidic card (MFC), 
een techniek die de mate van expressie van een gen aantoont. Met de MFC kunnen 
we in één monster op hetzelfde moment de expressie van alle 45 ABC transpor-
ters meten, met een zeer kleine hoeveelheid RNA. Primitieve en meer rijpe voor-
loper-cellen (CD34+CD38- en respectievelijk CD34+CD38+) werden gesorteerd uit 
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normaal beenmerg, perifere bloedstamcel transplantaten (n=11) en uit beenmerg 
van AML patiënten (n=13). In normale CD34+CD38- cellen vonden we zeer brede 
expressie van 36/45 ABC transporters. Opvallend was dat alle transporters een 
hogere expressie vertoonden in de stamcellen (CD34+CD38- fractie), voor 22 
transporters was dit ook een statistisch significant verschil in expressie. Naast 
de expressie van transporters waarvan de rol in drug transport en geneesmiddel- 
resistentie bekend is, zoals ABCB1 en ABCG2, vonden we veel ABC transporters 
die niet eerder beschreven zijn als chemotherapie transporters of waarvan nog 
helemaal geen functie bekend is. In leukemische stamcellen van diverse patiënten 
bleek het expressiepatroon grotendeels vergelijkbaar, al waren er ook verschillen. 
 Alle transporters waarvan beschreven is dat ze een rol spelen in de efflux van 
chemotherapie kwamen op leukemische CD34+CD38- cellen tot expressie. Onder-
zoek naar de functie van deze “nieuwe” ABC transporters is nodig om de rol in 
geneesmiddelresistentie te ontrafelen.
In hoofdstuk 5 hebben we gekeken naar het verloop van de expressie van 
ABC transporters als reactie op blootstelling aan cytostatica. In geneesmiddel- 
resistentie studies is tot nu toe alleen gekeken naar de mate van expressie en 
functie van ABC transporters bij diagnose en bij een recidief. De dynamiek van 
ABC transporterexpressie in leukemische cellen gedurende blootstelling aan 
chemotherapie kan mogelijk nieuwe ABC transporters identificeren die betrokken 
zijn bij geneesmiddel-transport en -resistentie. Ook kan het relevant zijn de snel-
heid van regulatie te kennen. We hebben eerst gekeken naar de verandering in 
ABC transporter-expressie, in de KG1a cellijn (een primitieve cellijn, gemaakt uit 
leukemiecellen van een AML patiënt) en in leukemische CD34+ cellen geïsoleerd 
uit beenmerg van AML patiënten, gedurende relatieve korte blootstelling (maxi-
maal 3 dagen) aan twee cytostatica, mitoxantrone en daunorubicine. Blootstelling 
aan beide chemotherapeutica resulteerde in een verhoogde expressie van een 
groot aantal ABC transporters. Deze bestonden uit zowel transporters die al eerder 
geassocieerd waren met geneesmiddeltransport en -resistentie als transporters 
waarvoor nog geen rol hierin beschreven is. Naast het blootstellen van cellen in 
vitro, hebben we ook bij patiënten voor en gedurende hun behandeling met chemo-
therapie leukemische blasten uit het bloed bestudeerd. Zowel in AML, ALL en CML 
blastencrisis en tijdens wisselende behandelschema’s vonden we in de meeste 
patiënten een aantal ABC transporters die hoger tot expressie kwamen 48 tot 72 
uur na de start van de behandeling. Ook hier vonden we zowel ABC transporters 
die al beschreven zijn in geneesmiddeltransport en -resistentie als nog onbekende 
transporters. Genexpressie is de eerste aanduiding, maar vervolgens is het ook 
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belangrijk om te kijken naar eiwitexpressie en een mogelijke functie van deze trans-
porters in geneesmiddeltransport en -resistentie.
Hoewel mitoxantrone en daunorubicine veel gebruikt worden in de behandeling 
van AML, worden deze cytostatica vrijwel altijd gecombineerd met Ara-C (cytara-
bine). Alhoewel meerdere resistentiemechanismen voor Ara-C een rol spelen, 
is efflux middels ABC transporters nooit bestudeerd. In hoofdstuk 6 hebben we 
gekeken naar een mogelijke rol voor ABC transporters in de resistentie tegen Ara-C. 
Met behulp van real-time RT-PCR op de MFC hebben we gekeken naar de dynamiek 
van alle ABC transporters gedurende blootstelling aan Ara-C in de leukemie cellijn 
KG1a. Ook na blootstelling aan Ara-C zagen we dat ABC transporters (hoewel minder 
in aantal dan na mitoxantrone of daunorubicine) werden geïnduceerd, waarvan 
ABCC6 de sterkste inductie liet zien. Deze hogere expressie hebben we ook in de 
leukemische cellen van een patiënt met AML, alleen behandeld met Ara-C, kunnen 
bevestigen. Deze sterke inductie van onder andere ABCC6 zou kunnen betekenen 
dat ABCC6 een rol speelt in de bescherming tegen Ara-C geïnduceerde celdood. 
Wanneer we ABCC6 tot overexpressie brengen in een cellijn zijn deze cellen minder 
gevoelig voor Ara-C, wat inderdaad een rol voor ABCC6 in de bescherming tegen 
Ara-C zou kunnen betekenen. Aangezien ABCC6 een transporter is hebben we ge-
keken of ABCC6 in staat is Ara-C de cel uit te pompen. We hebben echter geen actief 
transport van Ara-C door ABCC6 gevonden in een assay met radioactief Ara-C in 
membraanvesicles. Er is een rol voor ABCC6 gesuggereerd in de bescherming tegen 
oxidatieve stress. Aangezien Ara-C ook stress induceert, hebben we cellen bloot-
gesteld aan Ara-C en gekeken naar de productie van reactieve zuurstofradicalen. 
Onze resultaten laten echter geen bescherming van ABCC6 tegen oxidatieve stress 
zien. Vervolgstudies zijn nodig om het mechanisme achter de Ara-C resistentie door 
ABCC6 te ontrafelen.
Conclusie en toekomstperspectieven
De studies in dit proefschrift laten zien dat in primitieve leukemische CD34+CD38- 
cellen het transport door ABCB1 geremd is in vergelijking tot dezelfde fractie in 
normaal beenmerg. Omdat remming van ABCB1 transport geen toename van intra-
cellulaire concentratie chemotherapie heeft laat zien, hebben we gekeken naar een 
andere transporter, namelijk ABCG2. ABCG2 komt ook tot expressie op CD34+CD38- 
cellen en blokkade van transport door ABCG2 leidt tot een verhoging van de intra-
cellulaire concentratie van chemotherapie. Echter de blokkade is niet compleet wat 
duidt op transport van andere transporters. Door het uitvoeren van een screen van 
alle 45 transmembraan transporters tussen normale en leukemische CD34+CD38- 
cellen, hebben we de volgende conclusies kunnen trekken:
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•	 	Veel	ABC	transporters	komen	tot	expressie	op	normale	(36	van	de	45)	en	leuke-
mische (40 van de 45) CD34+CD38- cellen, waaronder ook de al met chemothera-
pie transport bekende ABC transporters.
•	 	Het	 ABC	 transporters	 expressieprofiel	 tussen	 normale	 en	 leukemische	
CD34+CD38- cellen was nagenoeg hetzelfde.
•	 	Na	 blootstelling	 aan	 chemotherapie	 en	 Ara-C	 was	 een	 sterke	 toename	 in	 
expressie van ABC transporters te zien binnen 24-72 uur.
De expressie van veel ABC transporters op normale en leukemische CD34+CD38- 
cellen leidde tot de hypothese dat het remmen van het transport van één enkele 
ABC transporter niet voldoende zal zijn. En omdat normale en leukemische cellen 
weinig verschillen, is de kans ook groot dat normale stamcellen “geraakt” zullen 
worden. Een mogelijke oplossing zou kunnen zijn om geen gebruikt te maken van 
specifieke remmers, maar om breedspectrum remmers te gebruiken. Deze remmers 
zullen het transport van meerdere ABC transporters stil leggen. 
We hebben laten zien dat het expressie patroon van ABC transporters zeer goed 
overeenkomt tussen normale en leukemische CD34+CD38- cellen. Een klein aantal 
transporters laten een verschil in expressie zien. Verder onderzoek naar de func-
tie van deze transporters zal nodig zijn, om te kunnen ontrafelen of deze gebruikt 
kunnen worden voor selectieve uitschakeling.
Een andere observatie was dat alle transporters hoger tot expressie kwamen 
op CD34+CD38- cellen in vergelijking tot de verder ontwikkelde CD34+CD38+ 
cellen. Dit roept de vraag op of ABC transporters ook een rol hebben in stamcel- 
ontwikkeling. De functie van ABC transporters in stamcellen is tot op heden nog 
onbekend. Enige studies laten reeds zien dat ABC transporters van belang zijn 
voor differentiatie van cellen, en dat de expressie van ABC transporters mogelijk 
gebruikt kan worden als selectiemarker. Meer onderzoek naar deze mogelijke rol 
van ABC transporters is zeker nodig.
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Dankwoord
Ja, het is af! Aangezien het niet gelukt zou zijn dit proefschrift te schrijven zonder 
hulp van anderen, wil ik in dit laatste hoofdstuk iedereen bedanken die de afgelopen 
jaren een bijdrage (hoe klein ook) heeft geleverd aan het tot stand komen van dit 
boekje. Een aantal mensen wil ik daarbij speciaal bedanken.
Allereerst gaat mijn dank uit naar mijn co-promotor Reinier. Gedurende de afgelopen 
jaren hebben we veel met elkaar te maken gehad. Ondanks je drukke bezigheden in 
de kliniek, wist je altijd tijd vrij te maken voor het onderzoek. Naast vakinhoudelijke 
interesse was er ook altijd de persoonlijke interesse, wat ik altijd zeer gewaardeerd 
heb. Ons gezamenlijke uitje naar Schotland zal ik dan ook niet snel vergeten, vooral 
niet het etentje met je geweldige gezin. De juiste combinatie hierin heeft er voor 
gezorgd dat ik het altijd naar mijn zin heb gehad op het CHL.
Marc en Bert, jullie hebben samen eigenlijk een duo-baan gevormd gedurende mijn 
promotie. Marc, jij hebt me de principes aangeleerd van het ABC-transporter onder-
zoek en de weerbarstige transport assays. Al waren we het niet altijd even goed 
eens, ik vond het fijn samen met jou aan “ons” onderzoek te werken. Bedankt voor 
je kritische blik op de geproduceerde data, de discussies en je grote gedrevenheid. 
Bert, na twee jaar van een afstandje meegedacht te hebben, ben je meer betrokken 
geraakt bij het ABC-transporter onderzoek. Jouw inbreng gaf weer een nieuwe draai 
aan het onderzoek. De korte afstand naar je kamer maakte het makkelijk snel even 
langs te lopen met nieuwe data, of voor een gezellig praatje. 
Theo, ondanks je drukke agenda en de “verre” afstand van het lab, wist je op de 
woensdagochtend besprekingen toch altijd weer kritische vragen te stellen, en 
daarmee je betrokkenheid te tonen. 
Joop, ondanks dat ik het buitenbeetje was van het lab (qua onderzoek), wil ik je 
bedanken voor je kritische kijk en wetenschappelijke bijdrage bij het ABC transporter 
onderzoek.
Het was even wennen op het moleculaire researchlab van het CHL. Maar door het 
grote enthousiasme van iedereen en de goede sfeer, zijn de 4 jaar omgevlogen. 
Jurgen en Sake, wat moest ik nu in het begin van jullie denken. Maar na het voor-
val met “de kist” is het helemaal goed gekomen, al viel ik voor jullie in eerste in-
stantie nogal tegen. Jurgen, bedankt dat ik samen met jou aan “de leuke kant van 
de paal” heb mogen zitten. Je bent een geweldig persoon. Sake, ondanks onze 
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grote verschillen, hebben we toch samen heel wat gezellige uurtjes doorgebracht. 
Jeannet, ik heb het altijd erg gezellig gevonden samen een labtafel te delen. Ook 
de komende jaren zullen we elkaar nog vaak tegen gaan komen, succes met je 
opleiding tot klinisch chemicus. Laurens en Sas, de twee JO’s die na mij op het 
CHL gekomen zijn, dat kon nooit iets worden! Jullie waren een goede, sportieve, 
aanvulling op de groep. Succes nog met (het afronden van) jullie promotie.
Leonie, bedankt dat jij me wegwijs hebt leren maken op het CHL. Samen met 
Liesbeth het bakkie koffie om 8 uur, was altijd een goed begin. Het was dan ook 
jammer dat je weg ging, maar je hebt voor jezelf een keuze gemaakt die “OK” is. 
Liesbeth en Ruth, de ervaren analisten op het lab, bedankt voor de vele uitgebreide 
en gezellige gesprekken en alle koffiepauzes. Liesbeth, jij wist echt alles. En dan 
niet alleen vakinhoudelijk! Ruth, jammer dat ik ook niet in Beuningen woonde. Het 
was altijd leuk samen naar huis te fietsen. Aswin, jij was echt te goed voor het lab. 
Ik weet niet hoeveel kilo ik er af heb moeten trainen door jouw bijdrage in de snoep-
pot. Bedankt voor je gezelligheid en het feit dat je altijd voor iedereen klaar stond, 
zelfs om “even” mee naar Amsterdam te gaan om muizenbeenmerg te isoleren. Sas 
I, bedankt voor je bijdrage aan mijn boekje. Ik vond het erg leuk met je te werken. 
Ook Aniek, Gorica, Willemijn, Aneta en alle stagiaires en studenten wil ik bedanken 
voor de gezellige tijd op het CHL.
Linda, je was mijn eerste stagiair, dus ook voor mij was het even wennen. Ik wil je 
bedanken voor alle immuunfluorescentie experimenten die je uitgevoerd hebt. Het 
was altijd een leuk uitje om samen achter de microscoop te zitten. Gabriel, or Buda, 
I think I will never get used to the Italian courtesy. I would like to thank you for all 
the work you’ve done. Hopefully we get the paper published very soon.
Iedereen van de moleculaire diagnostiek (Adrian, Ellen, Evelyn, Laura, Louis en 
Marion) ontzettend bedankt voor alle gezelligheid en voor al jullie hulp bij de vele 
taqman PCR’s. Er was altijd wel een deal te sluiten wanneer ik weer eens op “jullie” 
apparaat wilde draaien. Louis, bedankt voor het ontwerpen van de vele primer 
combinaties, en bij het uitzoeken van de sets voor de MFC.
Veel van het werk in dit boekje is tot stand gekomen door de hulp van mensen van 
verschillende onderdelen van het CHL. Heel wat uren zijn er doorgebracht achter 
de flow-cytometer, in de eerste jaren met Arie en Gertie die later fantastisch over-
genomen zijn door Rob en Jeroen. Enorm bedankt voor jullie inzet, en natuurlijk 
vond ik het altijd erg gezellig om samen met jullie die 300 cellen in het epje te 
kijken!
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Om cellen te kunnen sorteren, heb je natuurlijk materiaal nodig. En bij wie kon ik 
dan beter terecht dan bij de mensen van de BMT. Paul, Jos, Carel, Adrian, Eugenie, 
Marianne, Bennie en Sandra, enorm bedankt dat jullie altijd weer bereid waren be-
langrijk materiaal voor mij in te vriezen, op te zoeken, of apart te houden. Jos en 
Carel, vooral bij jullie voelde ik me altijd erg welkom…
Iedereen van de IFT, bedankt voor het elke keer maar weer uitvullen van die vele 
monoclonale antilichamen die ik dan eigenlijk meteen nodig had! Jan Boezeman, 
statistiek blijft een vak apart, ik ben blij dat jij er was voor de analyse van mijn 
expressie resultaten.
Om er zeker van te zijn dat ik niemand van het CHL vergeet, wil ik iedereen ontzet-
tend bedanken voor de gezellige tijd die ik gehad heb op het CHL. Zonder jullie was 
die nooit hetzelfde geweest.
Verder ben ik dank verschuldigd aan de medewerkers van de afdeling Farmacolo-
gie. Frans en Roos bedankt voor de gezamenlijke besprekingen van de ABC trans-
porter data, dit gaf altijd weer nieuwe inzichten en genoeg experimenten in het 
vooruitzicht. Jeroen, bedankt voor je grote inzet bij het uitvoeren van de ABCC6 
vesicle transport assays. 
Mabel, Jenne, Mieke en Angelique. We kennen elkaar nu al zo’n 10 jaar, en inmid-
dels zijn we allemaal (bijna) doctor of dokter. De etentjes, feestjes en uren doorge-
bracht op het grasveld bij de uni waren altijd erg gezellig. Hopelijk zullen we elkaar 
nog regelmatig blijven zien om oude herinneringen op te halen. Mabel, bedankt 
voor de gezellige lunches die we vaak gehad hebben, en voor het luisterend oor 
wanneer ik weer eens wat “lab”-frustratie kwijt moest. Ik vind het dan ook erg leuk 
dat je vandaag een van mijn paranimfen wilt zijn.
Een bijzonder dank je wel voor mijn familie, schoonfamilie en vrienden. Jullie wisten 
meestal niet zo goed wat ik daar in Nijmegen allemaal het doen was. Promoveren? 
Is dat net zo iets als afstuderen? Nu zien jullie het eindresultaat van 4 jaar “hard” 
werken. Ik wil jullie hier bedanken voor de interesse en het zorgen voor de afleiding 
en ontspanning in de afgelopen jaren.
Antwan, ik weet (nog) niet hoe ik je moet bedanken, maar misschien is een speciaal 
plaatsje in het dankwoord een begin… Enorm bedankt voor het ontwerpen van dit 
boekje. Het is voor mij helemaal goed geworden!
Bregje, mijn zusje, het waren altijd gezellige uurtjes wanneer je weer even langs 
kwam op het lab, om te kijken hoe hard we aan het werk waren! Ik vind het dan ook 
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erg leuk dat je vandaag naast me wilt staan als getuige, oh nee, hoe heet dat ook 
al weer! Ties en Pieter (mijn broertjes), de perfecte personen om alle belangrijke 
dingen even te vergeten en het niet perse ergens over te hebben. Bedankt voor 
deze ontspannende momenten, altijd lekker rustig!
Lieve pap en mam, zonder jullie onvoorwaardelijke steun zou ik hier nooit gestaan 
hebben. Mam, dit grote avontuur is al begonnen met jouw strijd voor mijn advies 
op de lagere school! Ontzettend bedankt voor jullie vertrouwen in mij, en voor het 
stimuleren en motiveren om datgene af te maken waar ik aan begon.
Lieve Joost, ja toch het laatste woord voor jou! Bedankt voor al je vertrouwen, liefde, 
steun en vele uren die je naar mijn verhalen over alle aspecten van het promoveren 
hebt willen luisteren. En inderdaad, de organisatie van een research lab zal nooit te 
vergelijken zijn met die van een commercieel bedrijf!
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Figure 1. ABCB1-mediated drug extrusion is reduced in CD34+CD38- progenitor cells in AML com-
pared with their normal counterparts. A, representative examples of normal bone marrow (NBM; top) 
and AML (bottom). CD34+CD38- cells were defined flowcytometrically as the CD34-FITC + cells (blue) 
with CD38-PE expression within the first decade of fluorescence emission (red) and compared with 
CD34+CD38+ cells (blue gated) with exclusion of a decade between CD38- and CD38+ cells. Gray, 
CD34- cells. CD34+CD38- cells exhibited restricted light-scattering characteristics (SSC), confirm-
ing the lymphoid appearance of these cells (inset). The median frequency of CD34+CD38- cells was 
0.1% of mononuclear cells (range, 0.1-0.3%) in normal bone marrow and 0.2% of mononuclear cells 
(range, 0.1-10%) in AML. No difference existed in average CD38 density between normal and leukemic 
CD34+CD38- cells (MFI, 0.57 +/- 0.05 SD; range, 0.40-0.70; MFI, 0.53 +/- 0.12 SD; range, 0.30-0.70). B, 
representative examples of flow cytometric assessment of ABCB1-mediated mitoxantrone transport in 
CD34+CD38- cells in normal bone marrow (top) and AML (bottom). Mean intracellular MFI was assessed 
in CD34+CD38- cells as described in Materials and Methods. Normal CD34+CD38- cells display low 
intracellular mitoxantrone fluorescence compared with CD34+CD38+ cells (inset), which can be increased 
significantly by blockage of ABCB1-mediated transport by verapamil/PSC-833 (EI, 2.29). CD34+CD38- 
cells in AML display increased intracellular mitoxantrone retention compared with CD34+CD38- cells 
from normal bone marrow due to reduced ABCB1-mediated transport as illustrated by a lack of effect of 
verapamil/PSC-833 on intracellular mitoxantrone fluorescence (EI, 0.98). C, representative examples 
of the effect of ABCB1 inhibition by verapamil on rhodamine 123 fluorescence in CD34+CD38- cells 
assessed by single-cell image analysis. For experimental procedure, see Materials and Methods. 
Encircled, cells. Normal CD34+CD38- cells (top) display low retention of rhodamine 123, which can be 
significantly increased when verapamil is added (EI, 3.24). ABCB1-mediated rhodamine 123 extrusion 
from CD34+CD38- cells is reduced in AML (bottom), illustrated by the lack of effect of ABCB1 inhibition 
by verapamil on intracellular rhodamine 123 fluorescence (EI, 1.00).
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Figure 5. ABCB1-mediated mitoxantrone transport identifies a subpopulation that harbors residual 
normal CD34+CD38- cells in a patient with CBFB-MYH11 AML. A patient was identified in which mito-
xantrone discriminated a population of CD34+CD38- mitoxantrone dull cells. The dull phenotype was 
determined by strong ABCB1-mediated efflux (CD34+CD38- ABCB1 efflux ++) within the range observed 
in CD34+CD38- cells observed in normal bone marrow (EI, 2.50). Real-time PCR confirmed the residual 
normal character of these cells.
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Figure 2 Characteristic examples of flow-cytometric assessment of BCRP expression and BCRP-mediated 
mitoxantrone efflux in CD34+CD38- hematopoietic in normal bone marrow and AML. A, definition of 
CD34+CD38- hematopoietic cells in human normal bone marrow and AML. CD34+CD38- cells were 
defined flow-cytometrically as the CD34-expressing cells (blue) with CD38 expression within the first 
decade of fluorescence emission (red) and compared with CD34+CD38+ cells (blue gated) with an 
exclusion of a decade between CD38- and CD38+. CD34- cells are shown in grey. CD34+CD38- cells 
were found invariably in both normal bone marrow (A1) and CD34+ (> 10% CD34+ cells in bone marrow 
by definition, A2) and CD34- leukemias (A3). The median frequency of CD34+CD38- cells was 0.1% of 
mononuclear cells in normal bone marrow (range 0.1-0.3%) and 0.2% in acute myeloid leukemia (range 
0.1-10 %). B, cellular mitoxantrone fluorescence in different cell populations after 2-hour incubation 
with mitoxantrone (10 µmol/L) in the absence of BCRP inhibitor. CD34+CD38- cells have a mitoxantrone 
“dull” phenotype. C, BCRP protein expression in CD34+CD38- cells as determined by the BXP21 
antibody (dotted line) versus isotype control. D, mitoxantrone fluorescence in CD34+CD38- cells in the 
presence (dotted line) or absence of the BCRP specific inhibitor KO143 (0.1 µmol/L).
